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ABSTRACT 
Numerous ways to meta-analyze single-case data have been proposed in the 
literature, however, consensus on the most appropriate method has not been reached. One 
method that has been proposed involves multilevel modeling.  This study used Monte 
Carlo methods to examine the appropriateness of Van den Noortgate and Onghena’s 
(2008) raw data multilevel modeling approach to the meta-analysis of single-case data.  
Specifically, the study examined the fixed effects (i.e., the overall average baseline level 
and the overall average treatment effect) and the variance components (e.g., the between 
person within study variance in the average baseline level, the between study variance in 
the overall average baseline level, the between person within study variance in the 
average treatment effect) in a three level multilevel model (repeated observations nested 
within individuals nested within studies).  More specifically, bias of point estimates, 
confidence interval coverage rates, and interval widths were examined as a function of 
specific design and data factors.  Factors investigated included (a) number of primary 
studies per meta-analysis, (b) modal number of participants per primary study, (c) modal 
series length per primary study, (d) level of autocorrelation, and (3) variances of the error 
terms.  The results of this study suggest that the degree to which the findings of this study 
are supportive of using Van den Noortgate and Onghena’s (2008) raw data multilevel 
modeling approach to meta-analyzing single-case data depends on the particular effect of 
interest.  Estimates of the fixed effects tended to be unbiased and produced confidence 
	  xiv	  
intervals that tended to overcover but came close to the nominal level as level-3 sample 
size increased.  Conversely, estimates of the variance components tended to be biased 
and the confidence intervals for those estimates were inaccurate.  
	  1 
	  	  
 
CHAPTER ONE: INTRODUCTION 
Single-case research has grown in popularity over the past decade and is being 
conducted in a variety of settings such as school psychology (Skinner, 2004), special 
education (Algozzine, Browder, & Karvonen, 2001), teacher education (Hsieh, 
Hemmeter, McCollum, & Ostrosky, 2009), and behavioral intervention research (Filter & 
Horner, 2009).  This type of research allows for the repeated measurement of one case 
over a certain period of time to assess a treatment’s effect on an individual case. 
Typically, data are collected during a baseline phase (prior to treatment) and then during 
or after the implementation of the treatment or intervention. This is the most basic design; 
additional design types include the removal of the intervention, reintroduction of the 
intervention, and maintenance of the intervention.  In addition, several cases or settings 
can be studied at the same time in a multiple baseline design. 
Across single-case studies there have been numerous ways to analyze this type of 
data, such as visual analysis, computing descriptive summaries, randomization tests, 
regression analysis, and multilevel modeling.  In addition to a variety of analysis options, 
a variety of effect size estimates have been proposed for use in single-case research, such 
as percentage of non-overlapping data (PND, Scruggs, Mastropieri, & Castro, 1987), a 
form of standardized mean difference (Busk & Serlin, 1992), change in values 
(Center, Skiba, & Casey, 1985-1986; Kromrey & Foster-Johnson, 1996; Beretvas & 
	  2 
Chung, 2008a), and the use of standardized regression coefficients in multilevel models 
(Van den Noortgate & Onghena, 2003a, 2007, 2008).   
Quantitative integration of study results, termed meta-analysis, involves the 
combining of data across multiple studies to evaluate and summarize research findings. 
The term meta-analysis was first coined by Glass (1976) and was defined as “the 
statistical analysis of a large collection of analysis results from individual studies for the 
purpose of integrating the findings” (p.3).  Meta-analysis has been used to synthesize 
results from a wide variety of studies, both non-experimental (e.g., gender differences) 
and experimental (e.g., intervention effectiveness).  This type of research is necessary to 
determine relationships among variables and the effectiveness of interventions across 
studies.  It also allows researchers to integrate study findings with the goal of 
generalization.  Quantitative integration of study findings should cross research domains 
and include all types of quantitative research, including single-case research.  
Meta-analysis of single-case research has resulted in much disagreement in the 
field.  In a study synthesizing single-case meta-analyses conducted between 1985 and 
2005, the majority of meta-analyses were simply reporting mean effect sizes across 
studies (Beretvas & Chung, 2008b).  However, another possible option for combining 
effect sizes across studies is the use of multilevel modeling.  Multilevel modeling has 
been proposed for use with single-case data by many researchers because of its flexibility 
in handling nesting of observations within people (Nugent, 1996; Shadish & Rindskopf, 
2007; Van den Noortgate & Onghena, 2003b).  One specific example is Van den 
Noortgate and Onghena’s (2008) application of multilevel modeling to the meta-analysis 
of single-case data.  Their study proposed the use of a multilevel model to meta-analyze 
	  3 
single-case data.  Equations 1-5 represent their proposed individual level raw data model.  
Equation 1 represents an outcome (y) that is modeled on measurement occasion i for 
participant j of study k ( ) as a linear function of a single-predictor, phase: 
 (1) 
where phase is a dichotomous variable indicating whether a measurement occasion or 
observation occurred during baseline or treatment phase. is the level of the outcome 
during baseline for participant j from study k,  is the treatment effect for participant j 
from study k, and  is within-phase error ( represents the variance of ).  
At the second level, the variation across participants is modeled in the following 
equations: 
 (2) 
and 
 (3) 
where the fixed effects are , the average baseline level for study k, and  , the 
average treatment effect for study k, and the error terms are  and   , allowing 
variation in both baseline levels and treatment effects among participants (  represents 
the variance of and represents the variance of ). 
At the third level, the variation across studies is modeled in the following 
equations: 
 (4) 
and 
 (5)   
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where the fixed effects are , the  overall average baseline level, and , the overall 
average treatment effect, and  the error terms are  and , which allow variation in 
both the average baseline levels and average treatment effects among studies 
( represents the variance of and represents the variance of ). It should be 
noted that in multilevel modeling analysis, errors on all levels are typically assumed to be 
normally distributed and have a mean of zero. 
Problem Statement 
Although the use of single-case designs has grown over the past decades, the 
majority of literature on meta-analysis focuses on group comparison studies and leaves 
out single-case research (Van den Noortgate & Onghena, 2008).  This lack of literature 
related to single-case designs is often why these designs are excluded from meta-
analyses.  This exclusion of single-case designs is concerning when one considers the 
plethora of information single-case research can add to the literature.  Single-case designs 
not only provide information related to average treatment effects but also offer 
information related to how that treatment effect is related to specific cases.  Meta-
analyses of single-case designs offer the ability to summarize and evaluate the overall 
effect without the loss of that specific case information.  In addition, the meta-analysis of 
single-case data increases the generalizabilty of research findings. 
Researchers have proposed a variety of methods to meta-analyze single-case data.  
Van den Noortgate and Onghena’s (2008) proposed method of using multilevel modeling 
to meta-analyze single-case data offers many advantages.  The use of multilevel 
modeling provides the flexibility of appropriately modeling the autocorrelational nature 
of single-case data, can take into consideration multiple effect sizes per study, and can 
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apply appropriate meta-analytic models, such as fixed or random effects models. 
Although the use of multilevel modeling offers advantages in the analysis of single-case 
data, there are still concerns as to whether the use of multilevel modeling is appropriate 
for single-case data.  Specifically, multilevel modeling is based on large sample theory, 
which is not representative of single-case data.  Therefore, it is necessary to further 
investigate the utility of inferences made from multilevel modeling when applied to 
single-case data.  
Purpose of the Study 
The purpose of this study was to examine the appropriateness of Van den 
Noortgate and Onghena’s (2008) raw data multilevel modeling approach to the meta-
analysis of single-case data.  Specifically, the study examined the fixed effects (i.e., the 
overall average baseline level and the overall average treatment effect) and the variance 
components (e.g., the between person within study variance in the average baseline level, 
the between study variance in the overall average baseline level, the between person 
within study variance in the average treatment effect) in a three level multilevel model.  
More specifically, bias of point estimates, confidence interval coverage rates, and interval 
widths were examined as a function of specific design and data factors.  The following 
research questions are of interest: 
Research Questions 
1. To what extent are the fixed effect estimates from a three level meta-analytic 
single-case model biased as a function of specific design factors (number of 
primary studies per meta-analysis, modal number of participants per primary 
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study, modal series length per primary study, level of autocorrelation, and 
variances of the error terms)? 
2. To what extent does the confidence interval coverage of the fixed effect estimates 
from a three level meta-analytic single-case model vary as a function of specific 
design factors (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
3. To what extent does the confidence interval width of the fixed effect estimates 
from a three level meta-analytic single-case model vary as a function of specific 
design factors (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
4. To what extent are the variance components from a three level meta-analytic 
single-case model biased as a function of specific design factors (number of 
primary studies per meta-analysis, modal number of participants per primary 
study, modal series length per primary study, level of autocorrelation, and 
variances of the error terms)? 
5. To what extent does the confidence interval coverage of the variance components 
from a three level meta-analytic single-case model vary as a function of specific 
design factors (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
	  7 
6. To what extent does the confidence interval width of the variance components 
from a three level meta-analytic single-case model vary as a function of specific 
design factors (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
Overview of Study 
Monte Carlo simulation methods were used to examine the appropriateness of the 
multilevel modeling inferences.  The use of simulation methods allowed for the control 
and manipulation of specific design and data factors.  The Monte Carlo study included 
five factors in the design (see Table 1).  These factors were (a) number of primary studies 
per meta-analysis (10, 30, and 80); (b) modal number of participants per primary study 
(small [mode = 4] and large [mode = 8]); (c) modal series length per primary study (small 
[mode = 10], medium [mode = 20], and large [mode = 30]); (d) level of autocorrelation 
(0, .2, and .4); and (e) variances of the error terms (most of the variance at level-1 [ = 
1, = .2, and = .05] and most of the variance at level-2 [ = 1, 
= 2, and = .5]).  The appropriateness of the inferences made from 
the estimates was evaluated in terms of coverage and width of 95% confidence intervals 
as well as bias of point estimates.
	  8 
 
Table 1 
Study Design 
Error Variances Number of 
Primary Studies 
per Meta-
Analysis 
Modal number 
of Participants 
per Primary 
Study 
Modal Series Length per 
Primary Study level-1 = 1; level-2 = .2; level-3 = .05 level-1 = 1; level-2 = 2; level-3 = .5 
   Level of Autocorrelation 
   0 .2 .4 0 .2 .4 
Small (mode = 10)       
Medium (mode = 20)       Small  (mode = 4) 
Large (mode = 30)       
Small (mode = 10)       
Medium (mode = 20)       
10 
Large  
(mode = 8) 
Large (mode = 30)       
Small (mode = 10)       
Medium (mode = 20)       Small  (mode = 4) 
Large (mode = 30)       
Small (mode = 10)       
Medium (mode = 20)       
30 
Large  
(mode = 8) 
Large (mode = 30)       
Small (mode = 10)       
Medium (mode = 20)       Small  (mode = 4) 
Large (mode = 30)       
Small (mode = 10)       
Medium (mode = 20)       
80 
Large  
(mode = 8) 
Large (mode = 30)       
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Limitations	  
The data in this study were simulated based on specific conditions.  Those 
conditions were chosen based on a review of single-case literature and meta-analyses of 
single-case data.  The specific conditions chosen for this study are only some of the 
possible options.  Therefore, the results of this study can only be generalized to studies 
with similar conditions.  Any conclusions beyond the observed conditions should be 
interpreted with caution.   
Definitions of Terms 
Autocorrelation. The degree to which errors from repeated observations are 
correlated with each other. 
Bias. The average difference between a known parameter estimate and an 
estimated parameter estimate. 
Confidence interval coverage. The proportion of 95% confidence intervals that 
contain the estimated parameter. 
Confidence interval width. The average difference between the upper and lower 
limits of the 95% confidence intervals for the estimated parameter. 
Effect size. A measure of the magnitude of the relationship between two variables. 
Fixed effects. Parameter estimates of the coefficients represented in the multilevel 
model (e.g., overall average baseline level, overall average treatment effect). 
Kenward-Roger degrees of freedom method. A method for estimating degrees of 
freedom that approximates the degrees of freedom and was developed to be used with 
unbalanced designs and complex covariance structures. This method is an extension of 
	  10 
the Satterthwaite method; it adjusts for small-sample size bias in the estimation of 
variances.  
Meta-analysis. The quantitative integration of study results that involves the 
combining of effects sizes across multiple studies to evaluate and summarize research 
findings. 
Multilevel modeling. A statistical model used to account for hierarchical or nested 
data, also known as hierarchical linear modeling. “A hierarchical linear model consists of 
one or more regression equations at each level in which the characteristics of the units 
from that level are used as predictors in describing the coefficients of the equation(s) of 
the level just below” (Van den Noortgate & Onghena, 2003a, p. 329). 
Primary studies. The original studies that comprise the sample for the meta-
analysis. 
Satterthwaite degrees of freedom method. A method that approximates the 
degrees of freedom, and was developed to be used with unbalanced designs and complex 
covariance structures. 
Series length. The level-1 sample size in the multilevel model, or the number of 
times a participant is observed.  
Single-case research. The study of a single participant or a group (e.g., a 
classroom), measured at multiple points in time to determine the effectiveness of one or 
more interventions or treatments.   
Treatment effect. The change in a dependent variable that is attributable to a 
specific treatment. 
	  11 
Variance components. Parameters that estimate variation within person, between 
persons within studies, and between studies.
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CHAPTER TWO: LITERATURE REVIEW 
This literature review will be divided into three parts.  First, single-case research 
is described.  Second, a brief overview of meta-analysis is described and finally, the 
meta-analysis of single-case research will be discussed.  
Single-Case Research 
Single-case research, like case studies, can be defined as the study of a single 
participant or group (e.g., a classroom). However, unlike case study research which 
gathers in depth narrative or anecdotal information on a single case, single-case research 
systematically measures a single case at multiple points in time to determine the 
effectiveness of one or more interventions or treatments (Kazdin, 2011).  Single case 
research designs have taken on a variety of different names, such as single-case, single-
subject, N=1, and intra-subject.  Regardless of the name identified by the researcher, the 
focus of this type of research is on the single case and its growth over time.  This type of 
research allows the researcher to focus on individual variations in the treatment effect, 
which have a tendency to be lost in group comparison designs where the focus is the 
average treatment effect (Barlow, Nock, & Hersen, 2009).   In addition to individual 
variation, this type of design also allows the individual to be measured at various points 
in time, thereby allowing the treatment effect to be evaluated with more than a single 
observation, which allows researchers to see how the treatment effect will change over 
time. Single-case research also allows practitioners to implement research in their own 
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setting, therefore reducing the gap between research and practice (Morgan & Morgan, 
2001).  Finally, due to the fact that only a small sample size is needed, researchers are 
able to study populations of people that have a low prevalence rate (e.g., children with 
autism, the homeless) (Van den Noortgate & Onghena, 2003a). 
Methodological Issues 
 Single-case research offers many advantages to researchers.  However, as with 
any type of research, with those advantages come certain methodological concerns.  One 
such concern comes in the form of generality of findings.  This concern stems from the 
fact that when studying a single case it is difficult to know if results from that particular 
case will be applicable to other cases (Barlow, Nock, & Hersen, 2009).  Although 
generality of findings can be a concern in single-case research specific replication 
strategies can be implemented to improve generalizations.  
 Another important methodological concern centers on a key feature of single-case 
research, repeated measurement.  Barlow, Nock, and Hersen (2009) suggest that repeated 
measurements need to be “specific, observable, and replicable” (p. 62).  A repeated 
measurement is (a) specific when it is obvious that a behavior has or has not occurred; (b) 
observable when multiple observers can measure it without difficulty; and (c) replicable 
when the methods used to observe the behaviors can be duplicated on several occasions 
(Barlow, Nock, & Hersen, 2009).  In addition, it is important to take into consideration 
the frequency of measurements.  Specifically, one should balance the importance of 
having enough data with which to evaluate change with the importance of not causing 
fatigue on the part of the subject.   
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Another issue to consider when using repeated measurements is the use of self- 
report data.  Often in research it is necessary to measure a participant’s perceptions of a 
particular behavior (e.g. feelings of depression, anxiety, or happiness, level of control 
over life choices), however, attempting to measure self-report data is not without 
limitations.  One possible limitation is the role social desirability (Crowne & Marlowe, 
1960) can play on self-report data.  It is possible that a true behavior change is not 
occurring and instead the participant is reporting what they think is socially desirable.  
Single-case researchers should be aware of these methodological issues and design their 
studies to minimize these concerns.          
Design Types 
All studies are based on specific types of research designs and within a single-
case framework there are multiple research designs that can be implemented.  Baseline 
logic is a set of guidelines that can be used to organize the experimental design process 
(Riley-Tillman & Burns, 2009). Baseline logic is comprised of four steps, (1) prediction, 
(2) affirmation of the consequent, (3) verification, and (4) replication by affirmation of 
the consequent (Riley- Tillman & Burns, 2009).  The first step, prediction, is used to 
determine what the behavior looks like prior to the intervention and is typically termed 
baseline or A phase.  This stage is necessary to illustrate what level the behavior is 
occurring at and how stable and/or variable the behavior is prior to the intervention 
(Riley-Tillman & Burns, 2009).  By examining these things researchers are able to 
predict what the behavior would look like if no intervention were implemented.  The 
second step of baseline logic, affirmation of the consequent, allows the researcher to first 
test whether the intervention had some impact on the participant’s behavior and is 
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typically termed treatment or B phase.  In this phase the intervention has been 
implemented and the behavior is being measured to determine if there is a predictable 
change in the data (Riley-Tillman & Burns, 2009).  Thus far in the steps of baseline logic 
the most basic single-case design type has been described, an AB, or interrupted time 
series, design (see Figure 1).  This type of design consists of observations of the 
dependent variable both before and after an intervention.  The observations that occur 
before an intervention are considered part of the baseline (A) phase, and the observations 
that occur after the intervention are considered part of the treatment (B) phase.   
 
Figure 1. Graphical display of interrupted time series design 
This basic AB design type is not without criticism.  For example, when using this 
type of design it is difficult to attribute a change in the data to the treatment and not to 
some other event which could have occurred at the same time.  Another plausible 
explanation for a shift in data could be developmental milestones or a change in 
instrumentation (Ferron & Rendina-Gobioff, 2005).  These limitations can be addressed 
Baseline (A) Treatment (B) 
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by utilizing more complex study designs, such as a reversal or multiple baseline design, 
which will also address the final two steps of baseline logic. 
The third step of baseline logic is verification.  This step is used to verify what 
was observed in the original baseline phase by removing the intervention and returning to 
a second baseline or A phase.  This step allows one to gain increased confidence in what 
was originally seen in the first baseline as well as attributing the changes observed in the 
treatment phase to the introduction of the intervention rather than some extraneous 
variable (Riley-Tillman & Burns, 2009).  This stage of baseline logic is clearly illustrated 
with the use of the most simplistic reversal design, an ABA design.    
Reversal, or withdrawal, designs are extensions of the basic AB design.  Although 
the terms reversal and withdrawal are often used interchangeably in the literature there is 
a slight distinction (Barlow, Nock, & Hersen, 2009). Reversal designs refer to situations 
when the intervention is reversed and applied to an incompatible behavior, whereas 
withdrawal designs refer to situations where the intervention is simply withdrawn and 
returned to the A phase (Barlow, Nock, & Hersen, 2009; Rusch& Kazdin, 1981).  
Nonetheless, the most simplistic reversal or withdrawal design is removal of the 
treatment from participants (ABA; see Figure 2).  This design consists of observations 
during an initial baseline (A) phase, then observations during a treatment (B) phase, 
followed by observations in a second baseline (A) phase.  The implementation of a 
second baseline phase allows the researchers to observe if the behavior reverts back to the 
original baseline levels. If this occurs then it is easier to attribute the changes observed to 
the treatment, and other alternative explanations become less plausible.  One major 
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limitation of this design is that in certain settings it may not be legal or ethical to remove 
treatment from a participant. 
 
Figure 2. Graphical display of ABA reversal design  
The final step of baseline logic, replication by affirmation of the consequent, is an 
attempt to strengthen what was observed in the initial treatment phase by reintroducing 
the intervention and creating an opportunity to observe the behavior change once again 
(Riley-Tillman & Burns, 2009).   This replication increases our confidence in the 
likelihood of a relationship existing between the participant’s behavior and the 
implementation of the intervention.  This replication can also be accomplished in other 
ways when the removal and reintroduction of the intervention is not feasible or is 
unethical.  
An extension of the most simplistic reversal design (ABA) is the reintroduction of 
a treatment phase in an ABAB design (see Figure 3).  This design consists of 
observations in an initial baseline (A) phase, then observations in an initial treatment (B) 
phase, followed by observations in a second baseline phase (A), and ending with 
Baseline (A) Treatment (B) Baseline (A) 
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observations in a final treatment (B) phase.  The inclusion of a final treatment phase 
provides the opportunity for replication of the initial treatment phase in which the 
observed behavior should revert back to the change seen in the initial treatment phase.  
 
Figure 3. Graphical display of ABAB reversal design  
One major limitation of single-case designs is their lack of generalization beyond 
the one case that is being studied.  The ability to generalize can be accomplished through 
replication.  Barlow, Nock, and Hersen (2009) state that there are at least three types of 
generalization in behavior change research: (1) generality of findings across participants, 
(2) generality of findings across behaviors, and (3) generality of findings across settings.  
One natural way of achieving these various types of generalizations is through 
replication.  There are various ways to replicate single-case experiments, such as 
replication of the baseline and treatment phase, as discussed previously in baseline logic, 
or simultaneous replication built into the study design (Van den Noortgate & Onghena, 
2007).  A multiple baseline design allows for this simultaneous replication and can often 
Baseline (A) Baseline (A) Treatment (B) Treatment (B) 
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be used when the removal and reintroduction of the intervention is not feasible or is 
unethical. 
A multiple baseline design is another type of extension of the traditional AB 
design (see Figure 4).  This extension of the AB design simply establishes a baseline and 
treatment phase for multiple participants, behaviors, or settings.  The initiation of the 
treatment phase is staggered across time, creating different baseline lengths for different 
participants, behaviors, or settings.  By staggering the length of the baseline phases, it is 
more plausible to attribute a change in the data to the treatment, as we would not expect 
changes in history or maturation to stagger themselves across time (Ferron & Rendina-
Gobioff, 2005).  While this type of design does have many advantages, it does still have a 
few limitations. For example, when there is a lack of independence between baselines or 
when treatment effects vary across participants, behaviors, or settings it is more difficult 
to accurately attribute changes in the data to the treatment. 
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Figure 4. Graphical display of multiple baseline design 
Baseline (A) Treatment (B) 
Person 1 
Person 2 
Person 3 
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Analysis Options 
Single-case research has been wrought with disagreement on the most appropriate 
method to analyze data.  These analysis options can be grouped into three broad 
categories: (1) visual analysis, (2) descriptive statistics, and (3) inferential statistics.  
Visual analysis.  Historically, visual analysis of data has been the preferred 
analysis option (Kazdin, 2011; Parsonson & Baer, 1992).  “The underlying rationale is to 
encourage investigators to focus on interventions that produce potent effects and effects 
that would be obvious from merely inspecting the data” (Kazdin, 2011, p.286). 
Proponents of visual analysis have argued that researchers who primarily rely on visual 
analyses of their graphed data are more likely to commit Type II (miss) errors than those 
who primarily rely on statistical analyses (Kazdin, 2011),in essence stating that visual 
analysts tend to be more conservative when evaluating the effectiveness of a particular 
treatment and therefore visual analysts commit fewer Type I (false alarm) errors 
(Parsonson & Baer, 1986).  However, despite these claims, there have been several 
criticisms of visual analysis (DeProspero & Cohen, 1979; Jones, Weinrott, & Vaught, 
1978; Matyas & Greenwood, 1990; Wampold & Furlong, 1981).  Matyas and Greenwood 
(1990) argued that visual analysts were not as conservative as previously claimed, 
committing Type II errors 0% to 22% of the time and Type I errors 16% to 84% of the 
time.  Additionally, Jones, Weinrott, and Vaught (1978) examined conclusions made 
from visual analysis as compared to statistical analysis and found that there was little 
agreement between the two.  Also, Jones et al. (1978) and DeProspero and Cohen (1979) 
examined inter-rater agreement among judges and found that reliability was low.  These 
conclusions support the assertion that visual analysis is not as consistently reliable and 
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conservative as once purported.  Therefore, single-case researchers can supplement visual 
analysis with varying statistical analysis options.   
Descriptive statistics.  One such statistical analysis option is computing 
descriptive statistics or summary measures. These descriptive statistics include within 
phase measures (i.e., means, medians, standard deviations, root mean square error, and 
trend lines) and between phases measures (i.e., varying types of effect sizes). Just as there 
is contention in the literature as to how to analyze single-case data, there is also 
disagreement over how to summarize these effects.  Effect sizes can be broken down into 
three overarching categories: (1) standardized mean difference, (2) regression based, and 
(3) non-regression based.   
One approach is the standardized mean difference (Busk & Serlin, 1992), where 
the difference in baseline and intervention means is divided by the baseline standard 
deviation ( ) or by the pooled standard deviation ( ). More formally,  
        (6) 
and 
        (7) 
where is the mean of the treatment phase, is the mean of the baseline 
phase, is the standard deviation of baseline phase, and is the pooled standard 
deviation across baseline and treatment phases.  Busk and Serlin (1992) recommend 
using the difference in baseline and treatment means divided by the baseline standard 
deviation (see Equation 6) when normality of the population distribution and equality of 
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the variances cannot be assumed.  Otherwise, if the assumptions of normality and 
equality of variances or at least the assumption of equality of the variances are met then it 
is suggested to pool the variances and calculate a standardized mean difference based on 
the formula in Equation 7 (Busk & Serlin, 1992).  
Another category of approaches for effect size calculations is regression based.  
These types of effect sizes are able to account for trends in data.  One variation of this 
approach includes the difference between the treatment trend line and the extension of the 
baseline trend line at the first point in treatment or at the last point in the treatment 
(Allison & Gorman, 1993).  Other variations include computation of an value 
representing a change in values corresponding to a change in level and a change in 
slope (Kromrey & Foster-Johnson, 1996) and standardizing regression coefficients that 
correspond to a shift in level and a shift in slope (Van den Noortgate & Onghena, 2003).  
A final category is non-regression based effect sizes.  There are several possible options 
in this category.  One possible option is the percentage of non-overlapping data (PND; 
Scruggs, Mastropieri, & Castro, 1987).  The PND is calculated by identifying the highest 
or lowest point (depending upon which direction the data is expected to move) in the 
baseline phase and then finding the percent of treatment phase data points that exceed it.  
Other possible options have been created as alternatives to the PND, such as (a) the 
percentage of data points exceeding the median (PEM; Ma, 2006), which is calculated by 
finding the percentage of treatment data points above the median level of baseline data 
points, (b) the mean baseline reduction (MBLR; Lundervold & Bourland, 1988), which is 
the difference between baseline and treatment phase means divided by the baseline mean 
and then multiplied by 100, and (c) the percentage of all non-overlapping data (PAND; 
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Parker, Hagan-Burke, & Vannest, 2007), which is the percentage of data points whose 
removal from either phase would eliminate all data overlap between phases. 
Inferential statistics.  Another possible statistical analysis option is inferential 
tests.  There are a plethora of options available; however, one of the most often employed 
and well-researched options are randomization tests.   
Randomization tests.  Randomization tests make no assumptions about the 
distribution of the data and only use information obtained from the sample to evaluate the 
null hypothesis. However, these tests do assume random assignment of the data points or 
measurement occasions to either baseline or treatment phase.  By randomly assigning 
measurement occasions to baseline or treatment, the study design can be classified as an 
experimental one (Onghena & Edgington, 2005).  The use of an experimental design 
minimizes threats to internal validity by accounting for extraneous variables in both 
baseline and treatment phases. 
The random assignment of measurement occasions can be thought of in two 
schemes. The first assumes the intervention can be alternated at any given measurement 
occasion.  For example, let’s assume a researcher wants to gather 12 observations on a 
single individual with 6 observations in baseline and 6 observations in treatment. The 
researcher could randomly assign the 12 observations to either baseline or treatment.  The 
second is utilized when alternating the intervention at any given measurement occasion is 
not feasible. This randomization scheme assigns the timing of the phase change from 
baseline to intervention (Barlow, Nock, & Hersen, 2009).  Specifically, the measurement 
occasions are assigned to a specific phase shift. For example, let’s assume we have a 
basic AB design with 27 total measurement occasions, and each phase must have a 
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minimum of four observations each.  The start of the intervention phase could occur on 
one of 20 possible occasions (see Figure 5).  The logic behind randomization tests is that 
if the treatment has no impact on the dependent variable, then what is observed will not 
be affected by the independent variable (treatment assignment); the order of the 
assignment of the independent variable should not matter (Barlow, Nock, & Hersen, 
2009).  This null hypothesis is tested by comparing an obtained test statistic to a 
randomization distribution that is formed by calculating a test statistic for all possible 
permutations of the data.  
 
Figure 5. Example randomization scheme assigning phase shift from baseline to 
treatment 
 
A limitation of this method is that it only allows inference of the presence of a 
treatment effect and not of the type of effect (i.e., change in level and change in slope) or 
how big that effect is (Morgan & Morgan, 2001; Onghena & Edgington, 2005).  In 
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addition, randomization tests are unable to provide interval estimates of the treatment 
effect (Ferron, Farmer, & Owens, 2010).  It is also difficult to estimate power for this 
type of test since it depends on many factors, such as effect size, design, series length, 
and form of randomization, to name a few (Ferron & Onghena, 1996; Onghena & 
Edgington, 2005). 
Regression analysis.  Regression methods have also been proposed in the 
literature as a possible analysis option for single-case data (Huitema & McKean, 1998).  
A regression analysis can be performed to compare the treatment phase mean to the 
baseline phase mean for a specific individual using the following model: 
 (8)   
where is the observed value at ith point in time, phase is a dummy coded variable (0 = 
baseline and 1= treatment),  is the baseline mean, is the difference in means 
between the baseline and the treatment phases, and is the error term at the ith point in 
time.  A treatment effect can be determined by testing the regression coefficient to 
determine statistical significance.  Equation 8 is the most basic model and can be further 
extended to include terms to evaluate trends in the phases (Center, Skiba, & Casey, 1985-
1986; Huitema & McKean, 2000).  Although the use of ordinary least squares (OLS) has 
been suggested for use with single-case data (Huitema & McKean, 1998; Shine & Bower, 
1971), specifically multiple baseline designs, a major limitation of this model is that it 
does not take into consideration the dependency of the errors and it assumes the errors 
modeled are independent.   
Autocorrelation.  Due to the fact that single-case research is based on the premise 
that a single case is being measured repeatedly across time, many have argued that the 
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errors produced by these repeated measurements will be more similar when they are close 
to each other in time and therefore positively autocorrelated (Kratochwill, Alden, 
Demuth, Dawson, Panicucci, & Arnston, 1974; Matyas & Greenwood, 1997).  Research 
has shown that positive autocorrelation can impact statistical inferences by increasing 
Type I error rates (finding a treatment effect when a treatment effect does not exist) 
(Matyas & Greenwood, 1990; Toothaker, Banz, Noble, Camp, & Davis, 1983).  Although 
there is agreement on the negative effects of autocorrelation, there has been debate on the 
extent to which single-case data are likely to illustrate autocorrelation (Busk & 
Marascuilo, 1988; Huitema, 1985; Huitema & McKean, 1998; Matyas & Greenwood, 
1997; Suen & Ary, 1987).  According to Kazdin (2011), “The current verdict after 
several studies is that serial dependence is likely to be present and ought to be taken into 
account in evaluation of the data” (p.409).   
Multilevel modeling.  As an alternative to the simple OLS regression model, the 
use of multilevel models has been suggested for analyzing single-case data (Ferron, Bell, 
Hess, Rendina-Gobioff, & Hibbard, 2009; Jenson, Clark, Kircher, & Kristjansson, 2007; 
Nugent, 1996; Shadish & Rindskopf, 2007; Van den Noortgate & Onghena, 2003a, 
2003b).  Multilevel models allow for the analysis of hierarchical data that are organized 
into two or more levels (Raudenbush & Bryk, 2002).  For example, in educational 
research when the focus is on the effectiveness of a new curriculum, students are 
assigned to the treatment (receive the new curriculum) or control group by classroom.   
The students (level one) in each of the classrooms are therefore nested within classrooms 
(level two).  Another example is when repeated measurements are gathered over time on 
a set of participants.  The measurements (level one) are therefore nested within the 
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participants (level two).  This type of data structure is representative of single-case data 
and for the purposes of this study the focus was on this second example.  
To examine single-case data within a study, a two level model can be used. The 
first level of the multilevel model is based on a simple linear regression model, 
 (9) 
where is the observed score at measurement occasion i for participant j, is a  
dichotomous variable indicating whether a measurement occasion or observation 
occurred during baseline or treatment,  is the baseline mean for participant j, is the 
treatment effect for participant j (i.e., the difference in means between baseline and 
treatment phases for participant j), and is the error at measurement occasion i for 
participant j, which accounts for within-phase error variance.  The errors for participant j 
are typically assumed to be independent with a variance of ( ).  However, this 
assumption of independence could be violated due to autocorrelation (Van den Noortgate 
& Onghena, 2003a).  Therefore, it is possible with the use of multilevel modeling to 
assume a more complex covariance structure, such as a first-order autoregressive 
structure, which would account for possible autocorrelation (Ferron, Farmer, & Owens, 
2010; Van den Noortgate & Onghena, 2003b).  It should also be noted that just as in OLS 
regression, the first level of the multilevel model could be expanded to account for trends 
in the data (Van den Noortgate & Onghena, 2003b). 
The second level of the multilevel model allows for variation across participants 
in both their baseline levels and their treatment effects. 
 (10) 
and 
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 (11) 
where is the average baseline, is the average treatment effect,  is an error term 
that indicates how far participant j’s baseline mean is from the average baseline mean 
with a variance of , and is an error term that indicates the difference between 
participant j’s treatment effect and the average treatment effect with a variance of .  
The error terms are assumed to be normally distributed and have a mean of zero.   
Multilevel modeling provides three different types of parameter estimates: (1) 
variance components, (2) fixed effects, and (3) individual estimates.  The variance 
components of a two-level model are the variance between participants’ baseline means 
(i.e., ) and the variance between participants’ treatment effects (i.e., ).  The fixed 
effects are the average baseline means across participants (i.e., ) and the average 
treatment effect across participants (i.e., ).  Finally, the individual estimates for each 
participant are the baseline mean for participant j (i.e., ) and the treatment effect for 
participant j (i.e., ).  
A major advantage of multilevel modeling over other statistical analysis options, 
such as OLS regression, is its flexibility in handling serial dependency or autocorrelation.  
As discussed previously, the nature of single-case data lends itself to serial dependency.  
Some researchers have argued that autocorrelation does not exist in single-case data and 
therefore an OLS piecewise regression technique is an appropriate analysis option 
(Center, Skiba, & Casey, 1985-1986), and still others have debated the use of interrupted 
time-series analysis because the influence of autocorrelation is removed prior to analysis 
of the data (Crosbie, 1993).  Although the interrupted time series method has the ability 
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to account for the influence of autocorrelation, it requires a large number of data points to 
adequately implement the procedure (Busse, Kratochwill, & Elliott, 1995; Crosbie, 
1993).  Multilevel modeling provides an alternative solution to handling serial 
dependency by having the flexibility to model a more complex covariance structure, such 
as a first-order autoregressive structure (Raudenbush & Bryk, 2002). 
According to Van de Noortgate and Onghena (2003a), several other advantages of 
the use of multilevel modeling exist as well.  One advantage of multilevel modeling is the 
flexibility of the model to handle heterogeneous variances and moderating variables.  
Another advantage of the use of multilevel models is that the individual parameter 
estimates are based on data from all the cases and therefore can still be relatively reliable, 
even with a small number of observations per case.  Lastly, software for estimating the 
parameters has become readily accessible.   
Although several advantages exist, some limitations or concerns also exist.  One 
concern focuses on sample size.  Multilevel models are typically estimated using 
restricted maximum likelihood methods.  Those methods were developed under a large-
sample theory and most recommendations specify the use of at least 30 units at the upper 
level (Hox, 1998).   Previous research has indicated that regardless of sample size, fixed 
effect parameter estimates are unbiased but variance components may be biased (Ferron, 
Bell, Hess, Rendina-Gobioff, & Hibbard, 2009; Maas & Hox, 2004;Mok, 
1995;Raudenbush & Bryk, 2002). 
Ferron, Bell, Hess, Rendina-Gobioff, and Hibbard (2009) investigated the quality 
of inferences from multilevel modeling of multiple baseline data.  Specifically, the 
authors examined, for the models in Equations 9 – 11, the interval estimates of the 
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average treatment effect.  Ferron et al. (2009) used Monte Carlo simulation methods to 
examine multiple baseline studies having four, six, or eight participants (level-2 sample 
size) and series lengths of 10, 20, or 30 (level-1 sample sizes) for each participant.  Their 
results indicated the fixed effect estimate of the average treatment effect was unbiased, 
regardless of sample size.  In addition to relative bias, confidence interval estimates were 
also examined and as long as the Kenward-Roger or Satterthwaite degrees of freedom 
methods were used, accurate confidence interval estimates could be obtained. 
Specifically, the coverage estimates were close to the nominal .95 value, ranging from 
.965 to .935, when autocorrelation was modeled.  
However, the results of Ferron et al. (2009) also indicated that estimates of the 
variance components tended to be biased.  Although the average relative bias estimates of 
the variance of the treatment effect did decrease as sample size got larger, ranging from 
34% when the sample size was four to 21% when the sample size was eight, a 21% 
upperward bias for a sample size of eight still represents substantial bias.  These results 
were similar to previous research on two level organizational models, where Maas and 
Hox (2004) indicated a 25% upperward bias in the level-2 variance components with a 
level-2 sample size of 10 and a level-1 sample size of 5.   
Ferron, Owens, and Bell (2010), in an extension of past research to include more 
complex treatment effects and a larger number of participants, found results similar to 
Ferron et al. (2009).  Equations 12 - 16 contain the model that was under investigation.  
Equation 12 represents the first level of the multilevel model where the outcome ( ) 
was modeled as a function of time (centered so 0 represents the first point in treatment), a 
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dichotomous variable (0 = baseline, 1 = intervention), and the interaction between 
time and phase, 
 (12) 
where  is the predicted value of the baseline trajectory for participant j when time = 0 
or the first point in treatment,  is the baseline slope for participant j, is the 
treatment effect for participant j (i.e., the difference in predicted values between baseline 
and treatment trajectories for participant j) at the first point in treatment,  is the 
change in slope from baseline to treatment for participant j, and is the error at 
measurement occasion i for participant j, which accounts for the within-phase error 
variance.  At level-2 each of the level-1 coefficients was allowed to vary across 
participants, 
,  (13) 
, (14) 
, (15) 
and 
. (16) 
Results from Ferron, Owens et al. (2010) indicated that fixed effects coverage estimates 
for both the average treatment effect and average change in slope ranged from .917 to 
.962 and .908 to .963, respectively, when the Kenward-Roger degrees of freedom method 
was used.  In addition, as participants increased from three to 32, the average fixed 
effects confidence interval coverage for the Kenward-Roger method increased. 
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Ferron, Farmer, and Owens (2010) continued to research the statistical 
functioning of multilevel modeling. Ferron, Farmer et al. (2010) moved beyond average 
treatment effects and their variance components to examining the accuracy of individual 
treatment effects and their confidence intervals (model given in Equations 9 – 11).  The 
researchers conducted a Monte Carlo simulation study that examined multiple baselines 
of four, six, or eight; series lengths of 10,20, or 30 observations; and autocorrelation 
values of 0, .1, .2, .3, or .4.  The confidence intervals of the empirical Bayes estimates of 
the individual treatment effects (i.e.,  from Equation 9), using the Kenward-Roger 
method, provided accurate confidence intervals across all design factors studied.  The 
precision of the confidence interval width was widest utilizing the Kenward-Roger 
method but rapidly decreased as series length increased.  In addition, the confidence 
interval coverage showed variation across study conditions when the OLS method of 
estimation was used.  The confidence interval was accurate when no autocorrelation was 
simulated and tended to undercover when positive autocorrelation was simulated. This 
finding was not too surprising, given previous research that examined the utility of OLS 
methods in the presence of autocorrelation (Matyas & Greenwood, 1990; Toothaker, 
Banz, Noble, Camp, & Davis, 1983).  
In conclusion, the research examining the use of multilevel modeling (specifically 
two-level models) to analyze single-case data has been promising.  The degree to which 
multilevel modeling is functioning properly, under small sample sizes, depends on the 
type of parameter being estimated (Ferron et al., 2009).  If the focus is on the variance 
components and sample sizes are small, then the estimates will not be very accurate.  
However, if the focus is on the fixed effects, the parameter estimates are often accurate, 
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as long as the error structure is correctly specified and the Kenward-Roger degrees of 
freedom method is used. 
Meta-Analysis 
The quantitative integration of findings is a necessary component of all types of 
research. The ability to integrate findings across studies allows researchers to make 
statements about the relationships between variables and the effectiveness of 
interventions across varying study characteristics.  The idea of research synthesis and 
moving beyond statistical significance has been around since the early 1900s but was not 
termed meta-analysis until 1976, by Gene Glass (Cooper & Hedges, 2009).  Glass (1976) 
defines meta-analysis as “…the analysis of analyses…the statistical analysis of a large 
collection of analysis results from individual studies for the purpose of integrating the 
findings” (p.3).  Although Glass (1976) was technically the first to coin the term “meta-
analysis”, other researchers have been involved in expanding the analysis options 
available in terms of meta-analysis methods (Glass, McGaw, & Smith, 1981; Hedges & 
Olkin, 1985; Hunter, Schmidt, & Jackson, 1982; Rosenthal & Rubin, 1986). 
Meta-analysis provides many advantages when summarizing results across 
research studies.  One advantage of meta-analysis is that it is a structured and systematic 
research technique that is open to replication.  The steps involved in conducting a meta-
analysis are required to be well documented and therefore open to replication.  “By 
making the research summarizing process explicit and systematic, the consumer can 
assess the author’s assumptions, procedures, evidence, and conclusions rather than take 
on faith that the conclusions are valid” (Lipsey & Wilson, 2001, p. 6).  In addition, the 
analysis is more sophisticated than traditional review processes such as “vote-counting”.  
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Vote-counting is simply the process of taking all the studies measuring the relationship of 
interest and counting the number of statistically significant results and the number of 
non-statistically significant results.  The category with the most counts wins, so if 
numerous non-significant studies are found then the conclusion may be reached that there 
was not a relationship or effect.  This method becomes problematic because statistical 
significance is dependent on sample size, so studies with small samples may find effects 
that are meaningful but may not find statistically significant results due to low power 
(Lipsey & Wilson, 2001; Schmidt, 1996).  Another major advantage of meta-analysis is 
its ability to move beyond a qualitative review of study findings and into a more detailed 
analysis of the relationships between the study characteristics and the study findings.  
This analysis of the relationships between study characteristics and study findings is 
typically called a moderator analysis and provides a means of explaining possible 
variation in effect sizes (Lipsey & Wilson, 2001).  A final advantage of meta-analysis is 
its ability to handle a large number of studies.  The procedures involved in a meta-
analysis allow researchers to systematically keep track of study details without losing 
information.  Lipsey and Wilson (2001) did append this advantage by stating, “Meta-
analysis does not require large numbers of studies and, in some circumstances, can be 
usefully applied to as few as two or three study findings” (p.7).  
Individual Participant Data Versus Aggregate Data 
There are two forms of meta-analysis: aggregate data meta-analysis and 
individual participant data meta-analysis.  In an aggregate data (AD) meta-analysis the 
statistical synthesis is conducted by utilizing summary statistics from published and/or 
unpublished studies to calculate effect sizes and then statistically combining these effect 
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sizes in order to obtain an average effect size across studies as well as an associated 
confidence interval.  In contrast, an individual participant data (IPD; Cooper & Patall, 
2009) meta-analysis “…involves the central collection, checking, and re-analysis of the 
raw data from each study in order to obtain combined results” (p.166).  After the raw data 
is collected from each study and if the outcomes across studies have been measured the 
same then the data is pooled and re-analyzed using traditional inferential statistics 
(Cooper & Patall, 2009).  Although IPD meta-analyses are rare in large group social 
science literature, they have been extensively investigated in the medical literature. 
Table 2 provides a listing of the relative benefits of both the IPD and AD meta-
analysis.  According to Cooper and Patall (2009), two major benefits of AD meta-
analysis are that the meta-analysis can be done relatively quickly and with relatively low 
cost incurred to the meta-analyst, as compared to the IPD meta-analysis. Two benefits of 
the IPD meta-analysis are (a) the ability to perform subgroup analyses that were not 
performed by the original researchers; and (b) the ability to check the data for possible 
errors.  While it is evident that both have benefits over the other, it is obvious that when 
availability of the data is not an issue the benefits of IPD meta-analysis outweigh those of 
AD meta-analysis (Cooper & Patall, 2009).  However, obtaining individual data from 
large-group studies is highly unlikely and the use of AD meta-analysis will continue until 
such “data sharing” becomes available.  It is, however, commonplace to include 
individual level data in studies utilizing a single-case design.  This notion of having 
access to the individual participant data is certainly an advantage for single-case meta-
analysts.  Nevertheless, AD meta-analysis has historically been the focus of meta-
analysis literature. 
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Table 2 
Benefits of Individual Participant Data and Aggregate Data Meta-Analysis 
Individual Participant Data (IPD) Meta-Analysis 
Subgroup analyses that were not originally conducted can be performed 
Data from the original studies can be checked 
Ability to ensure that the original analyses were conducted properly, as well as 
standardization analyses across studies 
Complex analyses can be performed more easily 
New information can be added to the data sets 
Moderator analyses can be conducted with greater power, assuming all individual 
participant data sets are available 
Between-study and within-study moderator analyses can be performed 
Aggregate Data (AD) Meta-Analysis 
Cost, in both money and time, is less 
Time to complete analysis is faster 
Ability to include group-level statistics for which individual participant data are not 
available 
Bias could be decreased if study results are associated with availability of individual 
participant data 
Power could be increased to detect effects if many studies are available without 
individual participant data 
Note: From “The Relative Benefits of Meta-Analysis Conducted With Individual 
Participant Data Versus Aggregated Data,” by H. Cooper and E.A. Patall, 2009, 
Psychological Methods, 14, p. 172. Copyright 2009 by the American Psychological 
Association. Adapted with permission. 
 
Procedures 
A meta-analysis, or research synthesis, moves beyond the traditional literature 
search and combines data into a quantitative analysis.  However, prior to and after the 
analysis stage of the meta-analysis process there are several steps that also need to be 
considered.  Cooper (2007) outlines six stages of research synthesis.  The first stage is to 
define the problem.  This stage consists of identifying and defining variables and the 
relationships among those variables in order to identify the research studies that will be 
relevant to the problem of interest.  One characteristic of a good meta-analysis is an 
explicit statement about inclusion and exclusion criteria (Lipsey & Wilson, 2001).  This 
allows the readers of the meta-analysis to determine the specific research domain and the 
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criteria for why a study was included or not.  The second stage is to collect the research 
evidence. Specifically, identify sources (e.g., databases, journals, conference 
proceedings) and key terms needed to identify relevant studies.  During this stage meta-
analysts attempt to identify and locate every study defined within the specified research 
domain that meets the eligibility requirements.  The third stage is to evaluate the data.  
Once the relevant studies have been collected, specific information or data must be 
extracted from the studies in order to best synthesize the information to address the 
problem of interest.  Specifically, this stage involves the coding of data.  “The coding 
procedures for meta-analysis revolve around a coding protocol that specifies the 
information to be extracted from each eligible study”(Lipsey & Wilson, 2001, p.73).  The 
fourth stage consists of data analysis.  This stage involves the identification and 
application of specific statistical procedures to quantitatively integrate the data from each 
individual study.  In an AD meta-analysis, the distribution of effect sizes are analyzed to 
examine the variability and obtain an estimate of the average effect size and its 
corresponding confidence interval, as well as testing for differences among effect sizes.  
In an IPD meta-analysis, raw data are obtained from all studies and if the outcomes were 
measured the same across the studies then the data are pooled together and re-analyzed 
using “traditional inferential statistics or more sophisticated techniques” (Cooper & 
Patall, 2009, p. 166).  The fifth stage involves the interpretation of the analysis results.  
Meta-analysis methods allow researchers to make inferences about specific relationships 
and the average magnitude of effects sizes across studies.  The sixth and final stage is 
presenting the meta-analysis results.  This stage involves making judgments about what 
to report and how to disseminate findings to a broader audience.  
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Analysis Considerations and Methods 
Although there are many steps involved in the meta-analysis process, a major 
component and arguably the most defining feature is the analysis or quantitative 
integration of data across studies.  
IPD meta-analysis.  In an IPD meta-analysis raw data or individual participant 
data are obtained from each study and then each participant’s data are incorporated into 
an analysis option that is appropriate for the research questions.  The use of IPD meta-
analysis allows for many possible analysis options including MANOVA, multiple 
regression, structural equation modeling (SEM), or multilevel modeling.  However, a 
recent review of IPD meta-analyses indicated that the most common analysis option used 
was a two-stage process that consisted of obtaining the raw data in each study converting 
to a standardized effect size and then combining the effect sizes across studies. This 
process parallels the processes involved in an AD meta-analysis (Simmonds et al., 2005).    
AD meta-analysis.  In order to quantitatively integrate findings, an AD meta-
analyst needs an effect size from each included study.  “An effect size is a number that 
reflects the magnitude of the relationship between two variables” (Borenstein, 2009, p. 
220).  Specifically, an effect size represents the strength and direction of an effect.  There 
are various types of effect sizes, and their applicability is specific to the research 
problem.  For example, an effect size could represent how much a treatment (independent 
variable) impacted social skills (dependent variable) as compared to no treatment, or an 
effect size could represent an index of the relationship between two variables such as 
depression and alcoholism.  These effect sizes are then combined and compared in a 
meta-analysis.     
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Effect sizes provide standardized estimates, which allow us to combine them 
across studies.  If all studies investigated exactly the same constructs and used the same 
sample sizes and instruments, then combining effect sizes would be easy; all studies 
would be exact replicates of each other.  However, this is rarely--if ever--the case and 
meta-analysts must make certain decisions to determine how to combine studies that 
differ in many methodological and substantive ways (Shadish & Haddock, 2009).   
Therefore, Hershberger, Wallace, Green, and Marquis (1999) suggested that the method 
chosen for combining effect sizes across studies “must be able to provide overall 
estimates of treatment effectiveness and the precision of those estimates as well as 
assessments of the magnitude and direction of effects of other variables or factors on 
treatment effectiveness” (p.119).    
Weights.  As illustrated earlier, not all studies are exact replicates of each other 
and therefore it has been suggested in the literature to account for varying study 
characteristics by weighting each effect size.  Shadish and Haddock (2009) suggest that 
weighting schemes rest on three assumptions.  First, studies with certain characteristics 
are less biased, with regard to inferences, than studies with other characteristics. Second, 
prior to combing effect sizes, the bias of those characteristics can be estimated.  Third, in 
order to compensate for the bias, suitable weights can be calculated and are defensible.  
Several weighting schemes have been proposed in the literature and adequately address 
all three of the assumptions outlined previously (Hedges & Olkin, 1985; Hunter & 
Schmidt, 2004).  However, most of the literature relating to the weighting of effect sizes 
focuses on large-group studies.  The types of weights proposed for large-group studies, 
such as the inverse of the variance or the within study sample size, would not be 
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appropriate for use with single-case data due to the relatively small sample sizes used in 
these types of designs.  Therefore, some singe-case researchers have suggested weighting 
each effect size by the number of observations in the series (Shadish& Rindskopf, 2007; 
Faith, Allison, & Gorman, 1996). 
Calculating the effect size mean and distribution.  After gathering effect sizes 
from each study and choosing an appropriate weighting scheme, the effect sizes are 
statistically combined to describe the distribution of the effect sizes.  Specifically, means 
and confidence intervals are calculated.  The mean effect size represents a point estimate 
of the population effect size, and the confidence interval indicates a range of possible 
values in which the population effect size is likely to be.  The confidence interval 
provides a degree of precision around the mean effect size and can also be used to 
determine statistical significance in relation to the null hypothesis that there is no effect in 
the population (Lipsey & Wilson, 2001).  
Meta-analysis models.  Beyond calculating mean effect sizes and confidence 
intervals lies another important component of meta-analysis: homogeneity of the effect 
size distribution. Meta-analysts must decide if the effect sizes included in their estimate 
of the mean effect size are all estimating a single population effect size or are from a 
distribution of population effect sizes.  This decision leads meta-analysts to choose 
between two types of statistical models, fixed or random effects.   
A fixed effects model assumes a common effect size across all studies 
( ) (Shadish & Haddock, 2009).  In other words, in a fixed effects 
model it is assumed that one true effect size exists in the population, with variability 
being only due to sampling error.  In contrast, under a random effects model one would 
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not assume that one population effect size exists but rather a distribution of population 
effect sizes exists.  Therefore differences in effect sizes are based on underlying 
population differences and are not just due to sampling error.  
The decision whether to use a fixed or random effects model does not have one 
single correct answer.  Some would argue that conceptually the random effects model 
makes the most sense due to the fact that it reduces to the fixed effects model when the 
variance component is zero or when no random variation exists (Shadish & Haddock, 
2009).  Others would encourage the use of a homogeneity test statistic, such as the Q 
statistic (Hedges & Olkin, 1985).  This test allows the homogeneity of variance to be 
tested statistically, indicating that rejection of homogeneity implies that it is tenable to 
assume that the variability among effects sizes is greater than what could have occurred 
due to sampling error alone (Lipsey & Wilson, 2001).  However, the Q statistic has low 
power with small sample sizes and therefore may fail to reject homogeneity when in fact 
there is variability among the effect sizes that is due to more than just sampling error.  
Still others would argue that the choice of models depends on the inferences the 
researcher hopes to make (Hedges & Vevea, 1998). 
Threats to Validity 
Researchers have discussed several potential threats to the validity of inferences 
made from meta-analysis (Matt & Cook, 2009).  Some threats relate specifically to 
inferences about the association between an independent and a dependent variable, such 
as an intervention effect on an outcome variable. These possible threats are (a) 
unreliability in primary studies, (b) restriction of range, (c) missing effect sizes, (d) 
unreliability of meta-analytic codings, (e) increased Type I error rates, (f) sampling bias, 
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(g) dependent effect sizes, (h) failure to use weighted effect sizes, (i) inappropriate meta-
analysis model selection, and (j) lack of statistical power (Matt & Cook, 2009).  Although 
a single study’s deficiencies will not likely threaten the inferences made from a meta-
analysis, the occurrence of a deficiency across multiple, included studies can lead to 
increased Type I or Type II errors (Matt & Cook, 2009). 
Another often and most persistent criticism of meta-analysis is the notion of 
apples and oranges (Lipsey & Wilson, 2001).  The apples and oranges issue deals with 
the inclusion of studies that deal with a wide variety of different constructs and/or utilize 
different instruments to measure variables.  This becomes an issue when combining 
effect sizes across studies and calculating a grand mean effect size.  However, at the heart 
of meta-analysis is the examination of the distribution of effect sizes, and often of 
primary interest to the meta-analyst is the identification of sources of variability that are 
due to study differences (Lipsey & Wilson, 2001).    
Single-Case Meta-Analysis 
Although the use of single-case designs to evaluate interventions has grown in 
popularity over the last decade, their inclusion in meta-analyses and the methodological 
research encouraging their inclusion has been limited (Busk & Serlin, 1992; Busse, 
Kratochwill, & Elliott, 1995; Jenson, Clark, Kircher, & Kristjansson, 2007; Shadish & 
Rindskopf, 2007; Shadish, Rindskopf, & Hedges, 2008; Van den Noortgate & Onghena, 
2003b).  Most research involving meta-analysis has focused on large-group studies 
(Glass, 1976; Hedges & Olkin, 1985; Hunter & Schmidt, 1990; Rosenthal& Rubin, 1986) 
and while these methods have worked well with results from large-group comparison 
studies, there is still disagreement over the best way to meta-analyze results from single-
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case studies (Beretvas & Chung, 2008).  Nevertheless, the inclusion of results from 
single-case studies in meta-analyses is necessary for many reasons.  
The inclusion of single-case studies in meta-analysis allows for information about 
the overall treatment effect without losing information about the individual cases.  A 
single-case study involves the repeated measurement of one or a few cases over time, 
offering information on the variability in the treatment effect of individual cases. When 
several single-case studies are aggregated together, the overall treatment effect can be 
estimated as well as the effects for individual cases (Van den Noortgate & Onghena, 
2003a).  In addition, the aggregation of several single-case studies increases the 
generalizabilty of the findings.  A major criticism of single-case designs is their lack of 
generalizabilty, and by combining several single-case studies together, it becomes tenable 
to assume greater generalizabilty of the results.    
Analysis Options 
The earliest proposal for meta-analyzing single-case data dates back to 1984, 
where Gingerich proposed the use of meta-analysis methods developed by Smith, Glass, 
and Miller (1980).  Specifically, Gingerich (1984) proposed calculating a standardized 
mean difference between post-test and pre-test scores with the standard deviation of the 
pre-test scores serving as the standardizing unit.  Although his idea for synthesizing 
single-case data across studies was well intended, his suggestion for using Glassian meta-
analytic methods does not take into account the serial dependence among single-case 
data.  His argument in favor of this method is actually more of an argument against the 
notion that serial dependency or autocorrelation is a characteristic of single-case data, a 
questionable argument given the nature of the data.   
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Summary measures.  Following Gingerich’s (1984) proposal, a non-parametric 
or non-regression based method was proposed.  Scruggs, Mastropieri, and Castro (1987) 
suggested an approach to calculate the percentage of non-overlapping data (PND) 
between treatment and baseline phases.  The PND is calculated by identifying the number 
of data points in treatment that exceed the highest data point in baseline divided by the 
total number of data points in treatment and then multiplied by 100.  “When computation 
is completed, these outcome measures can be combined across studies to determine 
relative effectiveness of particular treatments” (Scruggs, Mastropieri, & Castro, 1987, 
p.27).  Although relatively easy to compute, the use of PND as a meta-analytic approach 
has several limitations (Allison & Gorman, 1993).  Allison and Gorman (1993) point out 
that the PND has the potential to misrepresent treatment effects when there is a trend in 
the data, outliers are present in the treatment phase, and the treatment has had a negative 
effect on the outcome.  In addition, this proposed single-case meta-analytic approach 
does not take into consideration specific meta-analysis considerations such as the 
weighting of effect sizes or the use of appropriate meta-analytic models (i.e., fixed or 
random effects). 
Busk and Serlin (1992) suggest that the most appropriate effect size measure for 
both between- and within- subject experiments, given the assumptions of equality of 
variance and compound symmetry, is the standardized mean difference effect size, where 
the denominator is the square root of the mean square error in the design.  The authors 
describe four advantages for this type of effect size.  
 First, one single definition holds for all experimental designs.  Second, because 
the distribution of the effect-size measure is known, one can test the effect size 
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directly and build a confidence interval for it. Third, Hedges and Olkin’s meta-
analytic techniques can be used, because they are based on large-sample, normal 
approximations to the noncentral t distribution. And fourth, it is straightforward to 
convert individual ts to effect sizes. (Busk & Serlin, 1992, p. 195) 
However, if the assumptions needed to pool the within-phase variances are not met, then 
other methods are needed to calculate and test the effect size measure. Busk and Serlin 
(1992) present three approaches to obtain the effect size estimate.  The three approaches 
differ in the assumptions concerning the population distribution form and equality of 
variances.  The first approach, the Glassian original effect size estimate, makes no 
assumptions and the standardized mean difference score is calculated by taking the 
difference between the baseline and treatment phase means and dividing by the baseline 
standard deviation.  
The second approach assumes equality of variances across the baseline and 
treatment phases but still makes no assumption about the population distribution form.  In 
this approach the within-phase variances are pooled to obtain better estimates of the 
effect size.  In the third approach, assumptions are made about the population distribution 
as well as about equality of variances across baseline and treatment phase.  Calculation of 
the effect size measure doesn’t change; however, by making the assumption that the 
phase scores are from a normal distribution and that the within-phase variances are equal, 
the distribution of the effect size is considered to follow a noncentral t distribution and 
confidence intervals can be constructed for the individual effect estimates.  In addition, 
with the assumption of a normal distribution large-group meta-analytic methods can be 
used to synthesize effects across studies.  
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The third approach is most in line with what meta-analysts are hoping to do; 
however, most single-case data do not adhere to these strict assumptions of equality of 
variances, compound symmetry, and normality of the distribution across baseline and 
treatment phases.  Therefore, the use of confidence intervals and meta-analytic 
procedures that allow for the testing of specific hypotheses becomes inappropriate and 
limits the amount of information available to the meta-analysts.  In addition, the formula 
suggested by Busk and Serlin (1992) when no assumptions can be made yields a 
numerator and denominator that are not independent of each other and can no longer be 
used in large-group meta-analytic methods for combining effect sizes across studies. 
Inferential statistics.  Beyond the proposal of specific summary measures, other 
researchers have suggested the use of various inferential tests to meta-analyze single-case 
data (Allison & Gorman, 1993; Center, Skiba, & Casey, 1985-1986; Onghena & 
Edgington, 2005; Van den Noortgate & Onghena, 2003a, 2003b, 2007, 2008).  Onghena 
and Edgington (2005) propose the use of p value combining, based on the use of 
randomization tests, as a method to meta-analyze single-case data.  The authors 
demonstrate that if the single-case experiments used in a meta-analysis provide 
independent tests of the same null hypothesis, then the p values can be combined by 
summing the p values across studies and comparing the sum to all other possible sums 
that could have occurred. The proportion of summed p values that is as small or smaller 
than the observed summed p value is then calculated to determine if the overall treatment 
effect is significant.  Although the use of randomization tests does provide a meta-analyst 
with information related to whether there was or was not a treatment effect, it does not 
provide an estimate of the size of that treatment effect or the ability to test the impact of 
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other variables on the treatment effect.  In addition, it has been well documented that p 
values are influenced by the size of the treatment effect as well as the number of 
observations included in the analysis (Onghena & Edgington, 2005).  
A series of regression methods have also been suggested for use in meta-
analyzing single-case data. Center, Skiba, and Casey (1985-1986) proposed the use of a 
piecewise regression technique that utilized raw data from individual single case studies. 
The technique used the following model: 
 (17) 
where represents the number of points in baseline, is a term for change in level, 
is a term for the baseline trend, and  is an interaction term to measure the 
change in slope due to the treatment.  This technique produces two separate effect sizes 
( ), which can make interpretation more complicated.  However, based on what we 
know about single-case data, attempting to represent treatment effectiveness with an 
effect size that only illustrates a change in level would not adequately account for 
changes in slope or the combined effects of level and slope changes.   
Center, Skiba, and Casey (1985-1986) also proposed computing one effect size by 
calculating a difference in values between the full model (given in Equation 17) and a 
model without each of the parameters ( ), and then converting that difference in  
values into an F-statistic, which can be converted to an often recognized and easily 
interpretable d effect size.  By allowing investigation of changes in both slope and level 
this model proved to be a significant improvement over what was available at the time.  
Nevertheless, this technique did not take into account the autocorrelational nature of 
single case data and assumed that errors of successive observations were independent.  In 
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addition, none of the methods up to this point acknowledged crucial meta-analytical 
issues such as the use of fixed or random effects models, the weighting of effect sizes, or 
the use of multiple effect sizes per study. 
Allison and Gorman (1993) modified the method proposed by Center, Skiba, and 
Casey (1985-1986) to address concerns inherent in the model.  Three specific problems 
were discussed and the model was improved upon to rectify these problems.  The first 
problem was that under certain conditions the model could overestimate the effects of 
trend and thereby underestimate the overall effect size.  Allison and Gorman (1993) 
corrected for this by computing trend on the baseline data only instead of across both 
phases.  The second problem was that due to the nature of how the effect size is 
calculated, the effect can never go below zero.  This is problematic because it is not 
consistent with the notion that sometimes treatments can have a negative impact and 
worse results can be produced.  This problem was corrected for by recommending the 
application of the appropriate sign as indicated by the regression coefficient.  The third 
problem was that the effect could be overestimated due to an increase in predictability of 
the dependent variable, regardless of whether or not the change was in the intended 
direction or not (Alison & Gorman, 1993).  In order to address the third problem, the 
authors recommend that if the zero-order correlations have different signs, simply 
estimate the change in level because the change in slope will automatically attenuate its 
effect (Allison & Gorman, 1993).  This model was again a significant improvement over 
the previous models but still did not take into account autocorrelation or key meta-
analytic issues, such as weighting of effect sizes, independence of effect sizes, and meta-
analytic model selection.  
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Although each of these models provided advances on their predecessors, they still 
leave much to be desired in the form of meta-analyzing single case data.  Specifically, a 
method needs to be able to address the issue of autocorrelation, the standardization of 
effect sizes for combination across studies, and the use of a meta-analytical method that 
allows the further investigation of variability in effect sizes.  The use of multilevel 
modeling provides the tools to be able to accomplish all of these goals.    
Van den Noortgate and Onghena (2003a, 2003b, 2007, 2008) proposed the use of 
multilevel modeling to aggregate single-case data for the purposes of meta-analysis.  The 
authors have suggested aggregating single-case data in three different ways.  The first 
option includes individual level raw data from each primary study in the meta-analysis 
and makes the assumption that all dependent variables across studies are measured the 
same way.  Van den Noortgate and Onghena (2008) illustrated this first option in a series 
of models provided in Equations 18 through 22.  
Equation 18 represents within person variation, which can be modeled with a 
basic regression equation. Specifically, an outcome (y) is modeled on measurement 
occasion i for participant j in study k ( ) as a linear function of a single predictor, 
phase:  
 (18) 
where phase represents a dummy coded variable indicating whether measurement 
occasion i took place during the baseline (0) or treatment (1) phase. is the level of the 
outcome during baseline for participant j from study k,  is the treatment effect for 
participant j from study k , and  is within-phase error variance. 
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 At the second level, the variation across participants is modeled in the following 
equations: 
 (19) 
and 
 (20) 
where the fixed effects are ,the average baseline level for study k, and  ,the 
average treatment effect for study k, and the error terms are  and   that allow 
variation in both baseline levels and treatment effects among participants within study k. 
 At the third level, the variation across studies is modeled in the following 
equations: 
 (21) 
and 
 (22)   
where the fixed effects are ,the  overall average baseline level, and , the overall 
average treatment effect, and  the error terms are  and , which allow variation in 
both the average baseline levels and average treatment effects among studies. It should be 
noted that errors on all levels were assumed to be independently normally distributed and 
have a mean of zero.  However, multilevel models are quite flexible and the use of a 
complex covariance structure, such as a first order auto regressive structure, is possible to 
account for dependent errors. 
Van de Noortgate and Onghena’s (2008) second option assumes the dependent 
variable is measured differently across studies and therefore scores from individuals need 
to be standardized before combining them into one analysis.  First, the individual level 
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raw data are standardized by performing an OLS regression for each participant 
separately and dividing their scores by each resulting root mean squared error and then 
combining the data into the models defined in Equations 18 through 22 (Van den 
Noortgate & Onghena, 2008).   
The third option proposed by Van den Noortgate and Onghena (2008) does not 
include individual level data from each study in the meta-analysis.  Instead, standardized 
regression coefficients are calculated for each study and included in the meta-analysis as 
effect sizes representing a standardized change in level and change in slope.  In this 
option, Equation 18 needs slight modifications to appropriately meta-analyze single-case 
data.  The first level of the model is adapted to model the effect sizes or standardized 
regression coefficients from each study rather than the individual level data: 
 π
 0 jk = π0 jk + ejk      (23) 
with  π
 0 jk  representing the observed effect size for participant j in study k modeled as the 
true effects size ( ) for participant j in study k plus some random variation or error 
( ), where the level-1 error variance matrix is assumed known.  The second and third 
level equations (see Equations 19 – 22) describing variation across participants and 
between studies remain the same.   
Multilevel modeling estimates (co) variance at each level but typically only 
estimates fixed effect parameters at the highest level.  Therefore, variance and covariance 
estimates across all levels and fixed effects at the third level, the average baseline across 
studies and the average treatment effect across studies can be reported.  These types of 
parameter estimates offer the ability not only to provide information on the overall 
treatment effect but also information related to the variability of that overall average 
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treatment effect.  In addition, predictors can be added to the model to account for that 
variability.  
Van den Noortgate and Onghena (2008) argue that single-case study conclusions 
are restricted to the participants which were investigated, but multilevel modeling 
provides the ability to combine results from multiple participants and studies to gain 
information about not only the average treatment effect but also if and how the treatment 
effect varies across participants and studies.  Another advantage of multilevel modeling is 
that it can be used to aggregate data from single-case studies that include multiple 
participants.  This use of multiple data sources or effect sizes from the same study is 
typically problematic and has not been addressed by other proposed single-case meta-
analytic methods.  Multilevel modeling is structured to account for that “nesting” of data 
within studies by allowing variation within participants, between participants of the same 
study, and between studies (Van den Noortgate & Onghena, 2008).   
 Although all of the previous simulation research on multilevel modeling of single-
case data (Ferron et al., 2009; Ferron, Farmer et al., 2010; Ferron, Owens et al., 2010) has 
focused on two-level models and the use of a three-level model has only been applied to a 
real world data set (Van den Noortgate & Onghena, 2008), the results have been 
encouraging.  These findings provide motivation in the pursuit of empirically evaluating 
the utility of inferences made from a three-level model to meta-analyze single-case data.   
Applications of Single-Case Meta-Analysis 
 Beretvas and Chung (2008a) conducted a narrative review of single-case meta-
analyses that took place between 1985 and 2005; 24 articles were identified.  Their 
results indicated that the most commonly used metric to summarize study results was the 
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PND, and it was most commonly used in combination with percent zero data (PZD). The 
next most popular effect size utilized was the standardized mean difference in various 
forms.  Also, a form of time series analysis was used by a small percentage of studies, as 
well as the use of piecewise regression, which was incorrectly specified both times it was 
reported.   
Although most of the meta-analyses reviewed by Beretvas and Chung (2008a) 
focused on studies using more complex designs (e.g., multiple baseline, reversal, 
alternating treatment) than a simple AB design, the most common metric used to 
summarize results only focused on the comparison of an intervention phase to a baseline 
phase.  This focus can lead to a dependence of outcomes yielded by the same metric 
(Beretvas & Chung, 2008a).  The results of Beretvas and Chung’s (2008a) review 
indicated that the majority of meta-analyses reviewed did not clearly state how this 
dependence was handled.  When analyzing multiple treatments per study, the most 
common method reported was to average the indices together.  Further, when addressing 
the use of multiple measures per study, the majority of studies analyzed results separately 
for each measure and when multiple participants per study were involved, most of the 
meta-analyses ignored the dependence and treated each effect size as independent 
(Beretvas & Chung, 2008a).  In terms of analyses conducted, the majority of meta-
analyses simply averaged the effect sizes together.  In addition, a few studies performed 
moderator analyses to explore variability in the effect sizes.  
Farmer, Owens, Ferron and Allsopp (2010a) also conducted a review of single-
case meta-analyses.  Farmer et al. (2010a) searched for single-case meta-analyses that 
were conducted from 1999-2009.  Their search yielded 39 articles for inclusion.  Most of 
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the meta-analyses were related to education, with the majority in special education.  The 
majority of meta-analyses provided clear search procedures but did not tend to include 
detailed information about the primary study characteristics (Farmer et al., 2010a).  
However, when primary study information was provided, the meta-analyses reported the 
use of studies that included more complex designs and tended to exclude simple AB 
designs and those studies with less than three points per phase.  Similar to Beretvas and 
Chung (2008), the most common metric reported was the PND, and the majority of 
studies computed averages of the effect sizes.  The meta-analytic review also noted that 
limited information was provided regarding effect size calculation, meta-analytic method 
used, and any further analyses (e.g., moderator analyses) that were conducted.  Farmer et 
al. (2010a) cautioned single-case meta-analysts on the dangers of not providing enough 
information to their readers and concluded with a suggestion that a table be included in 
future single-case meta-analyses identifying the types of single-case designs used, the 
phases used in the calculation of the effect sizes, and the number of effect sizes used from 
each study.  
Summary 
Single-case designs provide the ability to intensively study the effect of a 
treatment on a single case over time.  The popularity of these designs has grown rapidly 
over the past decades to include research in school psychology (Skinner, 2004), special 
education (Algozzine, Browder, Karvonen, Test, & Wood, 2001), teacher education 
(Hsieh, Hemmeter, McCollum, & Ostrosky, 2009), and behavioral intervention research 
(Filter & Horner, 2009).  However, the integration of single-case designs in meta-analytic 
research has been far less frequent (Busk & Serlin, 1992; Busse, Kratochwill, & Elliott, 
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1995; Jenson, Clark, Kircher, & Kristjansson, 2007; Shadish & Rindskopf, 2007; 
Shadish, Rindskopf, & Hedges, 2008; Van den Noortgate & Onghena, 2003b).  This 
infrequency may be due to the lack of methodological consensus on how to best 
synthesize single-case results across studies.  Several methods have been proposed, such 
as the combining of the PND across studies (Scruggs, Mastropieri, & Castro 1987), the 
calculation of a standardized mean difference and use of traditional large-group meta-
analytic methods (Busk & Serlin, 1992), the combining of p values through the use of 
randomization tests (Onghena& Edgington, 2005), several regression based methods that 
account for changes in level and slope (Casey, Center, & Skiba, 1985-1986; Allison & 
Gorman, 1993), and the use of multilevel modeling (Van den Noortgate & Onghena, 
2003a, 2003b, 2007, 2008).  Among these methods, multilevel modeling has been 
recommended for use with single-case meta-analytic data due to features of the model 
that can handle characteristics of the data that are often problematic for other analysis 
options.  However, further investigation into the utility of the inferences made from 
multilevel modeling is necessary to provide guidance to future single-case meta-analysts.  
Furthermore, the empirical evaluation of a three level single-case meta-analytic model 
under conditions that are similar to the field of social science is needed.  Therefore, this 
study examined the utility of Van den Noortgate and Onghena’s (2008) raw data 
multilevel modeling approach to the meta-analysis of single-case data.  Specifically, the 
quality of the fixed effects (i.e., the overall average baseline level and the overall average 
treatment effect) and the variance components (e.g., the between person within study 
variance in the average baseline level, the between study variance in the overall average 
baseline level, the between person within study variance in the average treatment effect) 
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in a three level multilevel model were examined.  More specifically, it investigated 
confidence interval coverage rates, confidence interval widths, and bias of the point 
estimates as a function of specific design and data factors.  The raw data option was the 
most fitting method to first evaluate, as it is the most basic model of Van den Noortgate 
and Onghena’s (2008) three proposed options.        
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CHAPTER THREE: METHOD 
This chapter outlines the methods for this study, including the purpose, research 
questions, sample, and design. 
Purpose 
The purpose of this study was to examine the appropriateness of Van den 
Noortgate and Onghena’s (2008) raw data multilevel modeling approach to the meta-
analysis of single-case data. Specifically, the study examined the fixed effects (i.e., the 
overall average baseline level and the overall average treatment effect) and the variance 
components (e.g., the between person within study variance in the average baseline level, 
the between study variance in the overall average baseline level, the between person 
within study variance in the average treatment effect) in a three level multilevel model.  
More specifically, it investigated bias of the point estimates, confidence interval 
coverage, and confidence interval width as a function of specific design and data factors, 
such as the number of primary studies per meta-analysis, modal number of participants 
per primary study, modal series length per primary study, level of autocorrelation, and 
variances of the error terms. 
Research Questions 
1. To what extent are the fixed effect estimates from a three level meta-analytic 
single-case model biased as a function of specific design factors (number of 
primary studies per meta-analysis, modal number of participants per primary 
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study, modal series length per primary study, level of autocorrelation, and 
variances of the error terms)? 
2. To what extent does the confidence interval coverage of the fixed effect estimates 
from a three level meta-analytic single-case model vary as a function of specific 
design factors  (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
3. To what extent does the confidence interval width of the fixed effect estimates 
from a three level meta-analytic single-case model vary as a function of specific 
design factors  (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
4. To what extent are the variance components from a three level meta-analytic 
single-case model biased as a function of specific design factors  (number of 
primary studies per meta-analysis, modal number of participants per primary 
study, modal series length per primary study, level of autocorrelation, and 
variances of the error terms)? 
5. To what extent does the confidence interval coverage of the variance components 
from a three level meta-analytic single-case model vary as a function of specific 
design factors  (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
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6. To what extent does the confidence interval width of the variance components 
from a three level meta-analytic single-case model vary as a function of specific 
design factors  (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
Design 
This study utilized a 3 X 2 X 3 X 3 X 2 factorial design. The factorial design 
included five independent variables: (1) number of primary studies per meta-analysis (10, 
30, and 80); (2) modal number of participants per primary study (small [mode = 4] and 
large [mode = 8]); (3) modal series length per primary study (small [mode = 10], medium 
[mode = 20], and large [mode = 30]); (4) level of autocorrelation (0, .2, and .4); and (5) 
variances of the error terms (most of the variance at level-1 [ = 1, = .2, and 
= .05] and most of the variance at level-2 [ = 1, = 2, and 
= .5]).  For each of the 108 conditions, 5,000 data sets were simulated using 
SAS IML (SAS Institute Inc., 2008).  
The dependent variables were bias, the average difference between the known 
parameter value and the parameter estimate for both the fixed effects (  and ) and 
the variance components ( , , , , , and  ρ
  ), confidence interval 
coverage, the proportion of 95% confidence intervals that contain both the fixed effects 
estimates and the variance components, and confidence interval width, the average 
difference between the upper and lower limits of the 95% confidence intervals for both 
the fixed effects and the variance components.  
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Five experimental variables were examined: (1) number of primary studies per 
meta-analysis, (2) modal number of participants per primary study, (3) modal series 
length per primary study, (4) level of autocorrelation, and (5) variances of the error terms.  
Of these variables, (1), (2), and (3) represent aspects of the meta-analysis, (4) represents 
aspects of the primary studies within the meta-analysis, and (5) represents aspects of both 
the meta-analysis and the primary study data.  
Sample 
Crossing the two variance levels of the error terms with the three levels of 
autocorrelation, a total of six data conditions were examined for each of 18 combinations 
of number of primary studies per meta-analysis, modal number of participants per 
primary study, and modal series length per primary study.  For each of the 108 conditions 
(6*18), 5,000 data sets will be simulated using SAS IML (SAS Institute Inc., 2008).  The 
use of 5,000 replications leads to a standard error of .003 when coverage is .95, which is 
an adequate level of precision when estimating coverage.  
The sample for this study was generated through Monte Carlo simulation 
methods.  The sample generation consisted of two aspects: (1) primary study 
characteristics and (2) meta-analytic characteristics.  The primary study characteristics 
were based on specific values of the following factors: level of autocorrelation, and 
variances of the level-2 error terms.  The number of primary studies included in each 
meta-analysis, the modal number of participants per primary study, the modal series 
length per primary study, and the variances of the level-3 error terms address 
characteristics of the meta-analysis. The factors used to define the simulated data are 
further defined below. 
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Conditions Sampled 
Number of primary studies per meta-analysis.  The number of primary studies 
in each meta-analysis had three levels (10, 30, or 80). These values were chosen based on 
a review that was conducted by Farmer, Owens, Ferron, and Allsopp (2010b) on 39 
single-case meta-analyses in social science between the years of 1999 and 2009.  Farmer 
et al. (2010b) found that the number of primary studies included in the meta-analyses 
ranged from 3 to 117, with 60% of the meta-analyses including less than 30 primary 
studies.  
Modal number of participants per primary study.  The modal number of 
participants per primary study had two levels (small and large).  The small category 
contained 70% of primary studies with four participants, 20% of primary studies with six 
participants, and 10% of primary studies with eight participants in each meta-analysis, 
indicating a mode of 4 and an average of 4.7 participants per primary study.  The large 
category contained 70% of primary studies with eight participants, 20% with six 
participants, and 10% with four participants in each meta-analysis, indicating a mode of 8 
and an average of 7.2 participants per primary study.  These categories were defined 
based on findings from Farmer et al. (2010b), where the average number of participants 
per study ranged from 1.4 to 30.67, with 93% of those values falling at or below seven 
and Ferron, Farmer et al. (2010), who found in multiple baselines designs the number of 
participants ranged from 3 to 10, with a median of 4.  In addition, these levels were 
chosen based on recommendations of a minimum of four baselines and upwards of eight 
or nine to show treatment effects across behaviors, persons, or settings (Kazdin, 2011). 
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Modal series length per primary study.  The modal series length per primary 
study had three levels (small, medium, and large).  The small level contained 70% of 
primary studies with series lengths of 10, 20% of primary studies with series lengths of 
20, and 10% of primary studies with series lengths of 30 in each meta-analysis, indicating 
a mode of 10 and an average series length of 14 per primary study.  The medium level 
contained 70% of primary studies with series lengths of 20, 20% of primary studies with 
series lengths of 10, and 10% of primary studies with series lengths of 30 in each meta-
analysis, indicating a mode of 20 and an average series length of 19 per primary study.  
The large level contained 70% of primary studies with series lengths of 30, 20% with 
series lengths of 10, and 10% with series lengths of 20 in each meta-analysis, indicating a 
mode of 30 and an average series length of 25 per primary study.  These categories were 
chosen to represent a range of possible values in single-case meta-analyses.  These levels 
were chosen based on the consistency with previous simulation studies investigating the 
use of multilevel modeling as a method of analyzing single-case data where series length 
of 10, 20, and 30 were modeled (Ferron et al., 2009; Ferron, Farmer et al., 2010b; Ferron, 
Owens et al., 2010a). In addition, Ferron, Farmer et al. (2010) conducted a survey of 
multiple baseline studies published in 2008 and found that average series lengths ranged 
from seven to 58 with a median of 24.  
Level of autocorrelation.  The level of autocorrelation in the primary studies was 
0, .2, or .4.  These values cover the range of possible autocorrelation values typically 
found in behavioral studies (Busk & Marascuilo, 1988; Huitema, 1985; Matyas & 
Greenwood, 1996).  In addition, these values were consistent with past simulation studies 
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that investigated the utility of multilevel modeling (Ferron et al., 2009; Ferron, Farmer et 
al., 2010; Ferron, Owens et al., 2010).  
Variances of the error terms.  The variances of the error terms were comprised 
of two categories.  The first category modeled the data to have most of the variance at 
level-1 or within person, with values of 1 for the level-1 error term, .2 for the level-2 
error terms, and .05 for the level-3 error terms.  The second category modeled the data to 
have most of the variance at level-2, with values of 1 for the level-1 error variance, 2 for 
the level-2 error variances, and .5 for the level-3 error variances.  These values covered a 
range of possible values, such as those presented in Van den Noortgate and Onghena 
(2008) and previous simulation research (Ferron et al., 2009).  In addition, the variance in 
the average baseline levels equaled the variance in the average treatment effects.  
Constraining the level-2 variances to be equal was consistent with previous simulation 
research (Ferron et al., 2009; Ferron, Farmer et al. 2010; Ferron, Owens et al., 2010). 
Data Generation 
Data was generated based on Van den Noortgate and Onghena’s (2008) raw data, 
three level, single-case meta-analytic model shown in Equations 24 through 28. The raw 
data method was chosen as it is the most basic model and therefore was the most logical 
model to first evaluate.  At the first level, an outcome (y) was modeled on measurement 
occasion i for participant j of study k ( ) as a linear function of a single-predictor, 
phase: 
 (24) 
where phase was a dichotomous variable indicating whether a measurement occasion or 
observation occurred during baseline or treatment phase, was the level of the outcome 
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during baseline for participant j from study k,  was the treatment effect for participant 
j from study k , and  was within-phase error variance.  This within-phase participant 
model was consistent with the multilevel modeling application presented by Van den 
Noortgate and Onghena (2008).  In addition, it was the most basic interrupted time-series 
model (e.g., no trends or changes in trends); therefore it was the most logical model for 
an initial study into the three level meta-analytic modeling of single-case data.  If 
estimation problems occurred in the simplest model one would suspect that those same 
problems would likely occur in any further complex model.  Errors for the within 
participant model ( ) were generated using the ARMASIM function in SAS version 9.2 
(SAS Institute, 2008) with a variance of ( ) of 1.0 and autocorrelation values of 0, .2, 
or .4, as previously discussed. 
At the second level, the variation across participants was modeled using the 
following equations: 
 (25) 
and 
 (26) 
where the fixed effects were , the average baseline level for study k, and  , the 
average treatment effect for study k, and the error terms are  and  that allowed 
variation in both baseline levels and treatment effects among participants.Level-2 errors 
were generated from a normal distribution using the RANNOR random number generator 
in SAS version 9.2 (SAS Institute Inc., 2008).  The variance of the level-2 errors were 
defined based on the previously discussed levels of .2 or 2 and the covariance between 
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 and was set to 0.  The covariance between the level-2 errors was set to zero which 
was consistent with past simulation research (Ferron et al., 2009; Ferron, Farmer et al. 
2010; Ferron, Owens et al., 2010), as well as Van den Noortgate and Onghena’s (2003a, 
2007) application of multilevel modeling to single-case data.    
At the third level, the variation across studies was modeled using the following 
equations: 
 (27) 
and 
 (28)   
where the fixed effects were , the  overall average baseline level, and , the 
overall average treatment effect, and  the error terms are  and , which allowed 
variation in both the overall average baseline level and overall average treatment effect 
among studies.  Level-3 errors were generated from a normal distribution using the 
RANNOR random number generator in SAS version 9.2 (SAS Institute Inc., 2008).  The 
fixed effects (  and ) were set to 1.0.  The variance of the level-3 errors were 
defined based on the previously discussed levels of .05 or .5 and the covariance between 
 and was set to 0.  The covariance between the level-3 errors was set to zero 
which was consistent with past simulation research (Ferron et al., 2009; Ferron, Farmer et 
al. 2010; Ferron, Owens et al., 2010), as well as Van den Noortgate and Onghena’s 
(2003a, 2007) application of multilevel modeling to single-case data.    
Analysis of Each Simulated Meta-Analytic Data Set 
Each data set was analyzed using the same model that was used for data 
generation (see Equations 24 - 28).  The three level model was estimated using restricted 
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maximum likelihood (REML) via PROC MIXED with the Kenward-Roger degrees of 
freedom method in SAS version 9.2 (SAS Institute Inc., 2008).  In addition, a first order 
auto-regressive model for the level-1 errors was specified.  Based on the current model, 
the treatment effect was modeled as a change in level, and estimates were obtained for 
autocorrelation, variance within participants, variance in baseline levels across 
participants and studies, and variance in treatment effects across participants and studies.   
The estimated models were checked for consistency with data generation.  Several 
checks were used to verify the accuracy of the simulation program by running the 
program for a small number of replications.  The vectors created during data generation 
were examined for consistency with data specifications, output data sets from the PROC 
MIXED statements were created to ensure the intended models were being analyzed and 
the summary statistics from those data sets were compared to the output data sets for 
accuracy.   
Analysis to Estimate Bias of the Point Estimates, Confidence Interval Coverage and 
Confidence Interval Width 
For each of the 108 combinations of the five independent variables, bias of the 
fixed effects (  and ) and the variance components ( , , , , , and 
 ρ
 ) and confidence interval coverage and width of the fixed effects and variance 
components were the dependent variables.  Bias was calculated as the average difference 
between the known parameter value and the estimated parameter value. More formally, 
 
bias =
Σk=1
5000 γ1h − γ1h( )
5000  (29) 
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where  γ

1h  was the estimated parameter from the h
th simulated meta-analysis, and was 
the simulated parameter value from the hth simulated meta-analysis.  Relative bias was 
also calculated for those parameters whose known value was anything other than 1.0 so 
that bias could be represented as a percentage of the known parameter value.  More 
formally, 
 
bias =
Σk=1
5000 γ1h − γ1h
γ1h
⎛
⎝⎜
⎞
⎠⎟
5000  (30) 
where  γ

1h  was the estimated parameter from the h
th simulated meta-analysis, and was 
the simulated parameter value from the hth simulated meta-analysis.  Coverage was 
calculated as the proportion of the 95% confidence interval that contained the parameter 
value, and width was calculated as the average difference between the upper and lower 
limits of the 95% confidence intervals.  Bias, coverage, and width estimates were 
calculated based on values that were summarized across all 5,000 replications.   
Analyses to Examine Relationships Between Design Factors and Bias of the Point 
Estimates, Confidence Interval Coverage, and Confidence Interval Width 
Research Question One 
Research Question One, evaluation of the bias of the fixed effect estimates from 
the three level meta-analytic single-case model were addressed by examining box and 
whisker plots to illustrate the distribution of the bias estimates of the fixed effects.  In 
addition, generalized linear modeling (GLM) was used to examine variability of each of 
the bias estimates of the fixed effects as a function of the independent variables.  Models 
were built with the purpose of finding effects whose eta-squared values .06 or greater. 
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The effects size, eta-squared ( ), was calculated to determine the proportion of 
variability associated with each effect.  Those values were compared to Cohen’s (1988) 
standards for interpreting eta-squared values with a small effect size having an = .01, .a 
medium effect size having an = .06, and a large effect size having an  = .14 or 
greater.  Each model was first created as a main effects only model.  If this model 
explained 94% of the total variability then no further complex models were investigated.  
However, if less than 94% of the total variability was explained then interactions were 
included in the model.  Two-way interactions were added to the model first followed by 
three-way and then four-way interactions until at least 94% of the variability was 
explained.  Finally, line graphs were created to show bias estimates of the fixed effects as 
a function of the independent variables (both main effects and interactions) that had eta-
squared values of .06 or higher.  
Research Question Two 
Research Question Two, evaluation of the confidence interval coverage of the 
fixed effect estimates from a three level meta-analytic single-case model, were addressed 
by examining box and whisker plots to illustrate the distribution of the confidence 
interval coverage estimates of the fixed effects.  In addition, GLM was used to examine 
variability of each of the confidence interval coverage estimates of the fixed effects as a 
function of the independent variables.  Models were built with the purpose of finding 
effects whose eta-squared values .06 or greater. The effects size, eta-squared ( ), was 
calculated to determine the proportion of variability associated with each effect.  Those 
values were compared to Cohen’s (1988) standards for interpreting eta-squared values 
with a small effect size having an = .01, .a medium effect size having an = .06, and 
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a large effect size having an  = .14 or greater.  Each model was first created as a main 
effects only model.  If this model explained 94% of the total variability then no further 
complex models were investigated.  However, if less than 94% of the total variability was 
explained then interactions were included in the model.  Two-way interactions were 
added to the model first followed by three-way and then four-way interactions until at 
least 94% of the variability was explained.  Finally, line graphs were created to show 
confidence interval coverage estimates of the fixed effects as a function of the 
independent variables (both main effects and interactions) that had eta-squared values of 
.06 or higher.  
Research Question Three 
Research Question Three, evaluation of the confidence interval width of the fixed 
effect estimates from a three level meta-analytic single-case model, were addressed by 
examining box and whisker plots to illustrate the distribution of the confidence interval 
width estimates of the fixed effects.  In addition, GLM was used to examine variability of 
each of the confidence interval precision estimates of the fixed effects as a function of the 
independent variables.  Models were built with the purpose of finding effects whose eta-
squared values .06 or greater. The effects size, eta-squared ( ), was calculated to 
determine the proportion of variability associated with each effect.  Those values were 
compared to Cohen’s (1988) standards for interpreting eta-squared values with a small 
effect size having an = .01, .a medium effect size having an = .06, and a large effect 
size having an  = .14 or greater.  Each model was first created as a main effects only 
model.  If this model explained 94% of the total variability then no further complex 
models were investigated.  However, if less than 94% of the total variability was 
	  71 
explained then interactions were included in the model.  Two-way interactions were 
added to the model first followed by three-way and then four-way interactions until at 
least 94% of the variability was explained.  Finally, line graphs were created to show 
confidence interval width estimates of the fixed effects as a function of the independent 
variables (both main effects and interactions) that had eta-squared values of .06 or higher.  
Research Question Four 
Research Question Four, evaluation of the bias of the variance components from a 
three level meta-analytic single-case model, were addressed by examining box and 
whisker plots to illustrate the distribution of the bias estimates of the variance 
components.  In addition, GLM was used to examine variability of each of the bias 
estimates of the variance components as a function of the independent variables.  Models 
were built with the purpose of finding effects whose eta-squared values .06 or greater. 
The effects size, eta-squared ( ), was calculated to determine the proportion of 
variability associated with each effect.  Those values were compared to Cohen’s (1988) 
standards for interpreting eta-squared values with a small effect size having an = .01, .a 
medium effect size having an = .06, and a large effect size having an  = .14 or 
greater.  Each model was first created as a main effects only model.  If this model 
explained 94% of the total variability then no further complex models were investigated.  
However, if less than 94% of the total variability was explained then interactions were 
included in the model.  Two-way interactions were added to the model first followed by 
three-way and then four-way interactions until at least 94% of the variability was 
explained.  Finally, line graphs were created to show bias estimates of the variance 
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components as a function of the independent variables (both main effects and 
interactions) that had eta-squared values of .06 or higher.  
Research Question Five 
Research Question Five, evaluation of the confidence interval coverage of the 
variance components from a three level meta-analytic single-case model, was addressed 
by examining box and whisker plots to illustrate the distribution of the confidence 
interval coverage estimates of the variance components.  In addition, GLM was used to 
examine variability of each of the confidence interval coverage estimates of the variance 
components as a a function of the independent variables.  Models were built with the 
purpose of finding effects whose eta-squared values .06 or greater. The effects size, eta-
squared ( ), was calculated to determine the proportion of variability associated with 
each effect.  Those values were compared to Cohen’s (1988) standards for interpreting 
eta-squared values with a small effect size having an = .01, .a medium effect size 
having an = .06, and a large effect size having an  = .14 or greater.  Each model 
was first created as a main effects only model.  If this model explained 94% of the total 
variability then no further complex models were investigated.  However, if less than 94% 
of the total variability was explained then interactions were included in the model.  Two-
way interactions were added to the model first followed by three-way and then four-way 
interactions until at least 94% of the variability was explained.  Finally, line graphs were 
created to show confidence interval coverage estimates of the variance components as a 
function of the independent variables (both main effects and interactions) that had eta-
squared values of .06 or higher.    
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Research Question Six 
Research Question Six, evaluation of the confidence interval width of the variance 
components from a three level meta-analytic single-case model, was addressed by 
examining box and whisker plots to illustrate the distribution of the confidence interval 
width estimates of the variance components.  In addition, GLM was used to examine 
variability of each of the confidence interval width estimates of the variance components 
as a a function of the independent variables.  Models were built with the purpose of 
finding effects whose eta-squared values .06 or greater. The effects size, eta-squared 
( ), was calculated to determine the proportion of variability associated with each 
effect.  Those values were compared to Cohen’s (1988) standards for interpreting eta-
squared values with a small effect size having an = .01, .a medium effect size having 
an = .06, and a large effect size having an  = .14 or greater.  Each model was first 
created as a main effects only model.  If this model explained 94% of the total variability 
then no further complex models were investigated.  However, if less than 94% of the total 
variability was explained then interactions were included in the model.  Two-way 
interactions were added to the model first followed by three-way and then four-way 
interactions until at least 94% of the variability was explained.  Finally, line graphs were 
created to show confidence interval width estimates of the variance components as a 
function of the independent variables (both main effects and interactions) that had eta-
squared values of .06 or higher.    
 
 
 
	  74 
 
 
 
CHAPTER FOUR: RESULTS 
This chapter presents the results organized in the order of the research questions.  
This chapter begins by describing how the results were examined and then presents the 
results in two sections, the fixed effects and the variance components.  Each section 
presents each outcome measure (bias of the point estimate, confidence interval coverage, 
and confidence interval width) with the first section comprising the first three research 
questions and the second section comprising the last three research questions.  The 
following research questions were addressed: 
1. To what extent are the fixed effect estimates from a three level meta-analytic 
single-case model biased as a function of specific design factors (number of 
primary studies per meta-analysis, modal number of participants per primary 
study, modal series length per primary study, level of autocorrelation, and 
variances of the error terms)? 
2. To what extent does the confidence interval coverage of the fixed effect estimates 
from a three level meta-analytic single-case model vary as a function of specific 
design factors  (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
3. To what extent does the confidence interval width of the fixed effect estimates 
from a three level meta-analytic single-case model vary as a function of specific 
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design factors  (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
4. To what extent are the variance components from a three level meta-analytic 
single-case model biased as a function of specific design factors  (number of 
primary studies per meta-analysis, modal number of participants per primary 
study, modal series length per primary study, level of autocorrelation, and 
variances of the error terms)? 
5. To what extent does the confidence interval coverage of the variance components 
from a three level meta-analytic single-case model vary as a function of specific 
design factors  (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
6. To what extent does the confidence interval width of the variance components 
from a three level meta-analytic single-case model vary as a function of specific 
design factors  (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
There were 108 conditions simulated using the five factors of this Monte Carlo 
study. The five factors were the number of primary studies per meta-analysis (10, 30, and 
80), modal number of participants per primary study (small [mode = 4] and large [mode 
= 8]), modal series length per primary study (small [mode = 10], medium [mode = 20], 
and large [mode = 30]), level of autocorrelation (0, .2, and .4), and variances of the error 
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terms (most of the variance at level-1 [ = 1, = .2, and = .05] and 
most of the variance at level-2 [ = 1, = 2, and = .5]).  This yielded 
3 (number of primary studies per meta-analysis) X 2 (modal number of participants per 
primary study) X 3 (modal series length per primary study) X 3 (level of autocorrelation) 
X 2 (variances of the error terms) = 108 conditions.    
First, the dependent variables, bias of the point estimates, confidence interval 
coverage, and confidence interval width were evaluated for both the fixed effects and the 
variance components.  In addition, an index of relative bias was calculated for all 
parameter estimates whose known value was anything other than a value of 1.0.  This 
was accomplished by creating box plots, across all conditions, for each dependent 
variable.  Then, the results of the simulation were analyzed using PROC GLM in SAS for 
both the fixed effects and the variance components such that the dependent variables 
were bias, relative bias (where appropriate), confidence interval coverage, and confidence 
interval width and the independent variables were the five factors.  Models were built 
with the purpose of finding effects whose eta-squared values were .06 or greater.  The 
effect size, eta-squared ( ), was calculated to measure the degree of association 
between the independent variables main effects and the dependent variables along with 
the two-way, three-way, and four-way interaction effects between independent variables 
and the dependent variables.  Eta-squared is the proportion of variability in each of the 
outcome measures associated with each effect in this simulation study.  It is calculated as 
the ratio of the effect variance (SSeffect) to the total variance (SStotal). 
 (30) 
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The calculated eta-squared values were compared to Cohen’s (1988) standards for 
interpreting eta-squared values with a small effect size having an = .01, .a medium 
effect size having an = .06, and a large effect size having an  = .14 or greater.  Each 
model was first created as a main effects only model.  If this model explained 94% of the 
total variability then no further complex models were investigated.  However, if less than 
94% of the total variability was explained then interactions were included in the model.  
Two-way interactions were added to the model first followed by three-way and then four-
way interactions until at least 94% of the variability was explained.  Finally, line graphs 
were created to show bias and/or relative bias of the point estimates, confidence interval 
coverage, and confidence interval width estimates of the fixed effects and variance 
components as a function of the independent variables (both main effects and 
interactions) that had eta-squared values of .06 or higher.   
Fixed Effects 
The fixed effects are comprised of , the overall average baseline level, and 
, the overall average treatment effect.  The first research question involves the extent 
to which the fixed effects are biased as a function of the five factors used in this 
simulation study.  The second research question involves the extent to which the 
confidence interval coverage of the fixed effects varied as a function of the five factors 
used in this simulation study.  The third research question involves the extent to which 
the confidence interval width of the fixed effects varied as function of the five factors 
used in this simulation study.  
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Bias 
The distribution of bias values for each fixed effect is illustrated in box plots in 
Figure 6.   The overall average baseline level ( ) had bias values close to zero with an 
average bias value of 0.000 (SD = 0.002) and a range of values from -0.005 to 0.005.  In 
addition, the overall average treatment effect ( ) had bias values close to zero with a 
mean of 0.000 (SD = 0.001) and values ranging from -0.003 to 0.009.  As indicated by 
the results, there was limited variation in both of the fixed effects and none of the bias 
estimates exceeded 1% of the known parameter values (recall that all known fixed effect 
parameter values were set to 1.0).  Therefore, any further exploration was unwarranted.  
 
Figure 6. Box plots showing the distribution of bias estimates for each fixed effect in the 
three level model. 
 
Confidence Interval Coverage 
The distribution of confidence interval coverage rates for each fixed effect is 
illustrated in box plots in Figure 7.  The overall average baseline level ( ) had 
confidence interval coverage rates that tended to slightly overcover with values that 
ranged from a high of .973 to a low of .951, with a mean of .961 (SD = 0.005).  Similarly, 
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the overall average treatment effect ( ) had confidence interval coverage rates that 
ranged from a high of .971 to a low of .951, with a mean of .960 (SD = 0.005).  
 
Figure 7. Box plots showing the distribution of confidence interval coverage rates for 
each fixed effect in the three level model 
 
 Overall average baseline level. Variation in confidence interval coverage rates 
of the overall average baseline level was explored by modeling confidence interval 
coverage with the five main effects (number of primary studies per meta-analysis, modal 
number of participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms), all possible two-way interactions 
involving the number of primary studies per meta-analysis, all possible three-way 
interactions involving the number of primary studies per meta-analysis and three four-
way interactions.  One of the four-way interactions involved the number of primary 
studies per meta-analysis, modal number of participants per primary study, modal series 
length per primary study, and level of autocorrelation.  The next four-way interaction 
involved the number of primary studies per meta-analysis, modal number of participants 
per primary study, level of autocorrelation, and variances of the error terms, and the final 
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four-way interaction involved the number of primary studies per meta-analysis, modal 
series length per primary study, level of autocorrelation, and variances of the error terms.  
This model explained 96% of the variability in the confidence interval coverage rates of 
the overall average baseline level.  Eta-squared ( ) values for each of the main effects 
and interactions are in Table 3. 
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Table 3 
Eta-squared Values ( ) for Association of Design Factors with Confidence Interval 
Coverage of the Overall Average Baseline Level 
  
Number of Primary Studies  .762 
Modal Number of Participants  .005 
Modal Series Length  .001 
Autocorrelation .012 
Variances of the Error Terms .004 
Number of Primary Studies*Modal Number of Participants  .000 
Number of Primary Studies*Modal Series Length  .013 
Number of Primary Studies*Autocorrelation .005 
Number of Primary Studies*Variances of the Error Terms .001 
Number of Primary Studies*Modal Series Length*Autocorrelation .026 
Number of Primary Studies*Modal Series Length*Variances of the Error 
Terms 
.005 
Number of Primary Studies*Modal Series Length*Modal Number of 
Participants 
.012 
Number of Primary Studies*Modal Number of 
Participants*Autocorrelation 
.008 
Number of Primary Studies*Autocorrelation*Variances of the Error Terms .028 
Number of Primary Studies*Variances of the Error Terms*Modal Number 
of Participants 
.000 
Number of Primary Studies*Modal Number of Participants*Modal Series 
Length*Autocorrelation 
.036 
Number of Primary Studies*Modal Number of Participants* 
Autocorrelation * Variances of the Error Terms 
.014 
Number of Primary Studies*Modal Series Length*Autocorrelation * 
Variances of the Error Terms 
.027 
Total Explained .959 
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In order to explore these effects further line graphs were created for those main 
effects and/or interactions whose eta-squared values exceeded the pre-established 
standard of Cohen’s (1988) medium effect size criteria of or greater.  Therefore, 
the only effect that met this standard was the main effect of the number of primary 
studies per meta-analysis with an = .76.  The 95% confidence interval coverage rates 
of the overall average baseline level as a function of the number of primary studies per 
meta-analysis (see Figure 8) illustrated that as the number of primary studies per meta-
analysis increased from 10 to 30 to 80 the closer the coverage rates came to .95, with 
means of .968 (SD = 0.002), .960 (SD = 0.003), and .956 (SD = 0.003), respectively. 
 
Figure 8. Line graph showing the estimated confidence interval coverage rates for the 
overall average baseline level as a function of the number of primary studies per meta-
analysis. 
 
Overall average treatment effect. Variation in confidence interval coverage 
rates of the overall average treatment effect was explored by modeling confidence 
interval coverage with the five main effects (number of primary studies per meta-
analysis, modal number of participants per primary study, modal series length per 
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primary study, level of autocorrelation, and variances of the error terms), all possible 
two-way interactions involving the number of primary studies per meta-analysis, all 
possible three-way interactions involving the number of primary studies per meta-
analysis and three four way interactions.  One of the four-way interactions involved the 
number of primary studies per meta-analysis, modal number of participants per primary 
study, modal series length per primary study, and level of autocorrelation.  The next four-
way interaction involved the number of primary studies per meta-analysis, modal number 
of participants per primary study, level of autocorrelation, and the variances of the error 
terms, and the final four-way interaction included the number of primary studies per 
meta-analysis, modal series length per primary study, level of autocorrelation, and 
variances of the error terms.  This model explained 97% of the variability in the 
confidence interval coverage rates of the overall average treatment effect.  Eta-squared 
( ) values for each of the main effects and interactions are in Table 4. 
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Table 4 
Eta-squared Values ( ) for Association of Design Factors with Confidence Interval 
Coverage of the Overall Average Treatment Effect 
  
Number of Primary Studies  .701 
Modal Number of Participants  .009 
Modal Series Length  .013 
Autocorrelation .000 
Variances of the Error Terms .000 
Number of Primary Studies*Modal Number of Participants  .001 
Number of Primary Studies*Modal Series Length  .008 
Number of Primary Studies*Autocorrelation .015 
Number of Primary Studies*Variances of the Error Terms .018 
Number of Primary Studies*Modal Series Length*Autocorrelation .044 
Number of Primary Studies*Modal Series Length*Variances of the Error 
Terms 
.022 
Number of Primary Studies*Modal Series Length*Modal Number of 
Participants 
.009 
Number of Primary Studies*Modal Number of Participants*Autocorrelation .009 
Number of Primary Studies*Autocorrelation*Variances of the Error Terms .024 
Number of Primary Studies*Variances of the Error Terms*Modal Number of 
Participants 
.003 
Number of Primary Studies*Modal Number of Participants*Modal Series 
Length*Autocorrelation 
.041 
Number of Primary Studies*Modal Number of 
Participants*Autocorrelation*Variances of the Error Terms 
.030 
Number of Primary Studies*Modal Series Length*Autocorrelation*Variances 
of the Error Terms 
.021 
Total Explained .968 
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Similar to the results for the overall average baseline level, the only effect that 
met the standard of a medium effect size or greater was the main effect of the number of 
primary studies per meta-analysis with an = .70.  The 95% confidence interval 
coverage rates of the overall average treatment effect as a function of the number of 
primary studies per meta-analysis (see Figure 9) illustrated that as the number of primary 
studies per meta-analysis increased the closer the confidence interval coverage rates came 
to .95 with means of .966 (SD = 0.002), .960 (SD = .003), and .956 (SD = .002), 
respectively. 
 
Figure 9. Line graph showing the estimated confidence interval coverage rates for the 
overall average treatment effect as a function of the number of primary studies per meta-
analysis. 
 
Confidence Interval Width 
 The box plot illustrating the distribution of the confidence interval width 
estimates for each fixed effect is presented in Figure 10.  The confidence interval width 
estimates for the overall average baseline level ( ) ranged from a low of 0.099 to a 
high of 1.132, with a mean of 0.428 (SD = 0.291).  Similarly, the confidence interval 
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width estimates for the overall average treatment effect ( ) ranged from a low of 0.114 
to a high of 1.174, with a mean of 0.459 (SD = 0.293).   
 
Figure 10. Box plots showing the distribution of confidence interval width estimates for 
each fixed effect in the three level model. 
 
Overall average baseline level. Variation in confidence interval width estimates 
of the overall average baseline level was explored by modeling confidence interval width 
with the five main effects (number of primary studies per meta-analysis, modal number 
of participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms) and a two-way interaction involving the 
number of primary studies per meta-analysis and the variances of the error terms.  This 
model explained 99% of the variability in the confidence interval width estimates of the 
overall average baseline level.  Eta-squared ( ) values for each of the main effects and 
interaction are in Table 5. 
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Table 5 
Eta-squared Values ( ) for Association of Design Factors with Confidence Interval 
Width of the Overall Average Baseline Level 
  
Number of Primary Studies .472 
Modal Number of Participants  .023 
Modal Series Length  .000 
Autocorrelation .001 
Variances of the Error Terms .402 
Number of Participants * Variances of the Error Terms .089 
Total Explained .987 
 
To further examine these effects a line graph was created for those effects whose 
eta-squared values exceeded the pre-established standard of a medium effect size or 
greater. Therefore, confidence interval width was modeled as a function of the number of 
primary studies per meta-analysis (  = .47), variances of the error terms (  = .40), and 
their interaction (  = .09).  This model explained 96% of the variance in confidence 
interval width estimates of the overall average baseline level.  As the number of primary 
studies per meta-analysis increased from 10 to 30 to 80 the confidence interval width 
decreased, with means of 0.696 (SD = 0.316), 0.368 (SD = 0.165), and 0.220 (SD = 
0.098), respectively.  Conversely, as the variances of the error terms shifted from most of 
the variance at level-1 (or less variance at level-2 and level-3) to most of the variance at 
level-2 the confidence interval widths increased, with means of 0.244 (SD = 0.119) and 
0.612 (SD = 0.297), respectively.  The graph (see Figure 11) indicates that when the 
number of primary studies per meta-analysis was 30 or 80 the confidence interval widths 
slightly increased when the variance of the error terms shifted from most of the variance 
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at level-1 to most of the variance at level-2.  However, when the number of primary 
studies was 10 there was a greater increase of the estimated confidence interval widths 
when the variances of the error terms shifted from most of the variance at level-1 (M = 
0.396, SD = 0.053) to most of the variance at level-2 (M = 0.997, SD = 0.107).  In 
addition, confidence interval widths were smallest when the number of primary studies 
per meta-analysis was 80 and most of the variance of the error terms was at level-1 (or 
less variance at level-2 and level-3). 
 
Figure 11. Line graph showing the confidence interval width estimates of the overall 
average baseline level as a function of the variances of the error terms for each level of 
the number of primary studies per meta-analysis. 
 
Overall average treatment effect.  Variation in confidence interval width 
estimates of the overall average treatment effect was explored by modeling confidence 
interval width with the five main effects (number of primary studies per meta-analysis, 
modal number of participants per primary study, modal series length per primary study, 
level of autocorrelation, and variances of the error terms) and a two-way interaction 
involving the number of primary studies per meta-analysis and the variances of the error 
terms.  This model explained 99% of the variability in the confidence interval width 
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estimates of the overall average treatment effect.  Eta-squared ( ) values for each of the 
main effects and interaction are in Table 6. 
Table 6 
Eta-squared Values ( ) for Association of Design Factors with Confidence Interval 
Width of the Overall Average Treatment Effect 
  
Number of Primary Studies .534 
Modal Number of Participants  .029 
Modal Series Length  .002 
Autocorrelation .003 
Variances of the Error Terms .350 
Number of Participants * Variances of the Error Terms .078 
Total Explained .996 
 
 To explore the variation between confidence interval width estimates of the 
overall average treatment effect a line graph was created that modeled confidence interval 
width as a function of the number of primary studies per meta-analysis (  = .53), 
variances of the error terms (  = .35), and their interaction (  = .08).  This model 
explained 96% of the variance in confidence interval width estimates of the overall 
average treatment effect.  Similar to the confidence interval width estimates of the overall 
average baseline level, the results indicated that as the number of primary studies 
increased from 10 to 30 to 80, the average width decreased from 0.746 (SD = 0.299) to 
0.236 (SD = 0.093), respectively.  Conversely, as the variances of the error terms shifted 
from most of the variance at level-1 (or less variance at level-2 and level-3) to most of the 
variance at level-2 the confidence interval widths increased, with means of 0.287 (SD = 
0.140) and 0.632 (SD = 0.306), respectively.  The graph (see Figure 12) indicates that 
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when the number of primary studies per meta-analysis was 30 or 80 the confidence 
interval widths slightly increased when the variances of the error terms shifted from most 
of the variance at level-1 to most of the variance at level-2.  However, when the number 
of primary studies was 10 there was a greater increase of the estimated confidence 
interval widths when the variances of the error terms shifted from most of the variance at 
level-1 (M = 0.465, SD = 0.063) to most of the variance at level-2 (M = 1.028, SD = 
0.109).  In addition, confidence interval widths were smallest when the number of 
primary studies per meta-analysis was 80 and most of the variance of the error terms was 
at level-1 (or less variance at level-2 and level-3). 
 
Figure 12. Line graph showing the estimated confidence interval width of the overall 
average treatment effect as a function of the variances of the error terms for each level of 
the number of primary studies per meta-analysis. 
  
Variance Components 
The variance components are comprised of , between study variance in the 
overall average baseline level, , between study variance in the overall average 
treatment effect,  between person within study variance in the average baseline level, 
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, between person within study variance in the average treatment effect, , within 
person residual variance, and , amount of estimated autocorrelation.  The fourth 
research question involves the extent to which the variance components are biased as a 
function of the five factors used in this simulation study.  The fifth research question 
involves the extent to which the confidence interval coverage of the variance components 
varied as a function of the five factors used in this simulation study.  The sixth and final 
research question involves the extent to which the confidence interval width of the 
variance components varied as function of the five factors used in this simulation study.  
Bias 
The distribution of bias values for each variance component is illustrated in box 
plots in Figures 13 - 15.   Both level-3 variance components ( and ) tended to be 
underestimated (see Figure 13).  Between study variance in the overall average baseline 
level ( ) was biased with negative bias values ranging from -0.477 to -0.031 and a 
mean of -0.241 (SD = 0.201).  In addition, between study variance in the overall average 
treatment effect ( ) was biased with negative bias values ranging from -0.474 to -
0.024 and a mean of -0.237 (SD = 0.201).   
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Figure 13. Box plots showing the distribution of bias estimates for each level-3 variance 
component in the three level model. 
 
Conversely, the level-2 variance components (  and ) both tended to be 
overestimated (see Figure 14).  Between person within study variance in the average 
baseline level ( ) was biased with positive bias values ranging from 0.033 to 0.479 
and an average bias value of 0.243 (SD = 0.202).  Similarly, between person within study 
variance in the average treatment effect ( ) had positive bias values with a mean of 
0.238 (SD = 0.201) and values ranging from 0.027 to 0.476.   
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Figure 14. Box plots showing the distribution of bias estimates for each level-2 variance 
component in the three level model. 
 
The within person residual variance ( ) also tended to be slightly overestimated 
with an average bias value of 0.078 (SD = 0.082) and values ranging from -0.001 to 
0.194.  Recall that the population value for the within person residual variance was 1.0, 
thus an average bias estimate of 0.078 represents 8% of the average parameter value.  
The amount of estimated autocorrelation ( ) had bias values close to zero with a mean of 
0 (SD = 0.001) and values ranging from -0.002 to 0.001.  Figure 15 illustrates the 
distribution of bias values for the residual variance and the amount of estimated 
autocorrelation.  As indicated by the results, there was limited variation in the amount of 
estimated autocorrelation and the bias estimate did not exceed 1% of the known 
parameter value (see Relative Bias results section).  Therefore, any further exploration of 
the amount of estimated autocorrelation was unwarranted. 
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Figure 15. Box plots showing the distribution of bias estimates for the within person 
residual variance and amount of estimated autocorrelation in the three level model. 
 
 Between study variance in the overall average baseline level.  Variation in the 
bias estimates of the between study variance in the overall average baseline level was 
explored by modeling bias with the five main effects (number of primary studies per 
meta-analysis, modal number of participants per primary study, modal series length per 
primary study, level of autocorrelation, and variances of the error terms).  This model 
explained 99% of the variability in the bias estimates of the between study variance in the 
overall average baseline level.  Eta-squared ( ) values for each of the main effects are 
in Table 7. 
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Table 7 
Eta-squared Values ( ) for Association of Design Factors with Bias of the Between 
Study Variance in the Overall Average Baseline Level 
  
Number of Primary Studies  .005 
Modal Number of Participants  .001 
Modal Series Length  .000 
Autocorrelation .000 
Variances of the Error Terms .989 
Total Explained .995 
 
In order to further explore these effects a line graph was created for the main 
effect of variances in the error terms ( = .99), as it was the only effect that met the pre-
established standard of a medium effect size or greater.  The bias estimates of the 
between study variance in the overall average baseline level as a function of the variances 
of the error terms (see Figure 16) illustrated that as the variances of the error terms 
shifted from most of the variance at level-1 to most of the variance at level-2 the 
parameter estimates decreased to become increasingly underestimated and progressively 
more biased with mean bias estimates of -0.042 (SD = 0.004) to -0.440 (SD = 0.030), 
respectively.  
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Figure 16. Line graph showing the bias estimates for the between study variance in the 
overall average baseline level as a function of the variances of the error terms. Level-1 = 
most of the variance at level-1; Level-2 = most of the variance at level-2. 
 
Between study variance in the overall average treatment effect.  Variation in 
the bias estimates of the between study variance in the overall average treatment effect 
was explored by modeling bias with the five main effects (number of primary studies per 
meta-analysis, modal number of participants per primary study, modal series length per 
primary study, level of autocorrelation, and variances of the error terms). This model 
explained 99% of the variability in the bias estimates of the between study variance in the 
overall average treatment effect.  Eta-squared ( ) values for each of the main effects are 
in Table 8. 
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Table 8 
Eta-squared Values ( ) for Association of Design Factors with Bias of the Between 
Study Variance in the Overall Average Treatment Effect 
  
Number of Primary Studies  .006 
Modal Number of Participants  .001 
Modal Series Length  .000 
Autocorrelation .000 
Variances of the Error Terms .988 
Total Explained .995 
 
Similar to the bias estimates of the between study variance in the overall average 
baseline level, between study variance in the overall average treatment effect was further 
explored with a line graph for the main effect of variances in the error terms ( = .99).  
The bias estimates of the between study variance in the overall average treatment effect 
as a function of the variances of the error terms (see Figure 17) illustrated that as the 
variances of the error terms shifted from most of the variance at level-1 to most of the 
variance at level-2 the parameter estimates decreased to become increasingly 
underestimated and progressively more biased with mean bias estimates of -0.039 (SD = 
0.006) to -0.436 (SD = 0.031), respectively.  
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Figure 17. Line graph showing the bias estimates for the between study variance in the 
overall average treatment effect as a function of the variances of the error terms. Level-1 
= most of the variance at level-1; Level-2 = most of the variance at level-2. 
 
 Between person within study variance in the average baseline level.  Variation 
in the bias estimates of the between person within study variance in the average baseline 
level was explored by modeling bias with the five main effects (number of primary 
studies per meta-analysis, modal number of participants per primary study, modal series 
length per primary study, level of autocorrelation, and variances of the error terms).  This 
model explained 99% of the variability in the bias estimates of the between person within 
study variance in the average baseline level.  Eta-squared ( ) values for each of the 
main effects are in Table 9. 
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Table 9 
Eta-squared Values ( ) for Association of Design Factors with Bias of the Between 
Person Within Study Variance in the Average Baseline Level 
  
Number of Primary Studies  .004 
Modal Number of Participants  .001 
Modal Series Length  .000 
Autocorrelation .000 
Variances of the Error Terms .991 
Total Explained .996 
 
To further explore these effects a line graph was created for the main effect 
variances of the error terms ( = .99).  The bias estimates of the between person within 
study variance in the average baseline level as a function of the variances of the error 
terms (see Figure 18) illustrated that as the variances of the error terms shifts from most 
of the variance at level-1 to most of the variance at level-2 the parameter estimates 
increased to become progressively overestimated and more biased with mean bias 
estimates of 0.042 (SD = 0.004) to 0.444 (SD = 0.026), respectively. 
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Figure 18. Line graph showing the bias estimates for the between person within study 
variance in the average baseline level as a function of the variances of the error terms. 
Level-1 = most of the variance at level-1; Level-2 = most of the variance at level-2. 
 
Between person within study variance in the average treatment effect.  
Variation in the bias estimates of the between person within study variance in the average 
treatment effect was explored by modeling bias with the five main effects (number of 
primary studies per meta-analysis, modal number of participants per primary study, 
modal series length per primary study, level of autocorrelation, and variances of the error 
terms).  This model explained 99% of the variability in the bias estimates of the between 
person within study variance in the average treatment effect.  Eta-squared ( ) values for 
each of the main effects are in Table 10. 
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Table 10 
Eta-squared Values ( ) for Association of Design Factors with Bias of the Between 
Person Within Study Variance in the Average Treatment Effect 
  
Number of Primary Studies  .006 
Modal Number of Participants  .001 
Modal Series Length  .000 
Autocorrelation .000 
Variances of the Error Terms .989 
Total Explained .995 
 
 Similar to the bias results for the between person within study variance in the 
average treatment effect, the only effect that met the pre-established standard of a 
medium effect size or greater was the variances of the error terms ( = .99).  The bias 
estimates of the between person within study variance in the average treatment effect as a 
function of the variances of the error terms (see Figure 19) illustrated that as the 
variances of the error terms shifted from most of the variance at level-1 to most of the 
variance at level-2 the parameter estimates increased to become progressively 
overestimated and more biased with mean bias estimates of 0.039 (SD = 0.005) to 0.438 
(SD = 0.029), respectively. 
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Figure 19. Line graph showing the bias estimates for the between person within study 
variance in the average treatment effect as a function of the variances of the error terms. 
Level-1 = most of the variance at level-1; Level-2 = most of the variance at level-2. 
 
 Within person residual variance. Variation in the bias estimates of the within 
person residual variance was explored by modeling bias with the five main effects 
(number or primary studies per meta-analysis, modal number of participants per primary 
study, modal series length per primary study, level of autocorrelation, and variances of 
the error terms).  This model explained 99% of the variability in the bias estimates of the 
within person residual variance.  Eta-squared ( ) values for each of the main effects are 
in Table 11. 
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Table 11 
Eta-squared Values ( ) for Association of Design Factors with Bias of the Within 
Person Residual Variance 
  
Number of Primary Studies  .000 
Modal Number of Participants  .000 
Modal Series Length  .000 
Autocorrelation .999 
Variances of the Error Terms .000 
Total Explained .999 
 
In order to explore these effects further a line graph was created for the main 
effect of level of autocorrelation ( = .99).  The bias estimates of the within person 
residual variance as a function of the level of autocorrelation (see Figure 20) illustrated 
that as the level of autocorrelation increased from 0 to .200 to .400 so did the amount of 
bias, with values from 0.000 (SD = 0.001) to 0.042 (SD = 0.001) to 0.191 (SD = 0.001), 
respectively. 
 
Figure 20. Line graph showing the bias estimates for the within person residual variance 
as a function of the level of autocorrelation. 
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Relative Bias 
The distribution of relative bias estimates is illustrated in box plots (see Figure 21 
- 23) for all variance components with the exception of the within person residual 
variance parameter as its’ known parameter value was set to 1.0.  The level-3 variance 
components (  and ) were the most biased of all the variance components and 
tended to be underestimated (see Figure 21).  The relative bias estimates for the between 
study variance in the overall average baseline level ( ) had values ranging from -.954 
to -.624 with a mean of -.858 (SD = 0.077).  This average relative bias estimate 
represented an absolute value of 86% of the average parameter value, which is 
substantial.  Similarly, the between study variance in the overall average treatment effect 
( ) had relative bias estimates that ranged from -.948 to -.474 with an average of -.822 
(SD = 0.106).  This average relative bias estimate represented an absolute value of 82% 
of the average parameter value, which is also substantial.   
 
Figure 21. Box plots showing the distribution of relative bias estimates for each level-3 
variance component in the three level model 
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The level-2 variance components (  and ) were also biased but instead 
tended to be overestimated (see Figure 22) with the between person within study variance 
in the average baseline level ( ) having relative bias values ranging from .166 to .240 
with a mean of .217 (SD = 0.016).  This average relative bias estimate represented an 
absolute value of 22% of the average parameter value, which is substantial.  The between 
person within study variance in the average treatment effect ( ) had relative bias 
values ranging from .136 to .238 with an average of .208 (SD = 0.023).  This average 
relative bias estimate represented an absolute value of 21% of the average parameter 
value, which is also substantial.  
 
Figure 22. Box plots showing the distribution of relative bias estimates for each level-2 
variance component in the three level model 
 
The amount of estimated autocorrelation ( ) had relative bias values close to zero 
(see Figure 23) with a mean of -.001 (SD = 0.002) and values ranging from -.007 to .002.  
As indicated by the results, there was limited variation in the amount of estimated 
autocorrelation and the relative bias estimate did not exceed 1% of the known parameter 
value.  Therefore, any further exploration was unwarranted.  
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Figure 23. Box plots showing the distribution of relative bias estimates for amount of 
estimated autocorrelation in the three level model 
 
Between study variance in the overall average baseline level.  Variation in the 
relative bias estimates of the between study variance in the overall average baseline level 
was explored by modeling relative bias with the five main effects (number of primary 
studies per meta-analysis, modal number of participants per primary study, modal series 
length per primary study, level of autocorrelation, and variances of the error terms) and a 
two-way interaction involving the number of primary studies per meta-analysis and the 
variances of the error terms.  This model explained 94% of the variability in the relative 
bias estimates of the between study variance in the overall average baseline level.  Eta-
squared ( ) values for each of the main effects and interaction are in Table 12. 
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Table 12 
Eta-squared Values ( ) for Association of Design Factors with Relative Bias of the 
Between Study Variance in the Overall Average Baseline Level 
  
Number of Primary Studies  .664 
Modal Number of Participants  .156 
Modal Series Length  .003 
Autocorrelation .012 
Variances of the Error Terms .084 
Number of Primary Studies * Variances of the Error Terms .019 
Total Explained .938 
 
In order to further explore these effects line graphs were created for the main 
effects of number of primary studies per meta-analysis ( = .66), modal number of 
participants ( = .16), and variances in the error terms ( = .08).  This model explained 
90% of the variance in relative bias of the between study overall average baseline level.  
These main effects were chosen as they were the only effects that met the pre-established 
standard of a medium effect size or greater.  The relative bias estimates of the variance in 
the overall average baseline level as a function of the number of primary studies per 
meta-analysis (see Figure 24) illustrated that as the number of primary studies per meta-
analysis increased from 10 to 30 to 80 the parameter estimates became increasingly 
underestimated and progressively more biased moving from an average relative bias 
estimate of - .774 (SD = 0.067) to -.876 (SD = 0.035) to -.925 (SD = 0.021), respectively.  
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Figure 24. Line graph showing the relative bias estimates for the between study variance 
in the overall average baseline level as a function of the number of primary studies per 
meta-analysis. 
 
The relative bias estimates of the variance in the overall average baseline level as a 
function of modal number of participants per primary study (see Figure 25) illustrates 
that as the modal number of participants per primary study increased from small, with a 
mode of 4, to large, with a mode of 8, the parameter estimates became increasingly 
underestimated and progressively more biased moving from an average relative bias 
estimate of - .828 (SD = 0.085) to -.889 (SD = 0.054), respectively.  
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Figure 25. Line graph showing the relative bias estimates for the between study variance 
in the overall average baseline level as a function of the modal number of participants per 
primary study. 
 
The relative bias estimates of the variance in the overall average baseline level as a 
function of the variances of the error terms (see Figure 26) illustrated that as the 
variances of the error terms shifted from most of the variance at level-1 to most of the 
variance at level-2 the average parameter became increasingly underestimated and 
progressively more biased with the relative bias estimate moving from – 0.836 (SD = 
0.086) to -0.881 (SD = 0.060), respectively.  
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Figure 26. Line graph showing the relative bias estimates for the between study variance 
in the overall average baseline level as a function of the variances of the error terms. 
Level-1 = most of the variance at level-1; Level-2 = most of the variance at level-2. 
 
Between study variance in the overall average treatment effect.  Variation in 
the relative bias estimates of the between study variance in the overall average treatment 
effect was explored by modeling relative bias with the five main effects (number of 
primary studies per meta-analysis, modal number of participants per primary study, 
modal series length per primary study, level of autocorrelation, and variances of the error 
terms) and a two-way interaction between the number of primary studies per meta-
analysis and the variances of the error terms.  This model explained 94% of the 
variability in the relative bias estimates of the between study variance in the overall 
average treatment effect.  Eta-squared ( ) values for each of the main effects are in 
Table 13. 
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Table 13 
Eta-squared Values ( ) for Association of Design Factors with Relative Bias of the 
Between Study Variance in the Overall Average Treatment Effect 
  
Number of Primary Studies  .538 
Modal Number of Participants  .108 
Modal Series Length  .006 
Autocorrelation .018 
Variances of the Error Terms .228 
Number of Primary Studies * Variances of the Error Terms .046 
Total Explained .944 
 
Similar to the relative bias estimates of the between study variance in the overall 
average baseline level, these effects were further explored with line graphs for the main 
effects of number of primary studies per meta-analysis ( = .54), modal number of 
participants ( = .11), and variances in the error terms ( = .23). This model explained 
87% of the variability in the relative bias of the between study variance in the overall 
average treatment effect.  The relative bias estimates of the between study variance in the 
overall average treatment effect as a function of the number of primary studies per meta-
analysis (see Figure 27) illustrated that as the number of primary studies per meta-
analysis increased from 10 to 30 to 80 the average parameter became increasingly 
underestimated and progressively more biased with the relative bias estimate moving 
from -.719 (SD = 0.106) to -.843 (SD = 0.058) to -.904 (SD = 0.035), respectively.  
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Figure 27. Line graph showing the relative bias estimates for the between study variance 
in the overall average treatment effect as a function of the number of primary studies per 
meta-analysis. 
 
The relative bias estimates of the between study variance in the overall average treatment 
effect as a function of the modal number of participants per primary study (see Figure 28) 
illustrated that as the modal number of participants per primary study increased from 
small, with a mode of 4, to large, with a mode of 8, the average parameter became 
increasingly underestimated and progressively more biased with the relative bias estimate 
moving from -.788 (SD = 0.118) to -.857 (SD = 0.081), respectively.  
 
	  113 
 
Figure 28. Line graph showing the relative bias estimates for the between study variance 
in the overall average treatment effect as a function of the modal number of participants 
per primary study. 
 
The relative bias estimates of the between study variance in the overall average treatment 
effect as a function of the variances of the error terms (see Figure 29) illustrates that as 
the variances of the error terms shifted from most of the variance at level-1 to most of the 
variance at level-2 the average parameter estimate became increasingly underestimated 
and progressively more biased with the relative bias estimate moving from -.772 (SD = 
0.117) to -.872 (SD = 0.062), respectively.  
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Figure 29. Line graph showing the relative bias estimates for the between study variance 
in the overall average treatment effect as a function of the variances of the error terms. 
Level-1 = most of the variance at level-1; Level-2 = most of the variance at level-2. 
 
 Between person within study variance in the average baseline level.  Variation 
in the relative bias estimates of the between person within study variance in the average 
baseline level was explored by modeling relative bias with the five main effects (number 
of primary studies per meta-analysis, modal number of participants per primary study, 
modal series length per primary study, level of autocorrelation, and variances of the error 
terms), all possible two-way interactions involving the number of primary studies per 
meta-analysis, and all possible two-way interactions involving the modal number of 
participants per primary study.  This model explained 94% of the variability in the 
relative bias estimates of the between person within study variance in the average 
baseline level.  Eta-squared ( ) values for each of the main effects are in Table 14. 
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Table 14 
Eta-squared Values ( ) for Association of Design Factors with Relative Bias of the 
Between Person Within Study Variance in the Average Baseline Level 
  
Number of Primary Studies  .590 
Modal Number of Participants  .166 
Modal Series Length  .007 
Autocorrelation .021 
Variances of the Error Terms .094 
Number of Primary Studies * Modal Number of Participants .024 
Number of Primary Studies * Modal Series Length .005 
Number of Primary Studies * Autocorrelation .006 
Number of Primary Studies * Variances of the Error Terms .018 
Modal Number of Participants * Modal Series Length .005 
Modal Number of Participants * Autocorrelation .001 
Modal Number of Participants * Variances of the Error Terms .002 
Total Explained .939 
 
 To further explore these effects line graphs were created for the main effects of 
number of primary studies per meta-analysis ( = .59), modal number of participants per 
primary study ( = .17), and variances of the error terms ( = .09).  This model 
explained 85% of the variability in the relative bias estimates of the between person 
within study variance in the average baseline level.  The relative bias estimates of the 
between person within study variance in the average baseline level as a function of the 
number of primary studies per meta-analysis (see Figure 30) illustrated that as the 
number of primary studies per meta-analysis increased from 10 to 20 to 30 the parameter 
estimates increased to become progressively overestimated and slightly more biased, with 
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mean relative bias estimates of .200 (SD = 0.015) to .220 (SD = 0.009) to .230 (SD = 
0.005), respectively. 
 
Figure 30. Line graph showing the relative bias estimates for the between person within 
study variance in the average baseline level as a function of the number of primary 
studies per meta-analysis. 
 
The relative bias estimates of the between person within study variance in the average 
baseline level as a function of the modal number of participants per primary studies (see 
Figure 31) illustrates that as the modal number of participants per primary study 
increased from small, with a mode of 4, to large, with a mode of 8, the parameter 
estimates increased to become progressively overestimated and slightly more biased, with 
mean relative bias estimates of .210 (SD = 0.018) to .223 (SD = 0.012), respectively. 
 
	  117 
 
Figure 31. Line graph showing the relative bias estimates for the between person within 
study variance in the average baseline level as a function of the modal number of 
participants per primary study. 
 
The relative bias estimates of the between person within study variance in the average 
baseline level as a function of the variances of the error terms (see Figure 32) illustrated 
that as the variances of the error terms shifted from most of the variance at level-1 to 
most of the variance at level-2 the parameter estimates increased to become progressively 
overestimated and slightly more biased, with mean relative bias estimates of .212 (SD  = 
0.018) to .222 (SD = 0.013), respectively. 
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Figure 32. Line graph showing the relative bias estimates for the between person within 
study variance in the average baseline level as a function of the variances of the error 
terms. Level-1 = most of the variance at level-1; Level-2 = most of the variance at level-
2. 
 
Between person within study variance in the average treatment effect.  
Variation in the relative bias estimates of the between person within study variance in the 
average treatment effect was explored by modeling relative bias with the five main 
effects (number of primary studies per meta-analysis, modal number of participants per 
primary study, modal series length per primary study, level of autocorrelation, and 
variances of the error terms), a two-way interaction between the number of primary 
studies per meta-analysis and the modal number of participants per primary study, and a 
two-way interaction between the number of primary studies per meta-analysis and the 
variances of the error terms.  This model explained 94% of the variability in the relative 
bias estimates of the between person within study variance in the average treatment 
effect.  Eta-squared ( ) values for each of the main effects are in Table 15. 
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Table 15 
Eta-squared Values ( ) for Association of Design Factors with Relative Bias of the 
Between Person Within Study Variance in the Average Treatment Effect 
  
Number of Primary Studies  .537 
Modal Number of Participants  .100 
Modal Series Length  .005 
Autocorrelation .019 
Variances of the Error Terms .237 
Number of Primary Studies * Modal Number of Participants  .034 
Number of Primary Studies * Variances of the Error Terms .013 
Total Explained .945 
 
 Similar to the relative bias results for the between person within study variance in 
the average treatment effect, the main effects that met the pre-established standard of a 
medium effect size or greater were the number of primary studies per meta-analysis ( = 
.54), modal number of participants ( = .10), and variances of the error terms ( = .24).   
This model explained 88% of the variability in the between person within study variance 
of the average treatment effect.  The relative bias estimates of the between person within 
study variance in the average treatment effect as a function of the number of primary 
studies per meta-analysis (see Figure 33) illustrated that as the number of primary studies 
per meta-analysis increased from 10 to 30 to 80 the parameter estimates increased to 
become progressively overestimated and slightly more biased with mean relative bias 
estimates of .185 (SD = 0.022) to .211 (SD = 0.015) to .226 (SD = 0.008), respectively. 
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Figure 33. Line graph showing the relative bias estimates for the between person within 
study variance in the average treatment effect as a function of the number of primary 
studies per meta-analysis. 
 
The relative bias estimates of the between person within study variance in the average 
treatment effect as a function of the modal number of participants per primary study (see 
Figure 34) illustrated that as the modal number of participants per primary study 
increased from small, with a mode of 4, to large, with a mode of 8, the parameter 
estimates increased to become progressively overestimated and slightly more biased with 
mean relative bias estimates of .200 (SD = 0.025) to .215 (SD = 0.019), respectively. 
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Figure 34. Line graph showing the relative bias estimates for the between person within 
study variance in the average treatment effect as a function of the modal number of 
participants per primary study. 
 
The relative bias estimates of the between person within study variance in the average 
treatment effect as a function of the variances of the error terms (see Figure 35) 
illustrated that as the variances of the error terms shifted from most of the variance at 
level-1 to most of the variance at level-2 the parameter estimates increased to become 
progressively overestimated and slightly more biased with mean relative bias estimates of 
.196 (SD = 0.025) to .219 (SD = 0.015), respectively. 
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Figure 35. Line graph showing the relative bias estimates for the between person within 
study variance in the average treatment effect as a function of the variances of the error 
terms. Level-1 = most of the variance at level-1; Level-2 = most of the variance at level-
2. 
 
Confidence Interval Coverage 
The distribution of confidence interval coverage rates for each variance 
component is illustrated in box plots in Figures 36 - 38.  The level-3 variance components 
(  and ) tended to overcover (see Figure 36).  The between study variance in the 
overall average baseline level ( ) had confidence interval coverage rates with values 
that ranged from a high of 1.000 to a low of .978, with a mean of .998 (SD = 0.004).  
Similarly, the between study variance in the overall average treatment effect ( ) had 
confidence interval coverage rates that ranged from a high of 1.000 to a low of .934, with 
a mean of .995 (SD = 0.012).  
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Figure 36. Box plots showing the distribution of confidence interval coverage rates for 
the level-3 variance components in the three level model. 
 
The level-2 variance components (  and ) tended to undercover (see Figure 37).  
The between person within study variance in the average baseline level ( ) had 
confidence interval coverage rates with values that ranged from a high of .895 to a low of 
.083 with an average coverage rate of .612 (SD = 0.241).  Likewise, the between person 
within study variance in the average treatment effect ( ) had confidence interval 
coverage rates with values ranging from a high of .892 to a low of .109 with a mean of 
.675 (SD = 0.222).  
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Figure 37. Box plots showing the distribution of confidence interval coverage rates for 
the level-2 variance components in the three level model. 
 
The within person residual variance ( ) tended to undercover with values of confidence 
interval coverage rates ranging from a low of 0 to a high of .958 and a mean of .550 (SD 
= 0.398).  Conversely, the amount of estimated autocorrelation ( ) had confidence 
interval coverage rates that came close to the .95 coverage rate corresponding to a 
nominal level of .05 with values ranging from a low of .943 to a high of .956 and an 
average confidence interval coverage rate of .950 (SD = 0.003).  Figure 38 illustrates the 
box plots of confidence interval coverage rates for both the within person residual 
variance and the amount of estimated autocorrelation.  As indicated by the results, there 
was limited variation in the confidence interval coverage rates when estimating the 
amount of estimated autocorrelation and the 95% confidence interval coverage rates were 
on average close to the .95 coverage rate.  Therefore, any further exploration of 
confidence interval coverage rates for the amount of estimated autocorrelation is 
unwarranted. 
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Figure 38. Box plots showing the distribution of confidence interval coverage rates for 
the within person residual variance and amount of estimated autocorrelation in the three 
level model. 
 
 Between study variance in the overall average baseline level.  Variation in 
confidence interval coverage rates of the between study variance in the overall average 
baseline level was explored by modeling confidence interval coverage with the five main 
effects (number of primary studies per meta-analysis, modal number of participants per 
primary study, modal series length per primary study, level of autocorrelation, and 
variances of the error terms), all possible two-way interactions involving the number of 
primary studies per meta-analysis, all possible two-way interactions involving modal 
number of participants per primary study , all possible two-way interactions involving 
variances of the error terms, a three-way interaction involving the number of primary 
studies per meta-analysis, modal number of participants per primary study and variances 
of the error terms, and one four-way interaction involving the number of primary studies 
per meta-analysis, modal number of participants per primary study, level of 
autocorrelation, and variances of the error terms.  This model explained 96% of the 
variability in the confidence interval coverage rates of the between study variance in the 
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overall average baseline level.  Eta-squared ( ) values for each of the main effects and 
interactions are in Table 16. 
Table 16 
Eta-squared Values ( ) for Association of Design Factors with Confidence Interval 
Coverage of the Between Study Variance in the Overall Average Baseline Level 
  
Number of Primary Studies  .244 
Modal Number of Participants  .088 
Modal Series Length  .005 
Autocorrelation .013 
Variances of the Error Terms .081 
Number of Primary Studies*Modal Number of Participants  .156 
Number of Primary Studies*Modal Series Length  .007 
Number of Primary Studies*Autocorrelation .025 
Number of Primary Studies*Variances of the Error Terms .140 
Modal Number of Participants * Variances of the Error Terms .046 
Modal Number of Participants * Modal Series Length .003 
Modal Number of Participants * Autocorrelation .001 
Variances of the Error Terms * Modal Series Length .003 
Variances of the Error Terms * Autocorrelation .018 
Number of Primary Studies * Modal Number of Participants * Variances of the 
Error Terms 
.079 
Number of Primary Studies * Modal Number of Participants * Autocorrelation 
* Variances of the Error Terms 
.046 
Total Explained .955 
 
In order to explore these effects further line graphs were created for those main 
effects and interactions whose eta-squared values exceeded the pre-established standard 
of a medium effect size or greater.  Therefore, the effects that met this standard were the 
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main effects of the number of primary studies per meta-analysis ( = .24), modal 
number of participants per primary study ( = .09), variances of the error terms ( = 
.08), the two-way interaction of number of primary studies per meta-analysis with modal 
number of participants per primary study ( = .16), the two-way interaction of number 
of primary studies per meta-analysis with variances of the error terms ( = .14), and the 
three-way interaction involving number of primary studies per meta-analysis, modal 
number of participants, and variances of the error terms ( = .08).  This explained 79% 
of the variability of the confidence interval coverage rates for the between study variance 
in the overall average baseline level.  As the number of primary studies per meta-analysis 
increased from 10 to 30 to 80 the confidence interval coverage rates increased, with 
means of .996 (SD = 0.006), .999 (SD = 0.000), and 1.000 (SD = 0.000), respectively.  
Also, as the modal number of participants increased from small, with a mode of 4, to 
large, with a mode of 8, the confidence interval coverage rates increased from an average 
of .997 (SD = 0.005) to 1 (SD = 0.001), respectively.  Likewise, as the variances of the 
error terms shifted from most of the variance at level-1 to most of the variance at level-2 
the confidence interval coverage rates increased, with means of .997 (SD = 0.005) and 1 
(SD = 0.001), respectively.  The graph (see Figure 39) indicates that when the number of 
primary studies per meta-analysis was 10, the modal number of participants per primary 
study was small, and most of the variance in the error terms was at level-1 the confidence 
interval coverage rates were closest to the nominal level with a mean of .986 (SD = 
0.005).  In addition, all confidence interval coverage rates of the between study variance 
in the overall average baseline level increased when the variance of the error terms 
shifted from most of the variance at level-1 to most of the variance at level-2.  However, 
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when the number of primary studies was greater than 10 and/or the modal number of 
participants was large the increase in confidence interval coverage rates of the between 
study variance in the overall average baseline level was less noticeable.   
 
Figure 39. Line graph showing the estimated confidence interval coverage rates for the 
between study variance in the overall average baseline level as a function of the three-
way interaction between number of primary studies per meta-analysis, modal number of 
participants per primary study, and the variances of the error terms. 
 
Between study variance in the overall average treatment effect.  Variation in 
confidence interval coverage rates of the between study variance in the overall average 
treatment effect was explored by modeling confidence interval coverage with the five 
main effects (number of primary studies per meta-analysis, modal number of participants 
per primary study, modal series length per primary study, level of autocorrelation, and 
variances of the error terms), all possible two-way interactions involving the number of 
primary studies per meta-analysis, all possible two-way interactions involving modal 
number of participants per primary study , all possible two-way interactions involving 
variances of the error terms, a three-way interaction involving the number of primary 
studies per meta-analysis, modal number of participants per primary study and variances 
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of the error terms, and a four-way interaction involving the number of primary studies per 
meta-analysis, modal number of participants, level of autocorrelation, and variances of 
the error terms.  This model explained 98% of the variability in the confidence interval 
coverage rates of the between study variance in the overall average treatment effect.  Eta-
squared ( ) values for each of the main effects and interactions are in Table 17. 
Table 17 
Eta-squared Values ( ) for Association of Design Factors with Confidence Interval 
Coverage of the Between Study Variance in the Overall Average Treatment Effect 
  
Number of Primary Studies  .250 
Modal Number of Participants  .063 
Modal Series Length  .007 
Autocorrelation .025 
Variances of the Error Terms .132 
Number of Primary Studies*Modal Number of Participants  .082 
Number of Primary Studies*Modal Series Length  .012 
Number of Primary Studies*Autocorrelation .032 
Number of Primary Studies*Variances of the Error Terms .195 
Modal Number of Participants * Variances of the Error Terms .047 
Modal Number of Participants * Modal Series Length .001 
Modal Number of Participants * Autocorrelation .006 
Variances of the Error Terms * Modal Series Length .006 
Variances of the Error Terms * Autocorrelation .023 
Number of Primary Studies * Modal Number of Participants * Variances of the 
Error Terms 
.058 
Number of Primary Studies * Modal Number of Participants * Autocorrelation 
* Variances of the Error Terms 
.042 
Total Explained .975 
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Similar to the results for the between study variance in the overall average 
baseline level, a line graph was created for the number of primary studies per meta-
analysis ( = .25), modal number of participants per primary study ( = .06), variances 
of the error terms ( = .13), the two-way interaction of number of primary studies per 
meta-analysis with modal number of participants per primary study ( = .08), the two-
way interaction of number of primary studies per meta-analysis with variances of the 
error terms ( = .19), and the three-way interaction involving number of primary studies 
per meta-analysis, modal number of participants, and variances of the error terms ( = 
.06).  This model explained 77% of the variability in the confidence interval coverage of 
the between study variance in the overall average treatment effect.  As the number of 
primary studies per meta-analysis increased from 10 to 30 to 80 the confidence interval 
coverage rates of the between study variance of the overall average treatment effect 
increased, with means of .986 (SD = 0.018), .999 (SD = 0.003), and 1.000 (SD = 0.000), 
respectively.  Also, as the modal number of participants increased from small, with a 
mode of 4, to large, with a mode of 8, the confidence interval coverage rates of the 
between study variance of the overall average treatment effect increased with an average 
of .992 (SD = 0.016) to .998 (SD = 0.005), respectively.  Likewise, as the variances of the 
error terms shifted from most of the variance at level-1 to most of the variance at level-2 
the confidence interval coverage rates of the between study variance of the overall 
average treatment effect increased, with means of .991 (SD = 0.016) and .999 (SD = 
0.001), respectively.  The graph (see Figure 40) indicates that when the number of 
primary studies per meta-analysis was 10, the modal number of participants per primary 
study was small, and most of the variance of the error terms was at level-1 the confidence 
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interval coverage rates of the between study variance of the overall average treatment 
effect were closest to the nominal level with a mean of .960 (SD = 0.016).  In addition, all 
confidence interval coverage rates of the between study variance of the overall average 
treatment effect increased when the variance of the error terms shifted from most of the 
variance at level-1 to most of the variance at level-2.  However, when the number of 
primary studies was 10 and the modal number of participants was small the increase in 
confidence interval coverage rates of the between study variance of the overall average 
treatment effect was the most noticeable. 
 
Figure 40. Line graph showing the estimated confidence interval coverage rates for the 
between study variance in the overall average treatment effect as a function of the three-
way interaction between number of primary studies per meta-analysis, modal number of 
participants per primary study, and the variances of the error terms. 
 
Between person within study variance in the average baseline level.  Variation 
in the confidence interval coverage rates of the between person within study variance in 
the average baseline level was explored by modeling confidence interval coverage with 
the five main effects (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
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autocorrelation, and variances of the error terms) and a two-way interaction involving 
number of primary studies per meta-analysis and variances of the error terms.  This 
model explained 97% of the variability in the confidence interval coverage of the 
between person within study variance in the average baseline level.  Eta-squared ( ) 
values for each of the main effects and interaction are in Table 18. 
Table 18 
Eta-squared Values ( ) for Association of Design Factors with Confidence Interval 
Coverage of the Between Person Within Study Variance in the Average Baseline Level 
  
Number of Primary Studies .736 
Modal Number of Participants  .055 
Modal Series Length  .006 
Autocorrelation .011 
Variances of the Error Terms .119 
Number of Primary Studies * Variances of the Error Terms .041 
Total Explained .968 
 
 To further explore these effects line graphs were created for the main effects of 
number of primary studies per meta-analysis ( = .74), modal number of participants per 
primary study ( = .06), and variances of the error terms ( = 12).  The confidence 
interval coverage rates of the between person within study variance in the average 
baseline level as a function of the number of primary studies per meta-analysis (see 
Figure 41) illustrated that as the number of primary studies per meta-analysis increased 
from 10 to 30 to 80 confidence interval coverage rates of the between person within study 
variance in the average baseline level decreased with means of .840 (SD  = 0.036) to .656 
(SD = 0.112) to .340 (SD = 0.182), respectively.  
	  133 
 
Figure 41. Line graph showing the estimated confidence interval coverage rates for the 
between person within study variance in the average baseline level as a function of the 
number of primary studies per meta-analysis. 
 
The confidence interval coverage rates of the between person within study variance in the 
average baseline level as a function of the modal number of participants per primary 
study (see Figure 42) illustrated that as modal number of participants per primary study 
increased from small, with a mode of 4, to large, with a mode of 8, the confidence 
interval coverage rates of the between person within study variance in the average 
baseline level decreased with means of .668 (SD = 0.208) to .556 (SD = 0.261), 
respectively. 
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Figure 42. Line graph showing the estimated confidence interval coverage rates for the 
between person within study variance in the average baseline level as a function of the 
modal number of participants per primary study. 
 
The confidence interval coverage rates of the between person within study variance in the 
average baseline level as a function of the variances of the error terms (see Figure 43) 
illustrated that as variances in the error terms shifted from most of the variance in level-1 
to most of the variance in level-2 the confidence interval coverage rates of the between 
person within study variance in the average baseline level decreased with means of .695 
(SD = 0.178) to .529 (SD = 0.267), respectively. 
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Figure 43. Line graph showing the estimated confidence interval coverage rates for the 
between person within study variance in the average baseline level as a function of the 
variances of the error terms. 
 
Between person within study variance in the average treatment effect.  
Variation in the confidence interval coverage rates of the between person within study 
variance in the average treatment effect was explored by modeling confidence interval 
coverage with the five main effects (number of primary studies per meta-analysis, modal 
number of participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms) and a two-way interaction involving 
number of primary studies per meta-analysis and variances of the error terms.  This 
model explained 97% of the variability in the confidence interval coverage rates of the 
between person within study variance in the average treatment effect.  Eta-squared ( ) 
values for each of the main effects and interaction are in Table 19. 
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Table 19 
Eta-squared Values ( ) for Association of Design Factors with Confidence Interval 
Coverage of the Between Person Within Study Variance in the Average Treatment Effect 
  
Number of Primary Studies .554 
Modal Number of Participants  .038 
Modal Series Length  .004 
Autocorrelation .008 
Variances of the Error Terms .248 
Number of Primary Studies * Variances of the Error Terms .120 
Total Explained .972 
 
To further explore these effects a line graph was created that modeled the 
confidence interval coverage rates of the between person within study variance in the 
average treatment effect as a function of the number of primary studies per meta-analysis 
( = .55), variances of the error terms ( = .25) and their interaction ( = .12) and thus 
explaining 92% of the variability in the confidence interval coverage rates of the between 
person within study variance in the average treatment effect.  As the number of primary 
studies per meta-analysis increased from 10 to 30 to 80 the confidence interval coverage 
rates of the between person within study variance in the average treatment effect 
decreased, with means of .854 (SD = 0.030), .715 (SD = 0.116), and .457 (SD = 0.230), 
respectively.  Likewise, as the variances of the error terms shifted from most of the 
variance at level-1 to most of the variance at level-2 the confidence interval coverage 
rates of the between person within study variance in the average treatment effect 
decreased, with means of .785 (SD = 0.103) and .565 (SD = 0.254), respectively.  In 
addition, the graph (see Figure 44) indicates that when the number of primary studies per 
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meta-analysis was 10 and most of the variance was at level-1 the confidence interval 
coverage rates of the between person within study variance in the average treatment 
effect were closest to the nominal level with a mean of .876 (SD = 0.010).  The graph 
also illustrates a steep decline in confidence interval coverage rates of the between person 
within study variance in the average treatment effect as the number of primary studies per 
meta-analysis increased and when most of the variance in the error terms was at level-2 
with the worst coverage rates occurring when the number of primary studies per meta-
analysis was 80 (M= .248, SD = 0.960).  
 
Figure 44. Line graph showing the estimated coverage rates for the between person 
within study variance in the average treatment effect as a function of the variance of the 
error terms for each level of the number of primary studies per meta-analysis. 
 
Within person residual variance.  Variation of the confidence interval coverage 
rates of the within person residual variance was explored by modeling confidence interval 
coverage with the five main effects (number of primary studies per meta-analysis, modal 
number of participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms) and a two-way interaction involving the 
number of primary studies per meta-analysis and the level of autocorrelation.  This model 
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explained 98% of the variability in the confidence interval coverage rates of the within 
person residual variance.  Eta-squared ( ) values for each of the main effects and 
interactions are in Table 20. 
Table 20 
Eta-squared Values ( ) for Association of Design Factors with Confidence Interval 
Coverage of the Within Person Residual Variance 
  
Number of Primary Studies .055 
Modal Number of Participants  .003 
Modal Series Length  .008 
Autocorrelation .863 
Variances of the Error Terms .000 
Number of Primary Studies * Level of Autocorrelation .052 
Total Explained .981 
 
To further explore these effects line graphs were created that modeled the 
confidence interval coverage rates of the within person residual variance as a function of 
the number of primary studies per meta-analysis ( = .06), and the level of 
autocorrelation ( = .86).  The graph (see Figure 45) illustrates that as the number of 
primary studies per meta-analysis increased from 10 to 30 to 80 the confidence interval 
coverage rates of the within person residual variance decreased, with means of .665 (SD 
= 0.356), .547 (SD = 0.407), and .437 (SD = 0.406), respectively.  In addition, as the level 
of autocorrelation increased from 0 to .200 to .400 the confidence interval coverage rates 
of the within person residual variance decreased with means of .951 (SD = 0.003), .636 
(SD = 0.233), and .062 (SD = 0.109), respectively (see Figure 46).   
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Figure 45. Line graph showing the estimated confidence interval coverage rates of the 
within person residual variance as a function of the number of primary studies per meta-
analysis. 
 
 
Figure 46. Line graph showing the estimated confidence coverage rates of the within 
person residual variance as a function of the level of autocorrelation. 
 
Confidence Interval Width 
Interval widths were so large for the level-3 ( and ) and level-2 (  and 
) variance components that they provided no information.  Specifically, the 
confidence interval width estimates of between study variance in the overall average 
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baseline level ( ) ranged from a low of 3.890 X 10269 to a high of 3.197 X 10286, with 
a mean of 1.568 X 10285.  The confidence interval width estimates for the between study 
variance in the overall average treatment effect ( ) ranged from a low of 4.136 X 10269 
to a high of 5.919 X 10286, with a mean of 2.449 X 10285.  In addition, the confidence 
interval width estimates of the between person within study variance in the average 
baseline level ( ) ranged from a low of 0.077 to a high of 5.429 X 10282, with a mean 
of 5.027 X 10280.  The confidence interval width estimates for the between person within 
study variance in the average treatment effect ( ) ranged from a low of 0.103 to a high 
of 9.691 X 10286, with a mean of 9.419 X 10282.  As illustrated by the results, the 
confidence interval widths were so large for the level-3 and level-2 variance components 
that further investigation was unwarranted.  
The within person residual variance ( ) had an average confidence interval 
width estimate of 0.146 (SD = 0.075) and values ranging from 0.047 to 0.368.  The 
amount of estimated autocorrelation ( ) had a mean confidence interval width estimate 
of 0.090 (SD = 0.041) and values ranging from 0.034 to 0.177.  Figure 47 illustrates the 
distribution of confidence interval width estimates for the within person residual variance 
and the amount of estimated autocorrelation. 
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Figure 47. Box plots showing the distribution of confidence interval width estimates for 
the within person residual variance and the amount of estimated autocorrelation in the 
three level model. 
 
Within person residual variance.  Variation of the confidence interval widths in 
the within person residual variance was explored by modeling confidence interval width 
with the five main effects (number of primary studies per meta-analysis, modal number 
of participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms) and a two-way interaction involving the 
number of primary studies per meta-analysis and the level of autocorrelation.  This model 
explained 97% of the variability in the confidence interval width estimates of the within 
person residual variance.  Eta-squared ( ) values for each of the main effects and 
interactions are in Table 21. 
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Table 21 
Eta-squared Values ( ) for Association of Design Factors with Confidence Interval 
Width of the Within Person Residual Variance 
  
Number of Primary Studies .674 
Modal Number of Participants  .026 
Modal Series Length  .078 
Autocorrelation .160 
Variances of the Error Terms .000 
Number of Primary Studies * Level of Autocorrelation .029 
Total Explained .967 
 
To further explore these effects line graphs were created that modeled the 
confidence interval width estimates as a function of the number of primary studies per 
meta-analysis ( = .67), modal series length per primary study ( = .08), and the level 
of autocorrelation ( = .16) as they were the only effects that met the pre-established 
standard of a medium effect size or greater.  The confidence interval width estimates of 
the within person residual variance as a function of the number of primary studies per 
meta-analysis (see Figure 48) illustrated that as the number of primary studies per meta-
analysis increased from 10 to 30 to 80 confidence interval width estimates decreased with 
means of .227 (SD = 0.062) to .130 (SD = 0.035) to .080 (SD = 0.022), respectively.  
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Figure 48. Line graph showing the estimated confidence interval widths for the within 
person residual variance as a function of the number of primary studies per meta-analysis. 
 
The confidence interval width estimates of the within person residual variance as a 
function of the modal series length per primary study (see Figure 49) illustrates that as 
the modal series length increased from small, with a mode of 10, to medium, with a mode 
of 20, to large, with a mode of 30, the confidence interval width estimates of the within 
person residual variance decreased with means of .172 (SD = 0.084) to .143 (SD = 0.070) 
to .122 (SD = 0.061), respectively.  
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Figure 49. Line graph showing the estimated confidence interval widths for the with 
person residual variance as a function of the modal series length per primary study. 
 
The confidence interval width estimates of the within person residual variance as a 
function of the level of autocorrelation (see Figure 50) illustrated that as the level of 
autocorrelation increased from 0 to .200 to .400 the confidence interval width estimates 
of the within person residual variance increased with means of .117 (SD = 0.053) to .134 
(SD = 0.062) to .186 (SD = 0.087), respectively.  
 
Figure 50. Line graph showing the estimated confidence interval widths for the within 
person residual variance as a function of the level of autocorrelation. 
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Amount of estimated autocorrelation.  Variation in the confidence interval 
width estimates of the amount of autocorrelation was explored by modeling confidence 
interval width with the five main effects (number of primary studies per meta-analysis, 
modal number of participants per primary study, modal series length per primary study, 
level of autocorrelation, and variances of the error terms).  This model explained 97% of 
the variability in the confidence interval width estimates of the amount of autocorrelation.  
Eta-squared ( ) values for each of the main effects are in Table 22. 
Table 22 
Eta-squared Values ( ) for Association of Design Factors with Confidence Interval 
Width of the Amount of Estimated Autocorrelation 
  
Number of Primary Studies .827 
Modal Number of Participants  .031 
Modal Series Length  .107 
Autocorrelation .000 
Variances of the Error Terms .002 
Total Explained .967 
 
To further explore these effects line graphs were created that modeled the 
confidence interval width estimates as a function of the number of primary studies per 
meta-analysis ( = .83), and modal series length per primary study ( = .11).  The 
confidence interval width estimates of the amount of estimated autocorrelation as a 
function of the number of primary studies per meta-analysis (see Figure 51) illustrate that 
as the number of primary studies per meta-analysis increased from 10 to 30 to 80 
confidence interval width estimates of the amount of estimated autocorrelation decreased 
with means of .139 (SD = 0.025) to .080 (SD = 0.014) to .050 (SD = 0.009), respectively. 
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Figure 51. Line graph showing the estimated confidence interval widths for the amount 
of estimated autocorrelation as a function of the number of primary studies per meta-
analysis. 
 
The confidence interval width estimates of the amount of estimated autocorrelation as a 
function of the modal series length per primary study (see Figure 52) illustrated that as 
the modal series length increased from small, with a mode of 10, to medium, with a mode 
of 20, to large, with a mode of 30, the confidence interval width estimates of the amount 
of estimated autocorrelation decreased with means of .107 (SD = 0.045) to .088 (SD = 
0.038) to .074 (SD = 0.033), respectively.  
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Figure 52. Line graph showing the estimated confidence interval widths for the amount 
of estimated autocorrelation as a function of the modal series length per primary study. 
 
Relationships Among Dependent Variables 
One may have anticipated that relationships existed between certain dependent 
variables for example confidence interval coverage and confidence interval width.  In 
addition, when reviewing the results of this study it became apparent that relationships 
existed among the dependent variables per estimated effect. Therefore, correlations 
among the dependent variables were examined for each fixed effect and variance 
component.  Correlation coefficients were compared to Cohen’s (1988) standards for 
interpreting correlation coefficients with a weak relationship having an r = .1, a moderate 
relationship having an r = .3, and a strong relationship having an r = .5.  
Fixed Effects 
Overall average baseline level.  The relationships among the overall average 
baseline level dependent variables are summarized in Table 23.  A perusal of Table 23 
indicates a strong and positive relationship between confidence interval coverage and 
width of the overall average baseline level with a correlation of .671.  Specifically, as 
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confidence interval coverage of the overall average baseline level increased so did the 
width of the overall average baseline level.  In addition, the relationships between bias 
and confidence interval coverage and width of the overall average baseline level were 
weak.   
Table 23 
Summary of Correlations, Means, and Standard Deviations for the Overall Average 
Baseline Level Dependent Variables  
Dependent Variable 1 2 3 
1. Bias - .063 .056 
2. Confidence Interval Coverage  - .671 
3. Confidence Interval Width   - 
Mean 0.000 .961 0.427 
Standard Deviation 0.002 0.005 0.291 
Note. Values in the table are based on 108 conditions in the simulation 
 
Overall average treatment effect.  Similar to the correlation results for the 
overall average baseline level, a strong and positive relationship existed between 
confidence interval coverage and width of the overall average treatment effect with a 
correlation of .612.  Specifically, as confidence interval coverage of the overall average 
treatment effect increased so did the confidence interval width of the overall average 
treatment effect.  However, relationships involving the bias estimates of the overall 
average treatment effect were weak.  Relationships among the overall average treatment 
effect dependent variables are summarized in Table 24.   
Table 24 
Summary of Correlations, Means, and Standard Deviations for the Overall Average 
Treatment Effect Dependent Variables  
Dependent Variable 1 2 3 
1. Bias - .149 .012 
2. Confidence Interval Coverage  - .612 
3. Confidence Interval Width   - 
Mean 0.000 .960 0.459 
Standard Deviation 0.001 0.005 0.293 
Note. Values in the table are based on 108 conditions in the simulation 
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Variance Components 
Between study variance in the overall average baseline level.  The 
relationships among the between study variance in the overall average baseline level 
dependent variables are summarized in Table 25.  It should be noted that due to 
extremely large confidence interval width estimates of the between study variance in the 
overall average baseline level correlations between the confidence interval widths and the 
other dependent variables was not calculated.  An examination of Table 25 indicates 
several noteworthy relationships among the between study variance in the overall average 
baseline level dependent variables.  Specifically, the relationship between relative bias 
and confidence interval coverage of the between study variance in the overall average 
baseline level is strong and negative with a correlation of -.781.  This relationship 
indicates that as relative bias increased confidence interval coverage decreased.  A 
moderate, positive relationship existed between bias and relative bias of the between 
study variance in the overall average baseline level (r = .357) indicating that as bias 
increased so did relative bias.  Conversely, a moderate, negative relationship existed 
between bias and confidence interval coverage of the between study variance in the 
overall average baseline level (r = -.306) indicating that as bias increased confidence 
interval coverage decreased. 
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Table 25 
Summary of Correlations, Means, and Standard Deviations for the Between Study 
Variance in the Overall Average Baseline Level Dependent Variables 
Dependent Variable 1 2 3 
1. Bias - .357 -.306 
2. Relative Bias  - -.781 
3. Confidence Interval Coverage   - 
Mean -0.241 -.858 .999 
Standard Deviation 0.201 0.078 0.004 
Note. Values in the table are based on 108 conditions in the simulation 
 
Between study variance in the overall average treatment effect.  It should be 
noted that due to extremely large confidence interval width estimates of the between 
study variance in the overall average treatment effect correlations between the confidence 
interval widths and the other dependent variables was unwarranted.  Similar to the 
correlation results for the between study variance in the overall average baseline level, 
several noteworthy relationships among the between study variance in the overall average 
treatment effect dependent variables existed.  Specifically, the relationship between 
relative bias and confidence interval coverage of the between study variance in the 
overall average treatment effect is strong and negative with a correlation of -.850.  This 
relationship indicates that as relative bias increased confidence interval coverage 
decreased.  A strong, positive relationship existed between bias and relative bias of the 
between study variance in the overall average treatment effect (r = .536) indicating that 
as bias increased so did relative bias.  Conversely, a moderate, negative relationship 
existed between bias and confidence interval coverage of the between study variance in 
the overall average baseline level (r = -.384) indicating that as bias increased confidence 
interval coverage decreased.  Relationships among the dependent variables are 
summarized in Table 26.   
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Table 26 
Summary of Correlations, Means, and Standard Deviations for the Between Study 
Variance in the Overall Average Treatment Effect Dependent Variables 
Dependent Variable 1 2 3 
1. Bias - .536 -.384 
2. Relative Bias  - -.851 
3. Confidence Interval Coverage   - 
Mean -0.237 -.822 .995 
Standard Deviation 0.201 0.106 0.012 
Note. Values in the table are based on 108 conditions in the simulation 
 
Between person within study variance in the average baseline level.  The 
relationships among the between person within study variance in the average baseline 
level dependent variables are summarized in Table 27.  It should be noted that due to 
extremely large confidence interval width estimates of the between person within study 
variance in the average baseline level correlations between the confidence interval widths 
and the other dependent variables was unwarranted.  A perusal of Table 27 indicates 
several notable relationships among the between person within study variance in the 
average baseline level dependent variables.  Specifically, the relationship between 
relative bias and confidence interval coverage of the between person within study 
variance in the average baseline level was strong and negative with a correlation of -.802.  
This relationship indicates that as relative bias increased confidence interval coverage 
decreased.  A moderate, positive relationship existed between bias and relative bias of the 
between person within study variance in the average baseline level (r = .364) indicating 
that as bias increased so did relative bias.  Conversely, a moderate, negative relationship 
existed between bias and confidence interval coverage of the between person within 
study variance in the average baseline level (r = -.409) indicating that as bias increased 
confidence interval coverage decreased. 
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Table 27 
Summary of Correlations, Means, and Standard Deviations for the Between Person 
Within Study Variance in the Average Baseline Level Dependent Variables 
Dependent Variable 1 2 3 
1. Bias - .364 -.409 
2. Relative Bias  - -.802 
3. Confidence Interval Coverage   - 
Mean 0.243 .217 .612 
Standard Deviation 0.202 0.017 0.241 
Note. Values in the table are based on 108 conditions in the simulation 
 
Between person within study variance in the average treatment effect.  It 
should be noted that due to extremely large confidence interval width estimates of the 
between person within study variance in the average treatment effect correlations 
between the confidence interval widths and the other dependent variables was 
unwarranted.  Similar to the correlation results for the between participants within study 
variance in the average baseline level, several notable relationships among the between 
person within study variance in the average treatment effect dependent variables existed.  
Specifically, the relationship between relative bias and confidence interval coverage of 
the between person within study variance in the average treatment effect was strong and 
negative with a correlation of -.760.  This relationship indicated that as relative bias 
increased confidence interval coverage decreased.  A strong, positive relationship existed 
between bias and relative bias of the between person within study variance in the average 
treatment effect (r = .542) indicating that as bias increased so did relative bias.  
Conversely, a moderate, negative relationship existed between bias and confidence 
interval coverage of the between person within study variance in the average treatment 
effect (r = -.573) indicating that as bias increased confidence interval coverage decreased.  
Relationships among the dependent variables are summarized in Table 28.   
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Table 28 
Summary of Correlations, Means, and Standard Deviations for the Between Participant 
Within Study Variance in the Average Treatment Effect Dependent Variables 
Dependent Variable 1 2 3 
1. Bias - .542 -.573 
2. Relative Bias  - -.760 
3. Confidence Interval Coverage   - 
Mean 0.238 .208 .675 
Standard Deviation 0.201 0.023 0.222 
Note. Values in the table are based on 108 conditions in the simulation 
 
Within person residual variance.  The relationships among the within person 
residual variance dependent variables are summarized in Table 29.  A perusal of Table 29 
indicates a strong and negative relationship between bias and confidence interval 
coverage of the within person residual variance with a correlation of -.919.  Specifically, 
as bias of the within person residual variance increased so did the confidence interval 
coverage.  In addition, a moderate, positive relationship existed between bias and 
confidence interval width of the within person residual variance with a correlation of 
.402.  Conversely, the relationship between confidence interval coverage and width of the 
within person residual variance were weak.   
Table 29 
Summary of Correlations, Means, and Standard Deviations for the Within Person 
Residual Variance Dependent Variables  
Dependent Variable 1 2 3 
1. Bias - -.919 .402 
2. Confidence Interval Coverage  - -.133 
3. Confidence Interval Width   - 
Mean 0.078 .550 0.146 
Standard Deviation 0.082 0.398 0.075 
Note. Values in the table are based on 108 conditions in the simulation 
 
Amount of estimated autocorrelation.  The relationships among the amount of 
estimated autocorrelation dependent variables are summarized in Table 30.  A perusal of 
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Table 30 indicates several notable relationships among the amount of estimated 
autocorrelation dependent variables. Specifically, the relationship between bias and 
relative bias of the estimated autocorrelation was strong and positive with a correlation of 
.931.  This relationship indicated that as bias increased so did relative bias.  A strong, 
negative relationship existed between relative bias and confidence interval width of the 
amount of estimated autocorrelation (r = -.625) indicating that as relative bias increased 
confidence interval width decreased.  Similarly, a moderate, negative relationship existed 
between bias and confidence interval width (r = -.444) of the amount of estimated 
autocorrelation indicating that as bias increased confidence interval width decreased. 
Table 30 
Summary of Correlations, Means, and Standard Deviations for the Amount of Estimated 
Autocorrelation Dependent Variables  
Dependent Variable 1 2 3 4 
1. Bias - .931 .100 -.444 
2. Relative Bias  - .164 -.615 
3. Confidence Interval Coverage   - -.146 
4. Confidence Interval Width    - 
Mean 0.000 -.001 .950 0.090 
Standard Deviation 0.000 0.002 0.003 0.042 
Note. Values in the table are based on 108 conditions in the simulation 
 
Summary 
Please see Table 31 for a summary of the results.  The table is comprised of a 
column for each dependent variable (i.e., bias and/or relative bias of the point estimates, 
confidence interval coverage, and confidence interval width) and a row for each effect 
(i.e., fixed effects and variance components) with a brief summary provided in each cell.
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Table 31 
Summary of Results 
Parameter Estimate Bias Relative Bias Confidence Interval Coverage Confidence Interval Width 
Fixed Effects     
Overall Average 
Baseline Level 
- Unbiased (M = 0.00)  N/A -Tended to overcover (M = .961) 
- Came close to nominal level as 
level-3 sample size increased 
- Relatively small (M = 
0.428) 
- Intervals smallest when 
level-3 sample size was 
largest and less variance 
was at level-2 and level-3 
Overall Average 
Treatment Effect 
- Unbiased (M = 0.00) N/A -Tended to overcover (M = .960) 
- Came close to nominal level as 
level-3 sample size increased 
- Relatively small (M = 
0.459) 
-Intervals smallest when 
level-3 sample size was 
largest and less variance 
was at level-2 and level-3 
Variance Components     
Level-3     
Between Study 
Variance in the Overall 
Average Baseline 
Level 
- Biased (M = - 0.241) 
- Tended to be 
underestimated  
- Less biased when most 
of the variances in the 
error terms was at level-
1 
-Biased (M = -.858) 
- Less biased as level-3, 
level-2 sample sizes 
decreased and when 
most of the variances in 
the error terms was at 
level-1 
- Tended to overcover (M = 
.998) 
- Moved towards the nominal 
level when the level-3 and level-
2 sample sizes were smallest and 
most of the variances in the error 
terms was at level-1 
- Too large to provide any 
information (M = 1.568 X 
10285) 
Between Study 
Variance in the Overall 
Average Treatment 
Effect  
- Biased (M = - 0.237) 
- Tended to be 
underestimated 
- Less biased when most 
of the variances in the 
error terms was at level-
1 
-Biased (M = -.822) 
- Less biased as level-3, 
level-2 sample sizes 
decreased and when 
most of the variances in 
the error terms was at 
level-1 
- Tended to overcover (M = 
.995) 
- Moved towards the nominal 
level when the level-3 and level-
2 sample sizes were smallest and 
most of the variance in the error 
terms was at level-1 
- Too large to provide any 
information (M = 2.449 X 
10285) 
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Table 31 (Continued) 
Parameter Bias Relative Bias Confidence Interval Coverage Confidence Interval Width 
Level-2      
Between Person 
Within Study Variance 
in the Average 
Baseline Level 
- Biased (M = 0.243) 
- Tended to be 
overestimated 
- Less biased when most 
of the variance in the 
error terms was at level-
1 
-Biased (M = .217) 
- Less biased as level-3, 
level-2 sample sizes 
decreased and when 
most of the variance was 
at level-1 
-Tended to undercover (M = 
.612) 
- Moved towards the nominal 
level when the level-3 and 
level-2 sample sizes were 
smallest and when most of 
the variance was at level-1 
- Too large to provide any 
information (M = 5.027 X 
10280) 
Between Person 
Within Study Variance 
in the Average 
Treatment Effect 
- Biased (M = 0.238) 
- Tended to be 
overestimated 
- Less biased when most 
of the variance in the 
error terms was at level-
1 
-Biased (M  = .208) 
- Less biased as level-3, 
level-2 sample sizes 
decreased and when 
most of the variance in 
the error terms was at 
level-1 
- Tended to undercover (M = 
.675) 
- Moved towards the nominal 
level when the level-3 sample 
size was smallest and when 
most of the variance in the 
error terms was at level-1 
- Too large to provide any 
information (M = 9.419 X 
10282) 
Level-1     
Within Person 
Residual Variance 
- Biased (M = 0.078) 
- Tended to be slightly 
overestimated 
- Least biased when 
autocorrelation was 0 
N/A - Tended to undercover (M = 
.550) 
- Close to the nominal level 
when autocorrelation was 0  
- Relatively small intervals 
(M = 0.146) 
- Smallest intervals when 
level-3 and level-1 sample 
sizes were largest and level 
of autocorrelation was 0 
 
Amount of Estimated 
Autocorrelation 
- Unbiased (M = 0.001)  -Unbiased (M = -.001) - Close to the nominal level, 
regardless of condition (M = 
.950) 
- Relatively small intervals 
(M = 0.090) 
- Smallest intervals when 
level-3 and level-1 sample 
sizes were largest  
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Fixed Effects 
Results indicated that the fixed effects, both the overall average baseline level       
( ) and the overall average treatment effect ( ), were unbiased regardless of 
condition, with average bias values of zero.  However, confidence interval coverage rates 
of the fixed effects tended to overcover.  Variation in the confidence interval coverage 
rates of the overall average baseline level was explored by examining the only factor with 
a medium or larger effect size, the number of primary studies per meta-analysis (level-3 
sample size).  Further examination of this effect illustrated that as the level-3 sample size 
became larger the closer the confidence interval coverage rates came to a .95 coverage 
rate representing an alpha level of .05.  Likewise, the number of primary studies per 
meta-analysis had the same impact on the confidence interval coverage of the overall 
average treatment effect indicating that as the level-3 sample size increased the closer the 
confidence interval coverage rates came to a .95 coverage rate.   
Confidence interval widths of both fixed effects, the overall average baseline level 
and the overall treatment effect, were relatively small.  To gain a better understanding for 
widths of this size, it is helpful to recall that the level-1 variance was set to 1.0 and both 
fixed effects were set to 1.0.  Therefore, average confidence interval widths of 0.459 for 
the overall average treatment effect would produce an overall average treatment effect 
interval that ranged from around 0.770 to 1.230.  Variation in the confidence interval 
width estimates of the overall average baseline level were explored by creating a line 
graph showing the confidence interval width estimates as a function of the interaction 
between the number of primary studies per meta-analysis and the variances of the error 
terms.  The results indicated that confidence interval widths were smallest when the 
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number of primary studies per meta-analysis was 80 and most of the variance was at 
level-1 or less variance was at level-2 and level-3.  Similar results were found for the 
overall average treatment effect. 
Variance Components 
Level-3 and level-2 variance components tended to be biased, with level-3 
variance components tending to be underestimated and level-2 variance components 
tending to be overestimated.  Parameter estimates of the between study variance in the 
overall average baseline level ( ) and the between study variance in the overall 
average treatment effect ( ) tended to become increasingly underestimated and 
progressively more biased when the variances of the error terms shifted from most of the 
variance at level-1 to most of the variance at level-2.  Parameter estimates of the between 
person within study variance in the average baseline level ( ) and in the average 
treatment effect ( ) tended to become increasingly overestimated and progressively 
more biased when the variances of the error terms shifted from most of the variance at 
level-1 to most of the variance at level-2.  The within person residual variance ( ) was 
also biased with an average bias value being slightly above zero.  Parameter estimates of 
the within person residual variance tended to become increasingly overestimated and 
slightly more biased when the level of autocorrelation increased.  However, the amount 
of estimated autocorrelation ( ρ
 ) in the three level model was on average unbiased with 
the bias estimate not exceeding 1% of the known parameter value.   
Relative bias was also evaluated for any parameter whose known value was 
different from one.  Results indicated that the parameter estimates of the level-3 variance 
components (between study variance in the overall average baseline level and between 
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study variance in the overall average treatment effect) tended to be underestimated and 
became progressively more underestimated and biased when the number of primary 
studies per meta-analysis increased, the modal number of participants per primary study 
increased, and the variances of the error terms shifted from most of the variance at level-1 
to most of the variance at level-2.  In addition, the parameter estimates of the level-2 
variance components (between person within study variance in the average baseline level 
and between person within study variance in the average treatment effect) tended to be 
overestimated and became progressively more overestimated and biased when the 
number of primary studies per meta-analysis increased, the modal number of participants 
per primary study increased, and the variances of the error terms shifted from most of the 
variance at level-1 to most of the variance at level-2.   
Confidence intervals of the level-3 variance components tended to overcover but 
were closest to a .95 coverage rate when the number of primary studies per meta-analysis 
was 10, the modal number of participants per primary study was small, and most of the 
variance was at level-1.  In addition, as the variances of the error terms shifted from most 
of the variance at level-1 to most of the variance at level-2 confidence interval coverage 
rates for the level-3 variance components increased regardless of the number of primary 
studies per meta-analysis or modal number of participants per primary study.  Confidence 
intervals of the level-2 variance components and the residual variance tended to 
undercover.  The confidence interval coverage rates of the between person within study 
variance in the average baseline level tended to decrease when the number of primary 
studies per meta-analysis increased, the modal number or participants per primary study 
increased and the variances of the error terms shifted from most of the variance at level-1 
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to most of the variance at level-2.  The confidence interval coverage rates of the between 
person within study variance in the average treatment effect tended to decrease as the 
number of primary studies per meta-analysis increased and the variances of the error 
terms shifted from most of the variance at level-1 to most of the variance at level-2.  In 
addition, the confidence interval coverage rates of the within person residual variance 
decreased as the number of primary studies per meta-analysis and the level of 
autocorrelation increased.  Conversely, the confidence interval coverage rates of the 
amount of estimated autocorrelation were close to a .95 coverage rate regardless of 
condition. 
Confidence interval widths were so large for the level-3 and level-2 variance 
components that they provided no information.  However, the confidence interval width 
estimates for the within person residual variance produced relatively small intervals (M = 
0.146) and tended to decrease as the number of primary studies per meta-analysis, modal 
series length per primary study, and the level of autocorrelation increased.  For example, 
consider the fact that the within person residual variance was set to 1.0 therefore a small 
series length, with a mode of 10, would yield a confidence interval from about .914 to 
1.086, but a medium series length, with a mode of 20, would produce a confidence 
interval from .929 to 1.072, and a large series length, with a mode of 30, would provide 
an even tighter confidence interval from .939 to 1.061.  Similarly, the confidence interval 
width estimates for the amount of estimated autocorrelation were also relatively small (M 
= 0.090) and tended to decrease as the number of primary studies per meta-analysis and 
series length per primary study increased.  Therefore, based on the results of the 
confidence interval widths of the amount of estimated autocorrelation, when the amount 
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of estimated autocorrelation was set to 0 a level-3 sample size of 10 primary studies 
would produce a confidence interval from about -.070 to .070, but a level-3 sample size 
of 30 primary studies would lead to a confidence interval from around -.040 to .040, and 
a level-3 sample size of 80 would yield even greater precision with a confidence interval 
from about -.025 to .025.
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CHAPTER FIVE: DISCUSSION 
This chapter outlines a summary of the study and results, along with a discussion 
of the findings, limitations of the study, and implications.  
Summary of the Study 
Quantitative integration of study results, termed meta-analysis, involves the 
combining of data across multiple studies to evaluate and summarize research findings.  
The term meta-analysis was first coined by Glass (1976) and was defined as “the 
statistical analysis of a large collection of analysis results from individual studies for the 
purpose of integrating the findings” (p.3).  This type of research is an important way to 
determine relationships among variables and the effectiveness of interventions across 
studies.  It also allows researchers to integrate study findings with the goal of 
generalization.  Quantitative integration of study findings should cross research domains 
and include all types of quantitative research, including single-case research.   However, 
meta-analysis of single-case research has resulted in much disagreement in the field.   
Although the use of single-case designs has grown over the past decades, the 
majority of literature on meta-analysis focuses on group comparison studies and leaves 
out single-case research (Van den Noortgate & Onghena, 2008).  This lack of literature 
related to single-case designs is often why these designs are excluded from meta-
analyses.  This exclusion of single-case designs is concerning when one considers the 
plethora of information single-case research can add to the literature.  Single-case designs 
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not only provide information related to average treatment effects but also offers 
information related to how that treatment effect is related to specific cases.  Meta-
analyses of single-case designs offer the ability to summarize and evaluate the overall 
effect without the loss of that specific case information.  In addition, the meta-analysis of 
single-case data increases the generalizabilty of research findings. 
Researchers have proposed a variety of methods to meta-analyze single-case data.  
Van den Noortgate and Onghena’s (2008) proposed method of using multilevel modeling 
to meta-analyze single-case data offers many advantages.  The use of multilevel 
modeling provides the flexibility of appropriately modeling the autocorrelational nature 
of single-case data, can take into consideration multiple effect sizes per study, and can 
apply appropriate meta-analytic models, such as fixed or random effects models. 
Although the use of multilevel modeling offers advantages in the analysis of single-case 
data, there is still concern as to whether the use of multilevel modeling is appropriate for 
single-case data.  Specifically, multilevel modeling is based on large sample theory, 
which is not representative of single-case data.  Therefore, it was necessary to further 
investigate the appropriateness of inferences made from multilevel modeling when 
applied to single-case data.  
The purpose of this study was to examine the appropriateness of Van den 
Noortgate and Onghena’s (2008) raw data multilevel modeling approach to the meta-
analysis of single-case data.  Specifically, the study examined the fixed effects (i.e., the 
overall average baseline level and the overall average treatment effect) and the variance 
components (e.g., the between person within study variance in the average baseline level, 
the between study variance in the overall average baseline level, the between person 
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within study variance in the average treatment effect) in a three level multilevel model.  
More specifically, bias of point estimates, confidence interval coverage rates, and 
confidence interval widths were examined as a function of specific design and data 
factors. 
Monte Carlo simulation methods were used to examine the appropriateness of 
multilevel modeling inferences.  The use of simulation methods allowed for the control 
and manipulation of specific design and data factors.  The Monte Carlo study included 
five factors in the design.  These factors were (a) number of primary studies per meta-
analysis (10, 30, and 80); (b) modal number of participants per primary study (small 
[mode = 4] and large [mode = 8]); (c) modal series length per primary study (small 
[mode = 10], medium [mode = 20], and large [mode = 30]); (d) level of autocorrelation 
(0, .2, and .4); and (e) variances of the error terms (most of the variance at level-1 [ = 
1, = .2, and = .05] and most of the variance at level-2 [ = 1, 
= 2, and = .5]).  The values chosen for each of these factors were 
based on previous simulation research and observed factors of actual single-case meta-
analyses. 
The data for this study were generated based on Van den Noortgate and 
Onghena’s (2008) raw data, three level meta-analytic single-case model shown in 
Equations 24 through 28.  Each data set was analyzed using the same model that was 
used for data generation (see Equations 24 - 28).  The three level model was estimated 
using restricted maximum likelihood (REML) via PROC MIXED with the Kenward-
Roger degrees of freedom method in SAS version 9.2 (SAS Institute Inc., 2008).  In 
addition, a first order auto-regressive model for the level-1 errors was specified.  Based 
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on the current model, the treatment effect was modeled as a change in level, and 
estimates were obtained for autocorrelation, variance within participants, variance in 
baseline levels across participants and studies, and variance in treatment effects across 
participants and studies. 
The appropriateness of Van den Noortgate and Onghena’s (2008) raw data 
multilevel modeling approach to the meta-analysis of single-case data was evaluated by 
examining bias and/or relative bias of the point estimates, confidence interval coverage, 
and confidence interval width of both the fixed effects and the variance components.  
This was accomplished by creating box plots, across all conditions, for each dependent 
variable.  Then, the results of the simulation were analyzed using PROC GLM in SAS 9.2 
for both the fixed effects and the variance components such that the dependent variables 
were bias, relative bias (where appropriate), confidence interval coverage, and confidence 
interval width and the independent variables were the five factors.  Models were built 
with the purpose of finding effects whose eta-squared values were .06 or greater.  The 
effects size, eta-squared ( ), was calculated to determine the proportion of variability 
associated with each effect.  Those values were compared to Cohen’s (1988) standards 
for interpreting eta-squared values with a small effect size having an = .01, .a medium 
effect size having an = .06, and a large effect size having an  = .14 or greater.  Each 
model was first created as a main effects only model.  If this model explained 94% of the 
total variability then no further complex models were investigated.  However, if less than 
94% of the total variability was explained then interactions were included in the model.  
Two-way interactions were added to the model first followed by three-way and then four-
way interactions until at least 94% of the variability was explained. 
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Research Questions 
1. To what extent are the fixed effect estimates from a three level meta-analytic 
single-case model biased as a function of specific design factors (number of 
primary studies per meta-analysis, modal number of participants per primary 
study, modal series length per primary study, level of autocorrelation, and 
variances of the error terms)? 
2. To what extent does the confidence interval coverage of the fixed effect estimates 
from a three level meta-analytic single-case model vary as a function of specific 
design factors  (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
3. To what extent does the confidence interval width of the fixed effect estimates 
from a three level meta-analytic single-case model vary as a function of specific 
design factors  (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
4. To what extent are the variance components from a three level meta-analytic 
single-case model biased as a function of specific design factors  (number of 
primary studies per meta-analysis, modal number of participants per primary 
study, modal series length per primary study, level of autocorrelation, and 
variances of the error terms)? 
5. To what extent does the confidence interval coverage of the variance components 
from a three level meta-analytic single-case model vary as a function of specific 
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design factors  (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
6. To what extent does the confidence interval width of the variance components 
from a three level meta-analytic single-case model vary as a function of specific 
design factors  (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, level of 
autocorrelation, and variances of the error terms)? 
Discussion of Study Results 
Fixed Effects 
The extent to which the fixed effects from a three level meta-analytic single-case 
model were biased, as a function of the specific design factors, was evaluated by the 
average amount that the estimated parameter differed from the known parameter.  The 
results indicated that regardless of condition the fixed effects were unbiased with average 
bias values of zero.  The unbiased fixed effect estimates revealed in this research are 
consistent with previous research regarding the utility of the inferences made from fixed 
effects in two level models (Ferron et al., 2009; Raudenbush & Bryk, 2002).  Therefore, 
the use of fixed effects from a three level meta-analytic single-case model are likely to 
provide unbiased estimates of the average baseline level and average treatment effect 
across studies, if the model is correctly specified. 
The proportion of the 95% confidence intervals that contained the parameter 
value estimated the confidence interval coverage of the fixed effects from a three level 
meta-analytic single-case model.  The confidence interval coverage rates of the fixed 
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effects, both the overall average baseline level and the overall average treatment effect, 
tended to overcover with means of .961 and .960, respectively.  Further examination of 
the extent to which the fixed effects varied as a function of the specific design factors 
illustrated that the 95% confidence interval coverage rates of the fixed effects came close 
to a .95 coverage rate as the level-3 sample size increased.  These findings suggest that 
whenever possible researchers should increase the level-3 sample size or number of 
primary studies included in the meta-analysis.  In addition, these findings validate 
previous literature related to two level models for single-case data that states larger upper 
level units lead to greater accuracy and precision (Ferron et al., 2009). 
These findings are also consistent with general methodological research on more 
traditional designs of repeated measurements using multilevel models and the Kenward 
Roger degrees of freedom (Fouladi & Shieh, 2004; Gomez, Schaalje, & Fellingham, 
2005; Kenward & Roger, 1997; Kowalchuk, Keselman, Algina, & Wolfinger, 2004; 
Schaalje, McBride, &Fellingham, 2001).  These previous simulation studies have 
indicated that across a variety of conditions and sample sizes Type I error rates have been 
close to the nominal alpha level but variability in performance was noted.  For example, 
Gomez, Schaalje, and Fellingham (2005) examined a three-group design with three 
participants per group and each participant measured at three points in time and they 
found that Type I error control varied based on the type of covariance structure.  In 
particular, results indicated that when the data were generated and analyzed assuming 
compound symmetry the estimated Type I error rate was .052 (  = .05).  However, when 
the data were generated and analyzed assuming a 1st order autoregressive with random 
effects model the estimated Type I error rate was .1165 (  = .05).  
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The average difference between the upper and lower limits of the 95% confidence 
intervals defined the confidence interval widths of the fixed effects from a three level 
meta-analytic single-case model.  The confidence interval widths of the fixed effects, 
both the overall average baseline level and the overall average treatment were relatively 
small with average confidence interval width estimates of 0.428 and 0.459, respectively.  
To gain a better understanding for widths of this size, it is helpful to recall that the level-1 
variance was set to 1.0 and both fixed effects were set to 1.0.  Therefore, average 
confidence interval widths of 0.459 for the overall average treatment effect would 
produce interval estimates that ranged from around 0.770 to 1.230.  Further examination 
of the extent to which the confidence interval widths of the fixed effects varied as a 
function of the specific design factors indicated that the interaction between the level-3 
sample size and the variances of the error terms impacted the variability in confidence 
interval widths of the fixed effects.  Specifically, confidence interval widths of the fixed 
effects were smallest when the level-3 sample sizes were largest (mode = 80) and most of 
the variance in the error terms was at level-1 or less variance at level-2 and level-3.  
Similar to previous research examining two level models for single-case data (Ferron et 
al., 2009; Ferron et al., 2010), which found that confidence interval widths of the 
treatment effect decreased with more participants, more observations per participant, and 
smaller variance components, this study’s results would suggest that a larger number of 
upper level units and less variability between persons and studies would produce more 
precise confidence intervals of the fixed effects.  
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Variance Components 
The extent to which the variance components from a three level single-case meta-
analytic model were biased, as a function of the specific design factors, was evaluated by 
the average amount that the estimated parameter differed from the known parameter.  As 
expected, the level-3 and level-2 variance components tended to be biased.  Specifically, 
the level-3 variance components, both in the between study variance in the overall 
average baseline level and the between study variance in the overall average treatment 
effect, tended to be underestimated with means of -0.241 and -0.237, respectively.  The 
level-2 variance components, both the between person within study variance in the 
average baseline level and the between person within study variance in the average 
treatment effect, tended to be overestimated with means of 0.243 and 0.238, respectively.  
These findings are not too surprising given other research from a broader methodological 
perspective.  Previous Monte Carlo research on growth curve models with studies having 
as few as 30 participants and series lengths of 4 or 8 (Kwok, West, & Green, 2007) and 
series length of 5 or 8 (Murphy & Pituch, 2009) have all reported substantial bias in the 
variance components when the model was correctly specified and the number of 
participants was small (N = 30).  In the present study, bias in the level-3 variance 
components was mainly impacted by one factor, the variances of the error terms.  As the 
variances of the error terms shifted from most of the variance at level-1 to most of the 
variance at level-2, the level-3 variance components tended to become increasingly 
underestimated and progressively more biased.  Conversely, the level-2 variance 
components became increasingly overestimated and progressively more biased as the 
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variances in the error terms shifted from most of the variance at level-1 to most of the 
variance at level-2. 
Similar to previous research on two levels models with single-case data (Ferron et 
al., 2009), level-1 variance or within person residual variance was slightly biased but 
differing from previous research the bias in the estimates of within person residual 
variance remained constant at around 8% regardless of level-3 or level-2 sample size.  
However, results from this study did reveal the within person residual variance of the 
three level model became increasingly biased as the level of autocorrelation increased.  
This finding is not surprising given the notion that as autocorrelation increases the errors 
between observations within a person become more similar and therefore make it difficult 
to produce unbiased within person variability estimates.  However, the amount of 
estimated autocorrelation in the three level meta-analytic single-case model was on 
average unbiased.  Both the within person residual variance and amount of estimated 
autocorrelation bias results were not consistent with previous literature on two level 
models that found both parameters to be substantially biased (Ferron et al, 2009).  
However, this current study did focus on a three level model as opposed to the previously 
investigated two level model and therefore more information was ultimately available in 
the estimation of those parameters. 
The extent to which the variance components from a three level meta-analytic 
single-case model were biased, based on specific design factors, were also evaluated by 
examining relative bias for any parameter whose known value was different from one so 
as to gain an index of bias in relation to the known parameter value.  As was expected, 
based on previous literature (Ferron et al., 2009; Raudenbush & Bryk, 2002), the variance 
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components were biased; however, the trend in bias of the variance components was not 
expected.  Previous Monte Carlo research on two level models for singe-case data has 
shown biased variance components at both level-2 and level-1 but with a decrease in bias 
of the point estimates as the upper level units increased  (Ferron et al., 2009).  In this 
study when the level-3 and level-2 sample size increased and the variances of the error 
terms shifted from most of the variance at level-1 to most of the variance at level-2 the 
level-3 and level-2 variance components became increasing more biased, albeit in 
opposing directions.  Specifically, the level-3 variance components became increasingly 
underestimated and the level-2 variance components became increasingly overestimated.  
However, the level-3 sample size only went as high as 80 and the level-2 sample size 
only went as high as 8 therefore there is no way of knowing if and when the variance 
components would have begun showing less bias with larger sample sizes.  Another 
interesting finding of the present study that was contradictory to previous literature 
examining two level models for single-case data (Ferron et al., 2009), which found that 
the amount of autocorrelation tended to be biased and underestimated, was that on 
average the amount of estimated autocorrelation was unbiased with relative bias 
estimates not exceeding 1% of the known parameter value.  This finding suggests that it 
is tenable to assume that estimates of the amount of estimated autocorrelation from this 
three level meta-analytic single-case model, under these specific design conditions, are 
unbiased, if the model is correctly specified. 
The extent to which the confidence interval coverage estimates of the variance 
components from a three level meta-analytic single-case model produced accurate 
confidence intervals, as a function of specific design factors, was estimated by the 
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proportion of the 95% confidence intervals that contained the parameter value.  The 
level-3 variance components, both in the between study variance in the overall average 
baseline level and the between study variance in the overall average treatment effect, 
tended to overcover with means of .998 and .995, respectively.  Further examination of 
these effects indicated that the main factors that influenced the variability in confidence 
interval coverage rates of the level-3 variance components were the level-3 sample size, 
level-2 sample size, and the variances of the error terms.  Specifically, confidence 
interval coverage rates of the level-3 variance components were closest to a .95 coverage 
rate when the level-3 sample size was smallest (10 primary studies), level-2 sample size 
was smallest (mode = 10), and most of the variance in the error terms was at level-1.  
Recall that bias of the level-3 variance components was smallest when the level-3 sample 
size was smallest, level-2 sample size was smallest, and most of the variance in the error 
terms was at level-1.  Therefore, given the relative bias results, it was not surprising that 
the confidence interval coverage was problematic for the level-3 variance components.   
Similar results were found for the level-2 variance components and the within 
person residual variance.  The level-2 variance components, both the between person 
within study variance in the average baseline level and the between person within study 
variance in the average treatment effect, tended to undercover with means of .612 and 
.675, respectively.  Several design factors were found to have impacted the variability in 
the confidence interval coverage rates of the level-2 variance components.  The 
confidence interval coverage rates of the between person within study variance in the 
average baseline level tended to decrease and move farther away from a .95 coverage rate 
when the level-3 sample size increased, the level-2 sample size increased, and the 
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variances of the error terms shifted from most of the variance at level-1 to most of the 
variance at level-2.  In addition, the confidence interval coverage rates of the other level-
2 variance component, the between person within study variance in the average treatment 
effect, tended to decrease and move farther away from a .95 coverage rate as the level-3 
sample size increased and the variances of the error terms shifted from most of the 
variance at level-1 to most of the variance at level-2.  Recall that relative bias results of 
the level-2 variance components indicated that estimates of the level-2 variance 
components became more biased as the level-3 sample size increased, the level-2 sample 
size increased, and the variances of the error terms shifted from most of the variance at 
level-1 to most of the variance at level-2.  Therefore, it was not surprising that confidence 
interval coverage of the level-2 variance components was troublesome.  Additionally, 
these results are consistent with previous findings (Maas & Hox, 2004) from a broader 
methodological perspective on two-level organizational models, which found that 
coverage rates of the level-2 variance components tended to undercover with small 
sample sizes (N = 30).  
Confidence interval coverage rates were the most problematic for the within 
person residual variance with average confidence interval coverage rates well below the 
nominal level (M = .550).  However, confidence interval coverage rates of the within 
person residual variance were close to a .95 coverage rate when autocorrelation was zero.  
This finding was consistent given the bias results for the within person residual variance.  
Conversely, confidence interval coverage rates for the amount of estimated 
autocorrelation were close to a .95 coverage rate (M = .950), regardless of condition, 
which is not surprising given the bias results for the amount of estimated autocorrelation.   
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The average difference between the upper and lower limits of the 95% confidence 
intervals defined the confidence interval widths of the variance components from a three 
level meta-analytic single-case model.  Confidence interval widths for the level-3 and 
level-2 variance components were so large that they provided no information.  These 
findings are not surprising given previous research on two level models for single-case 
data (Ferron et al., 2009) where the results indicated that the confidence interval widths 
for the level-2 variance components were so large that they provided no information.   
However, the confidence interval width estimates for the within person residual 
variance produced relatively small interval widths (M = 0.146) which tended to become 
even smaller as the level-3 and level-1 sample size, and level of autocorrelation 
increased.  For example, consider the fact that the within person residual variance was set 
to 1.0 therefore a small series length, with a mode of 10, would yield a confidence 
interval from about .914 to 1.086, but a medium series length, with a mode of 20, would 
produce a confidence interval from .929 to 1.072, and a large series length, with a mode 
of 30, would provide an even tighter confidence interval from .939 to 1.061. These results 
are not too surprising considering the confidence interval coverage estimates for the 
within person residual variance tended to undercover. 
Likewise, the confidence interval width estimates for the amount of estimated 
autocorrelation were small (M = 0.090) and tended to decrease as the level-3 and level-1 
sample size increased.  Therefore, based on the results of the confidence interval widths 
of the amount of estimated autocorrelation, when the level of autocorrelation was set to 0 
a level-3 sample size of 10 primary studies would produce a confidence interval with 
from about -.070 to .070, but a level-3 sample size of 30 primary studies would lead to a 
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confidence interval from around -.040 to .040, and a level-3 sample size of 80 would 
yield even greater precision with a confidence interval from about -.025 to .025.  These 
findings suggest that it is tenable to assume as the level-3 and level-1 sample sizes 
increase the more precise the estimates of amount of estimated autocorrelation become, if 
the model is correctly specified. 
Limitations of the Study 
Based on the design of this study, there are generalizabilty limitations to consider 
with regard to this research study.  The Monte Carlo method used in this study provided 
control of specific factors to investigate the appropriateness of inferences made from a 
three level meta-analytic single-case model in specific situations.  While this is a benefit 
of simulation studies it also limits the generalizabilty of the study findings.  Therefore, 
the five design factors (number of primary studies per meta-analysis, modal number of 
participants per primary study, modal series length per primary study, variances of the 
error terms, and level of autocorrelation) determine the types of single-case meta-
analyses to which the study’s findings can be generalized.  In addition, another 
generalizabilty limitation of this study is the levels of the specific design factors.  These 
levels were chosen to represent a range of possible values seen in single-case meta-
analyses as well as previous simulation work.  However, they are not exhaustive of all 
possible values for each design factor.   
Another limitation to consider relates to the model under investigation.  The 
specific model (see Equations 24 – 28) chosen for investigation in this research study 
makes several assumptions.  First, Van den Noortgate and Onghena’s (2008) raw data 
three level meta-analytic single-case model assumes that all dependent variables were 
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measured the same across primary studies included in the meta-analysis.  Second, the 
model chosen for analysis was the most basic interrupted time-series model (e.g. no 
trends or changes in trends).  The benefit of choosing this model is that it is the most 
basic model and therefore the most logical for an initial study into the three level meta-
analytic modeling of single-case data.  In addition, model and data generation assumed 
normality of the level-1 errors, multivariate normality of the level-2 errors, multivariate 
normality of the level-3 errors, and homoscedasticity of the errors at all levels.  If the 
within person variance varied across the participants within studies or across studies, the 
autocorrelation varied, or a more complex time series model (e.g. 2nd order of higher) was 
needed then the model would be misspecified.  The results don’t allow for generalizations 
to performance when there is some degree of misspecification or there is use for more 
complex model specifications. 
Implications 
Researchers have suggested that use of multilevel modeling in meta-analyzing 
single-case data provides many advantages (Van den Noortgate & Onghena, 2003a, 2007, 
2008).  Specifically, multilevel modeling provides the ability to combine the results from 
multiple participants and studies to gain information about not only the overall treatment 
effect but also if and how the treatment effect varies across participants and studies (Van 
den Noortgate & Onghena, 2008).  Another advantage of multilevel modeling is that it 
can be used to aggregate data from single-case studies that include multiple participants.  
This use of multiple data sources or effect sizes from the same study is typically 
problematic and has not been addressed by other proposed single-case meta-analytic 
methods.  Multilevel modeling is structured to account for that “nesting” of data within 
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studies by allowing variation within participants, between participants of the same study 
and between studies (Van den Noortgate & Onghena, 2008). 
The results of this study suggest that the degree to which the findings of this study 
are supportive of using Van den Noortgate and Onghena’s (2008) raw data multilevel 
modeling approach to meta-analyzing single-case data depends on the particular effect of 
interest.  This in turn leads to specific implications for those who conduct meta-analyses 
of single-case studies, single-case researchers, and methodologists. 
Implications for Researchers Conducting Single-Case Meta-Analyses 
For researchers interested in the overall average baseline level and overall average 
treatment effect across studies, the results of this research study are encouraging.  If 
researchers conducting single-case meta-analyses have data that conform to the 
assumptions of the model examined they should feel comfortable interpreting the overall 
average baseline levels and overall average treatment effects across studies.  Still, 
researchers should be advised to increase the level-3 sample size or number of primary 
studies per meta-analysis whenever possible.  With larger level-3 sample sizes, greater 
accuracy and precision could be gained in estimating the overall average baseline levels 
and treatment effects across studies.  While single-case meta-analysts are constrained by 
the availability of primary studies they could adjust their methods for searching (e.g., 
expanding their search terms) whenever possible, but are limited by what the field has 
generated.  
On the other hand statements about the variation in treatment effects across 
studies, which are also valued by meta-analysts and single-case researchers, should be 
viewed cautiously.  Even assuming the model was correctly specified, the variance 
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components at all levels were biased and confidence intervals for those estimates were 
inaccurate.  Specifically, the level-3 (between study) variance components tended to 
overcover and the level-2 (between person within study) variance components and the 
within person residual variance both tended to undercover and did not show signs of 
improvement with larger level-3 sample sizes.  
Implications for Researchers Conducting Single-Case Studies 
For researchers conducting single-case studies, the results of this study provide a 
few recommendations.  The results of this study indicated that fixed effects were more 
precise any time the amount of variability in the model was smaller.  Specifically, this 
study examined shifts in variability at level-2 and level-3 but one may anticipate that 
paying close attention to ways of reducing variability overall would produce greater 
precision when estimating the overall average baseline levels and treatment effects across 
studies. For example, single-case researchers should pay attention to baseline variability 
or stability in effort to decrease variability at level-1.  Specifically, single-case 
researchers should consider increasing the number of data points in baseline to correctly 
specify the model in an effort to decrease the amount of variability at level-1.   
Single-case researchers should also pay attention to the extent to which the 
intervention is delivered as intended often termed treatment fidelity or integrity (Kazdin, 
2011).  For example, if a treatment or intervention was administered exactly like it was 
intended to be administered the associated treatment effect would be different than a 
treatment effect associated with a treatment or intervention administered differently than 
intended.  This modification in implementation or lack of treatment integrity could cause 
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increases in between person variability and ultimately decrease precision in the overall 
average baseline levels and treatment effects across studies. 
Measurement error can also impact variability and finding ways to decrease that 
measurement error could ultimately decrease variability overall.  For example, single-
case researchers should be consistent in their methods of measurement in an effort to 
decrease between person within study and between study variability.  Therefore, single-
case researchers should make every effort to measure outcomes at the same time of day 
and for the same amount of time across participants and even across studies assessing 
similar types of interventions.   
A final recommendation to single-case researchers is to consider previous single-
case research that has focused in their particular area of interest when determining the 
most appropriate outcome measure.  Specifically, if single-case researchers from similar 
areas of interest (e.g., reading, math) measured their outcomes variables the same across 
studies then single-case meta-analysts would have a larger number of primary studies to 
include in this specific meta-analytic model and could feel more confident in their 
interpretation of overall average baseline levels and treatment effects across studies. 
Implications for Methodologists 
 For methodologists studying the use of multilevel modeling to meta-analyze 
single-case data more research needs to be conducted on more complex treatment effects, 
such as delayed changes in level, trends in the data that change linearly or nonlinearly 
with time, and transitory effects.  Furthermore, violations of assumptions (e.g., 
nonnormality of the level-1, level-2, or level-3 errors, heteroscedasticity of errors at all 
levels) and various level-1 error models (e.g., high order autoregressive or moving 
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average models) needed to be investigated as well.  Investigation of these more complex 
models would allow for a better understanding of the applicability of the models to a 
variety of conditions. 
 Future research on other approaches to estimating variance components would 
also be of interest.  Clearly, the results of this study have indicated that the variance 
components at all levels are biased and provide inaccurate confidence intervals.  
Therefore, it would be interesting to investigate alternative methods for estimating 
variance such as the Bayesian approach.   
 Finally, this study focused on the use of a three level model to meta-analyze only 
single-case data.  It would be interesting to investigate ways to meta-analyze single-case 
and large group design data together.  This would allow meta-analysts the ability to 
synthesize research across a variety of research designs.  
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Appendix A: SAS Programming Code 
procprinttolog=junk;  
procprinttoprint = junk2;  
 
data j0; 
input Estimate Lower Upper; 
datalines; 
. . .  
. . .  
; 
 
data j00;  
input Estimate Lower Upper;  
datalines;  
. . .  
. . . 
. . .  
. . .  
. . . 
. . . 
;  
 
%global _print_; 
%let _print_ = off; 
 
*++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 
input for the macro are: 
n = 5000 (number of samples to generate) 
n3= 10,30,80 
avgseries = 0, 1, or 2 (0 = small, 1 = medium, 2 = large) 
avgpart= 0 or 1 (0 = small and 1 = large) 
varerror= 0 or 1 (0= most of the error at level-1 and 1= most of the 
error at level-2) 
gamma = 1 (fixed effects - intercept [gamma000], effect [gamma100]) 
phi = 0, -.2,or -.4 (produces positive autocorrelation)  
+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
; 
 
%macrohlmsim (n, n3, avgseries, avgpart, varerror, gamma, phi); 
 
%doi=1%to&n; 
 
prociml; 
 
*++++++++++++++++++++++++++++++++++++++++++++++++++++++ 
This part of the program creates the initial data set,which contains 
the following variables: 
n1: 10, 20, or 30 (number of time points or level-1 units) 
n2: 4, 6, or 8 (nuumber of participant or level-2 units) 
tau0 = .2 or .05  (level-2 variance in the intercept and treatment 
effect) 
tau1 = 2 or .5 (level-3 variance in the intercept and treatment effect) 
  IDlevel3: level 3 ID 
  IDlevel2:  level 2 ID  
time:  potential level-1 predictor 
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phase: dichotomous level-1 predictor (0=baseline, 1=treatment)  
y:  outcome  
  +++++++++++++++++++++++++++++++++++++++++++++++++++++; 
 
create j1 var{IDlevel3 IDlevel2 time phase y tau0 tau1}; 
 
do ID3=1 to &n3; 
n1=0; 
n2=0; 
if&n3= 10 then do; 
if&avgpart = 0& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | ID3 
= 6 | ID3 = 7) then n2 = 4; 
if&avgpart = 0& (ID3 = 8 | ID3 = 9) then n2 = 6; 
if&avgpart = 0& (ID3 = 10) then n2 = 8; 
if&avgpart = 1& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | ID3 
= 6 | ID3 = 7) then n2 = 8; 
if&avgpart = 1& (ID3 = 8 | ID3 = 9) then n2 = 6; 
if&avgpart = 1& (ID3 = 10) then n2 = 4; 
 
if&avgseries = 0& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | 
ID3 = 6 | ID3 = 7) then n1 = 10; 
if&avgseries = 0& (ID3 = 8 | ID3 = 9) then n1 = 20; 
if&avgseries = 0& (ID3 = 10) then n1 = 30; 
if&avgseries = 1& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | 
ID3 = 6 | ID3 = 7) then n1 = 20; 
if&avgseries = 1& (ID3 = 8 | ID3 = 9) then n1 = 10; 
if&avgseries = 1& (ID3 = 10) then n1 = 30; 
if&avgseries = 2& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | 
ID3 = 6 | ID3 = 7) then n1 = 30; 
if&avgseries = 2& (ID3 = 8 | ID3 = 9) then n1 = 10; 
if&avgseries = 2& (ID3 = 10) then n1 = 20; 
end; 
if&n3= 30 then do; 
if&avgpart = 0& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | ID3 
= 6 | ID3 = 7 | ID3 = 8 | ID3 = 9 | ID3 = 10 | ID3 = 11 | ID3 = 12 | 
ID3 = 13 | ID3 = 14 | ID3 = 15 | ID3 = 16 | ID3 = 17 | ID3 = 18 | ID3 = 
19 | ID3 = 20 | ID3 = 21) then n2 = 4; 
if&avgpart = 0& (ID3 = 22 | ID3 = 23 | ID3 = 24 | ID3 = 25 | ID3 = 26 | 
ID3 = 27)then n2 = 6; 
if&avgpart = 0& (ID3 = 28 | ID3 = 29 | ID3 = 30) then n2 = 8; 
if&avgpart = 1& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | ID3 
= 6 | ID3 = 7 | ID3 = 8 | ID3 = 9 | ID3 = 10 | ID3 = 11 | ID3 = 12 | 
ID3 = 13 | ID3 = 14 | ID3 = 15 | ID3 = 16 | ID3 = 17 | ID3 = 18 | ID3 = 
19 | ID3 = 20 | ID3 = 21) then n2 = 8; 
if&avgpart = 1& (ID3 = 22 | ID3 = 23 | ID3 = 24 | ID3 = 25 | ID3 = 26 | 
ID3 = 27)then n2 = 6; 
if&avgpart = 1& (ID3 = 28 | ID3 = 29 | ID3 = 30) then n2 = 4; 
 
if&avgseries = 0& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | 
ID3 = 6 | ID3 = 7 | ID3 = 8 | ID3 = 9 | ID3 = 10 | ID3 = 11 | ID3 = 12 
| ID3 = 13 | ID3 = 14 | ID3 = 15 | ID3 = 16 | ID3 = 17 | ID3 = 18 | ID3 
= 19 | ID3 = 20 | ID3 = 21) then n1 = 10; 
if&avgseries = 0& (ID3 = 22 | ID3 = 23 | ID3 = 24 | ID3 = 25 | ID3 = 26 
| ID3 = 27)then n1 = 20; 
if&avgseries = 0& (ID3 = 28 | ID3 = 29 | ID3 = 30) then n1 = 30; 
if&avgseries = 1& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | 
ID3 = 6 | ID3 = 7 | ID3 = 8 | ID3 = 9 | ID3 = 10 | ID3 = 11 | ID3 = 12 
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| ID3 = 13 | ID3 = 14 | ID3 = 15 | ID3 = 16 | ID3 = 17 | ID3 = 18 | ID3 
= 19 | ID3 = 20 | ID3 = 21) then n1 = 20; 
if&avgseries = 1& (ID3 = 22 | ID3 = 23 | ID3 = 24 | ID3 = 25 | ID3 = 26 
| ID3 = 27)then n1 = 10; 
if&avgseries = 1& (ID3 = 28 | ID3 = 29 | ID3 = 30) then n1 = 30; 
if&avgseries = 2& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | 
ID3 = 6 | ID3 = 7 | ID3 = 8 | ID3 = 9 | ID3 = 10 | ID3 = 11 | ID3 = 12 
| ID3 = 13 | ID3 = 14 | ID3 = 15 | ID3 = 16 | ID3 = 17 | ID3 = 18 | ID3 
= 19 | ID3 = 20 | ID3 = 21) then n1 = 30; 
if&avgseries = 2& (ID3 = 22 | ID3 = 23 | ID3 = 24 | ID3 = 25 | ID3 = 26 
| ID3 = 27)then n1 = 10; 
if&avgseries = 2& (ID3 = 28 | ID3 = 29 | ID3 = 30) then n1 = 20; 
end; 
if&n3= 80 then do; 
if&avgpart = 0& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | ID3 
= 6 | ID3 = 7 | ID3 = 8 | ID3 = 9 | ID3 = 10 | ID3 = 11 | ID3 = 12 | 
ID3 = 13 | ID3 = 14 | ID3 = 15 | ID3 = 16 | ID3 = 17 | ID3 = 18 | ID3 = 
19 | ID3 = 20 | ID3 = 21 | 
ID3 = 22 | ID3 = 23 | ID3 = 24 | ID3 = 25 | ID3 = 26 | ID3 = 27 | ID3 = 
28 | ID3 = 29 | ID3 = 30 | ID3 = 31 | ID3 = 32 | ID3 = 33 | ID3 = 34 | 
ID3 = 35 | ID3 = 36 | ID3 = 37 | ID3 = 38 | ID3 = 39 | ID3 = 40 | ID3 = 
41 | ID3 = 42 | ID3 = 43 | 
ID3 = 44 | ID3 = 45 | ID3 = 46 | ID3 = 47 | ID3 = 48 | ID3 = 49 | ID3 = 
50 | ID3 = 51 | ID3 = 52 | ID3 = 53 | ID3 = 54 | ID3 = 55 | ID3 = 56) 
then n2 = 4; 
if&avgpart = 0& (ID3 = 57 | ID3 = 58 | ID3 = 59 | ID3 = 60 | ID3 = 61 | 
ID3 = 62 | ID3 = 63 | ID3 = 64 | ID3 = 65 | ID3 = 66 | ID3 = 67 | ID3 = 
68 | ID3 = 70 | ID3 = 71 | ID3 = 72) then n2 = 6; 
if&avgpart = 0& (ID3 = 73 | ID3 = 74 | ID3 = 75 | ID3 = 76 | ID3 = 77 | 
ID3 = 78 | ID3 = 79 | ID3 = 80) then n2 = 8; 
if&avgpart = 1& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | ID3 
= 6 | ID3 = 7 | ID3 = 8 | ID3 = 9 | ID3 = 10 | ID3 = 11 | ID3 = 12 | 
ID3 = 13 | ID3 = 14 | ID3 = 15 | ID3 = 16 | ID3 = 17 | ID3 = 18 | ID3 = 
19 | ID3 = 20 | ID3 = 21 | 
ID3 = 22 | ID3 = 23 | ID3 = 24 | ID3 = 25 | ID3 = 26 | ID3 = 27 | ID3 = 
28 | ID3 = 29 | ID3 = 30 | ID3 = 31 | ID3 = 32 | ID3 = 33 | ID3 = 34 | 
ID3 = 35 | ID3 = 36 | ID3 = 37 | ID3 = 38 | ID3 = 39 | ID3 = 40 | ID3 = 
41 | ID3 = 42 | ID3 = 43 | 
ID3 = 44 | ID3 = 45 | ID3 = 46 | ID3 = 47 | ID3 = 48 | ID3 = 49 | ID3 = 
50 | ID3 = 51 | ID3 = 52 | ID3 = 53 | ID3 = 54 | ID3 = 55 | ID3 = 56) 
then n2 = 8; 
if&avgpart = 1& (ID3 = 57 | ID3 = 58 | ID3 = 59 | ID3 = 60 | ID3 = 61 | 
ID3 = 62 | ID3 = 63 | ID3 = 64 | ID3 = 65 | ID3 = 66 | ID3 = 67 | ID3 = 
68 | ID3 = 70 | ID3 = 71 | ID3 = 72) then n2 = 6; 
if&avgpart = 1& (ID3 = 73 | ID3 = 74 | ID3 = 75 | ID3 = 76 | ID3 = 77 | 
ID3 = 78 | ID3 = 79 | ID3 = 80) then n2 = 4; 
 
if&avgseries = 0& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | 
ID3 = 6 | ID3 = 7 | ID3 = 8 | ID3 = 9 | ID3 = 10 | ID3 = 11 | ID3 = 12 
| ID3 = 13 | ID3 = 14 | ID3 = 15 | ID3 = 16 | ID3 = 17 | ID3 = 18 | ID3 
= 19 | ID3 = 20 | ID3 = 21 | 
ID3 = 22 | ID3 = 23 | ID3 = 24 | ID3 = 25 | ID3 = 26 | ID3 = 27 | ID3 = 
28 | ID3 = 29 | ID3 = 30 | ID3 = 31 | ID3 = 32 | ID3 = 33 | ID3 = 34 | 
ID3 = 35 | ID3 = 36 | ID3 = 37 | ID3 = 38 | ID3 = 39 | ID3 = 40 | ID3 = 
41 | ID3 = 42 | ID3 = 43 | 
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ID3 = 44 | ID3 = 45 | ID3 = 46 | ID3 = 47 | ID3 = 48 | ID3 = 49 | ID3 = 
50 | ID3 = 51 | ID3 = 52 | ID3 = 53 | ID3 = 54 | ID3 = 55 | ID3 = 56) 
then n1 = 10; 
if&avgseries = 0& (ID3 = 57 | ID3 = 58 | ID3 = 59 | ID3 = 60 | ID3 = 61 
| ID3 = 62 | ID3 = 63 | ID3 = 64 | ID3 = 65 | ID3 = 66 | ID3 = 67 | ID3 
= 68 | ID3 = 70 | ID3 = 71 | ID3 = 72) then n1 = 20; 
if&avgseries = 0& (ID3 = 73 | ID3 = 74 | ID3 = 75 | ID3 = 76 | ID3 = 77 
| ID3 = 78 | ID3 = 79 | ID3 = 80) then n1 = 30; 
if&avgseries = 1& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | 
ID3 = 6 | ID3 = 7 | ID3 = 8 | ID3 = 9 | ID3 = 10 | ID3 = 11 | ID3 = 12 
| ID3 = 13 | ID3 = 14 | ID3 = 15 | ID3 = 16 | ID3 = 17 | ID3 = 18 | ID3 
= 19 | ID3 = 20 | ID3 = 21 | 
ID3 = 22 | ID3 = 23 | ID3 = 24 | ID3 = 25 | ID3 = 26 | ID3 = 27 | ID3 = 
28 | ID3 = 29 | ID3 = 30 | ID3 = 31 | ID3 = 32 | ID3 = 33 | ID3 = 34 | 
ID3 = 35 | ID3 = 36 | ID3 = 37 | ID3 = 38 | ID3 = 39 | ID3 = 40 | ID3 = 
41 | ID3 = 42 | ID3 = 43 | 
ID3 = 44 | ID3 = 45 | ID3 = 46 | ID3 = 47 | ID3 = 48 | ID3 = 49 | ID3 = 
50 | ID3 = 51 | ID3 = 52 | ID3 = 53 | ID3 = 54 | ID3 = 55 | ID3 = 56) 
then n1 = 20; 
if&avgseries = 1& (ID3 = 57 | ID3 = 58 | ID3 = 59 | ID3 = 60 | ID3 = 61 
| ID3 = 62 | ID3 = 63 | ID3 = 64 | ID3 = 65 | ID3 = 66 | ID3 = 67 | ID3 
= 68 | ID3 = 70 | ID3 = 71 | ID3 = 72) then n1 = 10; 
if&avgseries = 1& (ID3 = 73 | ID3 = 74 | ID3 = 75 | ID3 = 76 | ID3 = 77 
| ID3 = 78 | ID3 = 79 | ID3 = 80) then n1 = 30; 
if&avgseries = 2& (ID3 = 1 | ID3 = 2 | ID3 = 3 | ID3 = 4 | ID3 = 5 | 
ID3 = 6 | ID3 = 7 | ID3 = 8 | ID3 = 9 | ID3 = 10 | ID3 = 11 | ID3 = 12 
| ID3 = 13 | ID3 = 14 | ID3 = 15 | ID3 = 16 | ID3 = 17 | ID3 = 18 | ID3 
= 19 | ID3 = 20 | ID3 = 21 | 
ID3 = 22 | ID3 = 23 | ID3 = 24 | ID3 = 25 | ID3 = 26 | ID3 = 27 | ID3 = 
28 | ID3 = 29 | ID3 = 30 | ID3 = 31 | ID3 = 32 | ID3 = 33 | ID3 = 34 | 
ID3 = 35 | ID3 = 36 | ID3 = 37 | ID3 = 38 | ID3 = 39 | ID3 = 40 | ID3 = 
41 | ID3 = 42 | ID3 = 43 | 
ID3 = 44 | ID3 = 45 | ID3 = 46 | ID3 = 47 | ID3 = 48 | ID3 = 49 | ID3 = 
50 | ID3 = 51 | ID3 = 52 | ID3 = 53 | ID3 = 54 | ID3 = 55 | ID3 = 56) 
then n1 = 30; 
if&avgseries = 2& (ID3 = 57 | ID3 = 58 | ID3 = 59 | ID3 = 60 | ID3 = 61 
| ID3 = 62 | ID3 = 63 | ID3 = 64 | ID3 = 65 | ID3 = 66 | ID3 = 67 | ID3 
= 68 | ID3 = 70 | ID3 = 71 | ID3 = 72) then n1 = 10; 
if&avgseries = 2& (ID3 = 73 | ID3 = 74 | ID3 = 75 | ID3 = 76 | ID3 = 77 
| ID3 = 78 | ID3 = 79 | ID3 = 80) then n1 = 20; 
end; 
 
do ID2=1 to n2; 
cut=0; 
if n2=4 then do; 
if n1=10 then cut = 2 + ID2; 
if n1=20 then cut = 5 + ID2*2; 
if n1=30 then cut = 7 + ID2*3; 
end; 
if n2=6 then do; 
if n1=10 then cut = 1 + ID2; 
if n1=20 then cut = 3 + ID2*2; 
if n1=30 then cut = 5 + ID2*3; 
end; 
if n2=8 then do; 
if n1=10 then cut = 0 + ID2; 
if n1=20 then cut = 1 + ID2*2; 
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if n1=30 then cut = 3 + ID2*3; 
end; 
 
if&varerror= 0 then tau0 = .2;  
if&varerror= 0 then tau1 = .05; 
if&varerror= 1 then tau0 = 2;  
if&varerror= 1 then tau1 = .5; 
 
 IDlevel3=j(n1,1,ID3); 
 IDlevel2=j(n1,1,ID2); 
time=j(n1,1,0); 
phase=j(n1,1,0); 
do ii=1 to n1; 
time[ii,1]=(ii)-1; 
 if ii > cut then phase[ii,1]=1; 
end; 
rr=armasim({1,&phi},0,0,1,n1,0); 
b=1; 
c=0; 
d=0; 
*b=.90475830311225; 
*c=.14721081863342; 
*d=.02386092280190; 
a=-1*c; 
r=a+b#rr+c#rr##2+d#rr##3; 
u0=repeat(rannor(0)*sqrt(tau0),n1); *error at level-2 intercept; 
u1=repeat(rannor(0)*sqrt(tau0),n1); *error at level-2 treatment effect; 
u2=repeat(rannor(0)*sqrt(tau1),n1); *error at level-3 intercept; 
u3=repeat(rannor(0)*sqrt(tau1),n1); *error at level-3 treatment effect; 
gamma000=&gamma; 
gamma100=&gamma; 
intercep=gamma000+u0+u2; 
effect=gamma100+u1+u3; 
y=intercep+(effect#phase)+r; 
 
append; 
end; 
end; 
close j1; 
 
*+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 
The following set of commands used PROC MIXED to estimate the 
multilevel model.  This is done to create confidence intervals for the 
fixed effects and variance components. For each run, the point 
estimate, upper limit, and lower limit for the fixed effects and the 
variance components, are written into an output data sets.   
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++; 
 
*setting the data sets that will contain the tables for the fixed 
effects and variance components*; 
 
data j2;  
set j0;  
 
 
data j3;  
set j00;  
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*model commands and data set creation; 
 
proc mixed data =j1 covtestcl; 
class idlevel2 idlevel3;  
model y = phase / s cl alpha = .05ddfm = kenwardroger;  
randomint phase / sub = idlevel3; 
randomint phase / sub = idlevel2 (idlevel3);  
repeated / type = AR(1) sub = idlevel2 (idlevel3);  
ods output solutionF=j2  
 (keep = estimate lower upper);   
ods output covparms=j3 
  (keep = estimate lower upper);  
 
data j4;  
set j2;   
w = estimate; output;  
w = lower; output;  
w = upper; output;  
drop estimate lower upper;  
 
proc transpose data = j4  
out = j6  
(rename = (col1=est_int col2=low_int col3=up_int 
col4=est_pha col5=low_pha col6=up_pha)); 
 
 
data j5;  
set j3;  
w = estimate; output;  
w = lower; output;  
w = upper; output;  
drop estimate lower upper;  
 
proc transpose data = j5 
out = j7 
(rename = (col1=est_vc_int_lvl3 col2=low_vc_int_lvl3 
col3=up_vc_int_lvl3 
col4=est_vc_pha_lvl3 col5=low_vc_pha_lvl3 col6=up_vc_pha_lvl3 
col7=est_vc_int_lvl2 col8=low_vc_int_lvl2 col9=up_vc_int_lvl2 
col10=est_vc_pha_lvl2 col11=low_vc_pha_lvl2 col12=up_vc_pha_lvl2 
col13=est_vc_ar col14=low_vc_ar col15=up_vc_ar 
col16=est_vc_r col17=low_vc_r col18=up_vc_r)); 
 
*++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 
The following statements merge the output data sets resulting with one 
row of data containing the point estimates, lower limit, upper limit, 
for each fixed effect and variance component. The data set is then 
appended with a new row for each simulated data set.  
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++; 
 
data j8;  
merge j6 j7;  
 
 
data j9;  
set j8;  
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counter = &i;  
 
%if&i = 1%then%do; 
 
 
data j10;  
set j9;  
%end;  
%else%do;  
 
data j10;  
merge j10 j9;  
by counter;  
%end;  
 
*DM 'LOG;*CLEAR'; 
*DM 'LISTING;*CLEAR'; 
%end;  
 
*+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 
The following set of commands creates a series of indicator variables 
based on whether the fixed effect parameter and the variance component 
parameter falls between the lower and upper limit.  It then computes 
the width of the confidence interval.   
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++; 
 
data j11;  
set j10; 
if&varerror= 0 then tau0 = .2;  
if&varerror= 0 then tau1 = .05; 
if&varerror= 1 then tau0 = 2;  
if&varerror= 1 then tau1 = .5; 
 
cov_int=0; 
if (low_int<= &gamma) & (&gamma <= up_int) then cov_int=1; 
iflow_int=.thencov_int=.; 
 
cov_pha=0; 
if (low_pha<= &gamma) & (&gamma <= up_pha) then cov_pha=1; 
iflow_pha=.thencov_pha=.; 
 
cov_vc_int_lvl2=0; 
if (low_vc_int_lvl2 <= tau0) & (tau0 <= up_vc_int_lvl2) then 
cov_vc_int_lvl2=1; 
if low_vc_int_lvl2=.then cov_vc_int_lvl2=.; 
 
cov_vc_pha_lvl2=0; 
if (low_vc_pha_lvl2 <= tau0) & (tau0 <= up_vc_pha_lvl2) then 
cov_vc_pha_lvl2=1; 
if low_vc_pha_lvl2=.then cov_vc_pha_lvl2=.; 
 
cov_vc_int_lvl3=0; 
if (low_vc_int_lvl3 <= tau1) & (tau1 <= up_vc_int_lvl3) then 
cov_vc_int_lvl3=1; 
if low_vc_int_lvl3=.then cov_vc_int_lvl3=.; 
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cov_vc_pha_lvl3=0; 
if (low_vc_pha_lvl3 <= tau1) & (tau1 <= up_vc_pha_lvl3) then 
cov_vc_pha_lvl3=1; 
if low_vc_pha_lvl3=.then cov_vc_pha_lvl3=.; 
 
cov_vc_ar=0; 
if (low_vc_ar<= -1*&phi) & (-1*&phi <= up_vc_ar) then cov_vc_ar=1; 
iflow_vc_ar=.thencov_vc_ar=.; 
 
cov_vc_r=0; 
if (low_vc_r<= 1) & (1<= up_vc_r) then cov_vc_r=1; 
 
wid_int=up_int-low_int; 
 
wid_pha=up_pha-low_pha; 
 
wid_vc_int_lvl2=up_vc_int_lvl2-low_vc_int_lvl2; 
 
wid_vc_pha_lvl2=up_vc_pha_lvl2-low_vc_pha_lvl2; 
 
wid_vc_int_lvl3=up_vc_int_lvl3-low_vc_int_lvl3; 
 
wid_vc_pha_lvl3=up_vc_pha_lvl3-low_vc_pha_lvl3; 
 
wid_vc_ar=up_vc_ar-low_vc_ar; 
 
wid_vc_r=up_vc_r-low_vc_r; 
 
 
 
*++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 
Means are then calculated, giving estimates of bias in the fixed and 
variance component effect estimates, the coverage probabilities for 
each effect, and the average CI width. 
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++; 
proc means noprint data = j11;  
varest_int 
cov_int 
wid_int 
 
est_pha 
cov_pha 
wid_pha 
 
est_vc_int_lvl2 
cov_vc_int_lvl2  
wid_vc_int_lvl2  
 
 est_vc_pha_lvl2 
cov_vc_pha_lvl2 
wid_vc_pha_lvl2   
 
est_vc_int_lvl3 
cov_vc_int_lvl3  
wid_vc_int_lvl3  
 
 est_vc_pha_lvl3 
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cov_vc_pha_lvl3 
wid_vc_pha_lvl3 
 
est_vc_ar 
cov_vc_ar 
wid_vc_ar 
 
 est_vc_r 
cov_vc_r 
wid_vc_r; 
 
output out=j12  
mean =  est_int 
cov_int 
wid_int 
 
est_pha 
cov_pha 
wid_pha 
 
est_vc_int_lvl2 
cov_vc_int_lvl2  
wid_vc_int_lvl2  
 
 est_vc_pha_lvl2 
cov_vc_pha_lvl2 
wid_vc_pha_lvl2   
 
est_vc_int_lvl3 
cov_vc_int_lvl3  
wid_vc_int_lvl3  
 
 est_vc_pha_lvl3 
cov_vc_pha_lvl3 
wid_vc_pha_lvl3 
 
est_vc_ar 
cov_vc_ar 
wid_vc_ar 
 
 est_vc_r 
cov_vc_r 
wid_vc_r 
 
 n = n_sims; 
 ods listing;  
 
%global _print_; 
%let _print_ = on; 
 
data j13;  
set j12;  
 
reps=&n; 
Average_Series=&avgseries; 
Average_Part=&avgpart; 
Error_Variance=&varerror; 
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fixed=&gamma; 
phi=&phi; 
conv=n_sims/reps;  
 
 
data j14; 
set j13; 
file print; 
file'Y:\Documents\Dissertation\Results\DISS.txt' mod lrecl=400; 
put @1(Average_Series)(1.0) @3(Average_Part)(1.0) 
@5(Error_Variance)(1.0)  
     @7 (fixed)(2.0) @10 (phi)(4.1)  @15 (conv)(6.4)  
     @22 (est_intcov_intwid_int 
 
est_phacov_phawid_pha 
  
est_vc_int_lvl2 cov_vc_int_lvl2 wid_vc_int_lvl2  
 
 est_vc_pha_lvl2 cov_vc_pha_lvl2 wid_vc_pha_lvl2   
 
est_vc_int_lvl3 cov_vc_int_lvl3 wid_vc_int_lvl3 
 
est_vc_pha_lvl3 cov_vc_pha_lvl3 wid_vc_pha_lvl3 
 
est_vc_arcov_vc_arwid_vc_ar 
 
 est_vc_rcov_vc_rwid_vc_r 
 
 reps) (10.4); 
 
run;  
%mend;  
*++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 
input for the macro are: 
n = 5000 (number of samples to generate) 
n3= 10,30,or 80 
avgseries = 0, 1, or 2 (0 = small, 1 = medium, 2 = large) 
avgpart= 0 or 1 (0 = small and 1 = large) 
varerror= 0 or 1 (0= most of the error at level-1 and 1= most of the 
error at level-2) 
gamma = 1 (fixed effects - intercept [gamma000], effect [gamma100]) 
phi = 0, -.2,or -.4 (produces positive autocorrelation)  
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++; 
 
%hlmsim(5000,10,0,0,0,1,-.2); 
 
run; 
 
 
 
